sulfuric ester - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	sulfuric ester	go back to main search page
Accession:	CHEBI:26819	browse the term
Definition:	An ester of an alcohol and sulfuric acid.
Synonyms:	related_synonym:	Formula=O4SR2; SMILES=[]OS(=O)(=O)O[]; sulfate ester; sulfuric acid ester; sulfuric acid esters

show annotations for term's descendants Sort by:
Rat (1845) Mouse (2095) Human (1861) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (13) Green Monkey (0) Naked Mole-rat (0) All
Genes (1861)

17-beta-Estradiol-3,17-beta-sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione S-transferase alpha 1

multiple interactions

estradiol 3,17-disulfate binds to and results in decreased activity of GSTA1 protein

NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860

2-hydroxy-5-nitrophenyl hydrogen sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

steroid sulfatase

decreases activity

4-nitrocatechol sulfate results in decreased activity of STS protein

NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358

4-methylumbelliferone sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 11

multiple interactions

4-methylumbelliferyl sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

solute carrier family 22 member 24

multiple interactions

4-methylumbelliferyl sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]

NCBI chr11:63,079,940...63,144,221
Ensembl chr11:63,079,940...63,144,221

G

solute carrier family 22 member 9

multiple interactions

4-methylumbelliferyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]

NCBI chr11:63,369,785...63,410,294
Ensembl chr11:63,369,785...63,410,294

4-nitrophenyl hydrogen sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 11

multiple interactions

4-nitrophenyl sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

steroid sulfatase

decreases activity

4-nitrophenyl sulfate results in decreased activity of STS protein

NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358

beta-D-glucosamine 6-sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA synthetase long chain family member 1

decreases expression

glucosamine 6-O-sulfate results in decreased expression of ACSL1 mRNA

NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818

G

arachidonate 5-lipoxygenase

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 mRNA]

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

CCAAT enhancer binding protein alpha

decreases expression

glucosamine 6-O-sulfate results in decreased expression of CEBPA mRNA; glucosamine 6-O-sulfate results in decreased expression of CEBPA protein

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of CHUK protein]

NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596

G

fatty acid binding protein 4

decreases expression

glucosamine 6-O-sulfate results in decreased expression of FABP4 mRNA

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

Fas cell surface death receptor

decreases expression

glucosamine 6-O-sulfate results in decreased expression of FAS mRNA

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein]

NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460

G

interleukin 1 beta

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

leptin

decreases expression

glucosamine 6-O-sulfate results in decreased expression of LEP mRNA

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

lipase E, hormone sensitive type

decreases expression

glucosamine 6-O-sulfate results in decreased expression of LIPE mRNA

NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,497...42,427,388

G

lipoprotein lipase

decreases expression

glucosamine 6-O-sulfate results in decreased expression of LPL mRNA

NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259

G

mitogen-activated protein kinase 1

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

nuclear factor kappa B subunit 1

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein]

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

nitric oxide synthase 2

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

phospholipase A2 group IVA

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A protein]

NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981

G

perilipin 1

decreases expression

glucosamine 6-O-sulfate results in decreased expression of PLIN1 mRNA

NCBI chr15:89,664,367...89,679,367
Ensembl chr15:89,664,367...89,679,427

G

peroxisome proliferator activated receptor gamma

decreases expression

glucosamine 6-O-sulfate results in decreased expression of PPARG mRNA; glucosamine 6-O-sulfate results in decreased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

prostaglandin-endoperoxide synthase 2

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

sterol regulatory element binding transcription factor 1

decreases expression

glucosamine 6-O-sulfate results in decreased expression of SREBF1 mRNA; glucosamine 6-O-sulfate results in decreased expression of SREBF1 protein

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

tumor necrosis factor

multiple interactions

glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

carrageenan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of AKT1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

albumin

decreases expression
multiple interactions

Carrageenan results in decreased expression of ALB protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of ALB protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of ALB protein]

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

annexin A1

affects response to substance
multiple interactions

ANXA1 protein affects the susceptibility to Carrageenan
ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan]

NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,629

G

amyloid P component, serum

increases expression

Carrageenan results in increased expression of APCS protein

NCBI chr 1:159,587,826...159,588,865
Ensembl chr 1:159,587,826...159,588,865

G

catalase

decreases activity
multiple interactions

Carrageenan results in decreased activity of CAT protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased activity of CAT protein]
fucoxanthin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]

PMID:26418808 PMID:28844677 PMID:34789018

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL2 protein]

PMID:12444156 PMID:20383154

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL3 protein]

PMID:12444156 PMID:20383154

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

Carrageenan results in increased expression of CCL5 protein
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]

PMID:12444156 PMID:14654164

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

chymase 1

increases expression
multiple interactions

Carrageenan results in increased expression of CMA1 protein
adelmidrol inhibits the reaction [Carrageenan results in increased expression of CMA1 protein]

NCBI chr14:24,505,353...24,508,265
Ensembl chr14:24,505,353...24,508,265

G

C-reactive protein

increases expression
multiple interactions

Carrageenan results in increased expression of CRP protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of CRP protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of CRP protein]

NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589

G

C-X-C motif chemokine ligand 1

increases expression

Carrageenan results in increased expression of CXCL1 protein

NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308

G

C-X-C motif chemokine ligand 2

multiple interactions
increases secretion
increases expression

IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of CXCL2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein]

PMID:12444156 PMID:14654164 PMID:21549112

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 8

multiple interactions
increases expression

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of CXCL8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of CXCL8 protein]
Carrageenan results in increased expression of CXCL8 mRNA; Carrageenan results in increased expression of CXCL8 protein

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

early growth response 1

increases expression
multiple interactions

Carrageenan results in increased expression of EGR1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen promotes the reaction [Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]]; Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Urethane inhibits the reaction [Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]]

PMID:1327382 PMID:11164833

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190

G

galanin and GMAP prepropeptide

decreases response to substance

GAL protein results in decreased susceptibility to Carrageenan

NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175

G

G protein-coupled receptor 132

increases expression

Carrageenan results in increased expression of GPR132 mRNA

NCBI chr14:105,049,395...105,065,430
Ensembl chr14:105,049,395...105,065,445

G

G protein-coupled receptor 4

increases expression

Carrageenan results in increased expression of GPR4 mRNA

NCBI chr19:45,589,764...45,602,212
Ensembl chr19:45,589,764...45,602,212

G

G protein-coupled receptor 65

increases expression

Carrageenan results in increased expression of GPR65 mRNA

NCBI chr14:88,005,135...88,014,811
Ensembl chr14:88,005,135...88,014,811

G

heme oxygenase 1

decreases expression
multiple interactions

Carrageenan results in decreased expression of HMOX1 mRNA; Carrageenan results in decreased expression of HMOX1 protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of HMOX1 protein]

PMID:28844677 PMID:34789018

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heat shock protein family A (Hsp70) member 1A

increases expression

Carrageenan results in increased expression of HSPA1A protein

NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946

G

intercellular adhesion molecule 1

multiple interactions
increases expression

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]
Carrageenan results in increased expression of ICAM1 mRNA; Carrageenan results in increased expression of ICAM1 protein

PMID:11181422 PMID:14709329 PMID:22330755 PMID:27803785 PMID:34789018

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 10

increases secretion
multiple interactions
increases expression

Carrageenan results in increased secretion of IL10 protein
indole-3-guanylhydrazone hydrochloride promotes the reaction [Carrageenan results in increased secretion of IL10 protein]; Indomethacin promotes the reaction [Carrageenan results in increased secretion of IL10 protein]
Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL10 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL10 protein]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA]

PMID:11181422 PMID:19735303 PMID:28844677 PMID:29499192

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 alpha

multiple interactions
decreases expression

Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 1 beta

increases secretion
increases expression
multiple interactions

Carrageenan results in increased secretion of IL1B protein
Carrageenan results in increased expression of IL1B mRNA; Carrageenan results in increased expression of IL1B protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of IL1B protein]

PMID:11181422 PMID:16368644 PMID:17320857 PMID:20383154 PMID:21549112 More...

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions
increases expression
increases secretion

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL6 protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Diclofenac inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL6 protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of IL6 protein]

PMID:11181422 PMID:20383154 PMID:22330755 PMID:23774260 PMID:24412305 More...

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

kallikrein related peptidase 3

increases expression
multiple interactions

Carrageenan results in increased expression of KLK3 protein
procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of KLK3 protein]

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of MAPK1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 14

increases expression
multiple interactions

Carrageenan results in increased expression of MAPK14 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]

NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,752...36,122,511

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of MAPK3 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 9

multiple interactions
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased expression of MMP9 protein]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

myeloperoxidase

multiple interactions
increases activity
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased activity of MPO protein]; arvelexin analog inhibits the reaction [Carrageenan results in increased expression of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Diclofenac inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Ibuprofen inhibits the reaction [Carrageenan results in increased expression of MPO protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Carrageenan results in increased activity of MPO protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased activity of MPO protein]
Carrageenan results in increased expression of MPO mRNA; Carrageenan results in increased expression of MPO protein

PMID:9890637 PMID:15860553 PMID:18429935 PMID:23872256 PMID:24412305 More...

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

metallothionein 1X

multiple interactions

[Methylnitrosourea co-treated with Carrageenan] results in increased expression of MT1 protein

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

NFE2 like bZIP transcription factor 2

affects localization
decreases expression
multiple interactions

Carrageenan affects the localization of NFE2L2 protein
Carrageenan results in decreased expression of NFE2L2 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan affects the localization of NFE2L2 protein]

PMID:28844677 PMID:34789018

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

Carrageenan results in increased expression of NFKB1 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

multiple interactions

NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

nerve growth factor

increases expression
multiple interactions

Carrageenan results in increased expression of NGF protein
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NGF protein]

NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770

G

nitric oxide synthase 2

multiple interactions
increases expression
increases activity

adelmidrol inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of NOS2 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]
Carrageenan results in increased activity of NOS2 protein
Carrageenan results in increased expression of NOS2 mRNA; Carrageenan results in increased expression of NOS2 protein

PMID:7542281 PMID:9890637 PMID:15860553 PMID:18429935 PMID:22330755 More...

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

Carrageenan results in decreased expression of NQO1 protein
procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of NQO1 protein]

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

opioid receptor mu 1

decreases expression

Carrageenan results in decreased expression of OPRM1 protein

NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867

G

purinergic receptor P2X 7

multiple interactions

[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Carrageenan

NCBI chr12:121,132,876...121,188,032
Ensembl chr12:121,132,819...121,188,032

G

platelet and endothelial cell adhesion molecule 1

multiple interactions
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased expression of PECAM1 protein]

NCBI chr17:64,319,415...64,390,860
Ensembl chr17:64,319,415...64,413,776

G

prostaglandin E synthase

multiple interactions
increases expression

arvelexin analog inhibits the reaction [Carrageenan results in increased expression of PTGES protein]

PMID:17258197 PMID:25451575

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin E synthase 2

multiple interactions
increases activity

2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone

NCBI chr 9:128,120,693...128,128,440
Ensembl chr 9:128,120,693...128,128,462

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; dragon's blood inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; nimesulide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; triflusal inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
Carrageenan results in increased expression of PTGS2 mRNA; Carrageenan results in increased expression of PTGS2 protein

PMID:10101034 PMID:14654164 PMID:15860553 PMID:17258197 PMID:18814970 More...

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
increases expression
multiple interactions
increases localization

Carrageenan results in increased phosphorylation of RELA protein
Carrageenan results in increased expression of RELA protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of RELA protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased localization of RELA protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of RELA protein]

PMID:21549112 PMID:22561171 PMID:34789018

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

selectin P

increases expression
multiple interactions

Carrageenan results in increased expression of SELP protein
imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of SELP protein]

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

somatostatin receptor 4

decreases response to substance

SSTR4 results in decreased susceptibility to Carrageenan

NCBI chr20:23,035,312...23,039,237
Ensembl chr20:23,035,312...23,039,237

G

signal transducer and activator of transcription 3

increases expression
multiple interactions

Carrageenan results in increased expression of STAT3 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transforming growth factor beta 1

increases secretion

Carrageenan results in increased secretion of TGFB1 protein

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tight junction protein 1

multiple interactions

3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; Carrageenan results in decreased expression of and affects the localization of TJP1 protein; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]

NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915

G

tumor necrosis factor

increases secretion
increases expression
multiple interactions

Carrageenan results in increased secretion of TNF protein
Carrageenan results in increased expression of TNF mRNA; Carrageenan results in increased expression of TNF protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of TNF protein]; diaoxinxuekang inhibits the reaction [Carrageenan results in increased expression of TNF protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of TNF protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; adelmidrol inhibits the reaction [Carrageenan results in increased expression of TNF protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of TNF protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of TNF protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Rutin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of TNF protein]

PMID:11181422 PMID:12444156 PMID:14654164 PMID:16368644 PMID:17320857 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

Carrageenan results in increased expression of VCAM1 mRNA
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

cholesterol sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 11 subfamily A member 1

decreases expression

cholesteryl sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

steroidogenic acute regulatory protein

decreases expression

cholesteryl sulfate results in decreased expression of STAR mRNA; cholesteryl sulfate results in decreased expression of STAR protein

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

sulfotransferase family 2B member 1

increases abundance

SULT2B1 protein results in increased abundance of cholesteryl sulfate

NCBI chr19:48,552,172...48,599,427
Ensembl chr19:48,552,172...48,599,425

chondroitin sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylsulfatase B

decreases abundance

ARSB protein results in decreased abundance of Chondroitin Sulfates

NCBI chr 5:78,777,209...78,985,958
Ensembl chr 5:78,777,209...78,986,087

G

bradykinin receptor B2

multiple interactions

[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates

NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166

G

brain derived neurotrophic factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

complement C3

increases cleavage

Chondroitin Sulfates analog results in increased cleavage of C3 protein

NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562

G

complement C5

increases cleavage

Chondroitin Sulfates analog results in increased cleavage of C5 protein

NCBI chr 9:120,952,335...121,074,865
Ensembl chr 9:120,932,987...121,075,195

G

caspase 3

multiple interactions

[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

multiple interactions

[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

catalase

multiple interactions

Chondroitin Sulfates inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]

PMID:12736501 PMID:15089041

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

affects binding

Chondroitin Sulfates binds to CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

cathepsin B

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein]; Chondroitin Sulfates promotes the reaction [CTSB protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]

NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533

G

cathepsin K

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL3 protein]

NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577

G

cathepsin L

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein]

NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469

G

cathepsin S

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein]

NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957

G

C-X-C motif chemokine ligand 1

multiple interactions

Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein]

NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308

G

C-X-C motif chemokine ligand 10

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein]

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 11

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein]

NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415

G

C-X-C motif chemokine ligand 2

multiple interactions

Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein]

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 3

multiple interactions

Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL3 protein]

NCBI chr 4:74,036,589...74,038,689
Ensembl chr 4:74,036,589...74,038,807

G

C-X-C motif chemokine ligand 9

multiple interactions

Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein]

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

coagulation factor XII

increases activity

Chondroitin Sulfates analog results in increased activity of F12 protein

NCBI chr 5:177,402,141...177,409,564
Ensembl chr 5:177,402,133...177,416,583

G

fibroblast growth factor 10

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein; Chondroitin Sulfates analog binds to FGF10 protein

PMID:12221095 PMID:15385557

NCBI chr 5:44,300,247...44,389,420
Ensembl chr 5:44,300,247...44,389,706

G

fibroblast growth factor 16

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein; Chondroitin Sulfates analog binds to FGF16 protein

PMID:12221095 PMID:15385557

NCBI chr X:77,447,389...77,457,278
Ensembl chr X:77,447,389...77,457,278

G

fibroblast growth factor 18

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein; Chondroitin Sulfates analog binds to FGF18 protein

PMID:12221095 PMID:15385557

NCBI chr 5:171,419,647...171,457,626
Ensembl chr 5:171,419,647...171,457,626

G

fibroblast growth factor 2

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein; Chondroitin Sulfates analog binds to FGF2 protein

PMID:12221095 PMID:15385557

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 23

increases activity

Chondroitin Sulfates analog results in increased activity of FGF23 protein

NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712

G

glial cell derived neurotrophic factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein

NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041

G

heparin binding EGF like growth factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein; Chondroitin Sulfates analog binds to HBEGF protein

PMID:12221095 PMID:15385557

NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603

G

interleukin 1 beta

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

inter-alpha-trypsin inhibitor heavy chain 1

multiple interactions

TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates]

NCBI chr 3:52,777,599...52,792,068
Ensembl chr 3:52,777,595...52,792,068

G

kallikrein B1

increases activity

Chondroitin Sulfates analog results in increased activity of KLKB1 protein

NCBI chr 4:186,210,853...186,258,471
Ensembl chr 4:186,226,438...186,258,471

G

midkine

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein; Chondroitin Sulfates analog binds to MDK protein

PMID:12221095 PMID:15385557

NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837

G

matrix metallopeptidase 3

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein

NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609

G

myeloperoxidase

multiple interactions

[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

nuclear factor kappa B subunit 1

multiple interactions

[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein]

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

multiple interactions

[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

nitric oxide synthase 2

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

platelet derived growth factor subunit B

multiple interactions

Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]]

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

platelet derived growth factor receptor beta

multiple interactions

Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]]

NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872

G

prostaglandin E synthase

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

pleiotrophin

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein; Chondroitin Sulfates analog binds to PTN protein

PMID:12221095 PMID:15385557

NCBI chr 7:137,227,341...137,343,733
Ensembl chr 7:137,227,341...137,343,774

G

protein tyrosine phosphatase non-receptor type 11

affects binding

PTPN11 protein binds to Chondroitin Sulfates

NCBI chr12:112,418,947...112,509,918
Ensembl chr12:112,418,351...112,509,918

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

TIMP metallopeptidase inhibitor 3

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA

NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041

G

tumor necrosis factor

multiple interactions

[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF

PMID:14697411 PMID:20110869

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF alpha induced protein 6

multiple interactions

TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates]

NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046

G

TNF receptor superfamily member 11b

multiple interactions
increases expression

[Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein
Chondroitin Sulfates results in increased expression of TNFRSF11B protein

NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885

G

TNF superfamily member 11

multiple interactions
decreases expression

[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA]
Chondroitin Sulfates results in decreased expression of TNFSF11 mRNA

NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013

G

vascular endothelial growth factor A

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

dehydroepiandrosterone sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

Dehydroepiandrosterone Sulfate results in decreased activity of ABCB11 protein
Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

acyl-CoA oxidase 1

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA
PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA]

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

BCL2 apoptosis regulator

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein
Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 1

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein
Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein]

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989

G

carnitine palmitoyltransferase 1A

multiple interactions
increases expression

[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CPT1A protein
Dehydroepiandrosterone Sulfate results in increased expression of CPT1A protein

NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410

G

cytochrome P450 family 2 subfamily C member 18

multiple interactions

[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C11 protein

NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions

[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C6 protein
CYP2C19 gene SNP affects the reaction [1-naphthol affects the abundance of Dehydroepiandrosterone Sulfate]

PMID:25786523 PMID:33771511

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)

multiple interactions

CYP2D6 gene SNP affects the reaction [1-naphthol affects the abundance of Dehydroepiandrosterone Sulfate]

NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865

G

cytochrome P450 family 3 subfamily A member 4

affects metabolic processing
multiple interactions

CYP3A4 protein affects the metabolism of Dehydroepiandrosterone Sulfate
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP3A2 protein

PMID:2271712 PMID:25786523

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 7

affects abundance
multiple interactions
increases oxidation
increases hydroxylation

CYP3A7 promoter polymorphism affects the abundance of Dehydroepiandrosterone Sulfate
Ritonavir inhibits the reaction [CYP3A7 protein results in increased oxidation of Dehydroepiandrosterone Sulfate]
CYP3A7 protein results in increased hydroxylation of Dehydroepiandrosterone Sulfate

PMID:15985487 PMID:33821626

NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196

G

cytochrome P450 family 4 subfamily A member 22

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA; Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 protein
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP4A1 protein

PMID:8700121 PMID:25786523

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA
PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA]

NCBI chr 3:185,190,624...185,254,049
Ensembl chr 3:185,190,624...185,281,990

G

fatty acid binding protein 1

increases expression
multiple interactions

Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA
PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA]

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased expression of FOS protein

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190

G

interleukin 1 beta

multiple interactions
increases abundance

Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dehydroepiandrosterone Sulfate]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

mitogen-activated protein kinase 1

multiple interactions

[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased phosphorylation of MAPK1 protein

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

N-acetyltransferase 1

multiple interactions

Dehydroepiandrosterone Sulfate inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]; Dehydroepiandrosterone Sulfate promotes the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]

NCBI chr 8:18,170,467...18,223,689
Ensembl chr 8:18,170,477...18,223,689

G

proopiomelanocortin

increases abundance

POMC results in increased abundance of Dehydroepiandrosterone Sulfate

NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases response to substance

PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A3 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA]
PPARA protein results in increased susceptibility to Dehydroepiandrosterone Sulfate

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

prolactin

increases abundance

PRL protein results in increased abundance of Dehydroepiandrosterone Sulfate

NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826

G

sirtuin 1

increases expression

Dehydroepiandrosterone Sulfate results in increased expression of SIRT1 protein

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

sirtuin 6

increases expression

Dehydroepiandrosterone Sulfate results in increased expression of SIRT6 protein

NCBI chr19:4,174,109...4,182,563
Ensembl chr19:4,174,109...4,182,566

G

solute carrier family 10 member 6

increases transport

SLC10A6 protein results in increased transport of Dehydroepiandrosterone Sulfate

NCBI chr 4:86,823,468...86,849,384
Ensembl chr 4:86,823,468...86,849,384

G

solute carrier family 22 member 11

affects transport

SLC22A11 protein affects the transport of Dehydroepiandrosterone Sulfate

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

solute carrier family 22 member 12

multiple interactions

Potassium promotes the reaction [SLC22A12 protein results in increased uptake of Dehydroepiandrosterone Sulfate]

NCBI chr11:64,591,220...64,602,344
Ensembl chr11:64,590,641...64,602,353

G

solute carrier family 22 member 24

affects transport

SLC22A19 protein affects the transport of Dehydroepiandrosterone Sulfate

NCBI chr11:63,079,940...63,144,221
Ensembl chr11:63,079,940...63,144,221

G

solute carrier family 22 member 7

increases transport

SLC22A7 protein results in increased transport of Dehydroepiandrosterone Sulfate

NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538

G

solute carrier family 22 member 8

affects transport
increases uptake

SLC22A8 protein affects the transport of Dehydroepiandrosterone Sulfate
SLC22A8 protein results in increased uptake of Dehydroepiandrosterone Sulfate

PMID:11306713 PMID:16098483 PMID:17255469

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier family 22 member 9

multiple interactions
increases uptake

Dehydroepiandrosterone Sulfate inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]
SLC22A9 protein results in increased uptake of Dehydroepiandrosterone Sulfate

PMID:17132213 PMID:18441515

NCBI chr11:63,369,785...63,410,294
Ensembl chr11:63,369,785...63,410,294

G

solute carrier organic anion transporter family member 1B1

multiple interactions

Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B1 protein results in increased susceptibility to cyanoginosin LR]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B1 protein results in increased susceptibility to Okadaic Acid]

NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796

G

solute carrier organic anion transporter family member 1B3

multiple interactions

Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]

NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911

G

SRC proto-oncogene, non-receptor tyrosine kinase

increases phosphorylation

Dehydroepiandrosterone Sulfate results in increased phosphorylation of SRC protein

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

steroid sulfatase

affects metabolic processing

STS protein affects the metabolism of Dehydroepiandrosterone Sulfate

NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358

dermatan sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain derived neurotrophic factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

coagulation factor II, thrombin

multiple interactions

[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein

NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506

G

fibroblast growth factor 10

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein

NCBI chr 5:44,300,247...44,389,420
Ensembl chr 5:44,300,247...44,389,706

G

fibroblast growth factor 16

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein

NCBI chr X:77,447,389...77,457,278
Ensembl chr X:77,447,389...77,457,278

G

fibroblast growth factor 18

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein

NCBI chr 5:171,419,647...171,457,626
Ensembl chr 5:171,419,647...171,457,626

G

fibroblast growth factor 2

affects binding
increases activity

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein
Dermatan Sulfate analog results in increased activity of FGF2 protein

PMID:15385557 PMID:15563459

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 23

increases activity

Dermatan Sulfate analog results in increased activity of FGF23 protein

NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712

G

fibroblast growth factor 7

increases activity

Dermatan Sulfate analog results in increased activity of FGF7 protein

NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775

G

glial cell derived neurotrophic factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein

NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041

G

heparin binding EGF like growth factor

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein

NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603

G

midkine

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein

NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837

G

platelet derived growth factor receptor alpha

decreases expression

Dermatan Sulfate results in decreased expression of PDGFRA mRNA

NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245

G

platelet derived growth factor receptor beta

decreases expression

Dermatan Sulfate results in decreased expression of PDGFRB mRNA

NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872

G

pleiotrophin

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein

NCBI chr 7:137,227,341...137,343,733
Ensembl chr 7:137,227,341...137,343,774

G

serpin family D member 1

multiple interactions

[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein

NCBI chr22:20,774,113...20,787,720
Ensembl chr22:20,774,113...20,787,720

G

vascular endothelial growth factor A

affects binding

[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575

G

ATP binding cassette subfamily A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily A member 17, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA17 mRNA

NCBI chr16:2,340,922...2,426,699
Ensembl chr16:2,361,144...2,425,685
Ensembl chr16:2,361,144...2,425,685

G

ATP binding cassette subfamily B member 1

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435

G

ATP binding cassette subfamily B member 6 (LAN blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994

G

ATP binding cassette subfamily C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr 6:43,427,541...43,451,994
Ensembl chr 6:43,427,366...43,450,430

G

ATP binding cassette subfamily C member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

ATP binding cassette subfamily C member 4 (PEL blood group)

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

ATP binding cassette subfamily C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939

G

ATP binding cassette subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522

G

ATP binding cassette subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr12:21,797,389...21,941,426
Ensembl chr12:21,797,389...21,942,543

G

ATP binding cassette subfamily F member 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 7:151,211,484...151,227,205
Ensembl chr 7:151,211,484...151,227,205

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,304,389

G

ATP binding cassette subfamily G member 2 (JR blood group)

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

abl interactor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr10:26,746,596...26,860,958
Ensembl chr10:26,746,593...26,861,087

G

acetyl-CoA acyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 3:38,122,715...38,137,127
Ensembl chr 3:38,103,129...38,137,242

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:49,782,164...49,813,533
Ensembl chr18:49,782,164...49,813,953

G

acetyl-CoA carboxylase alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ACACA protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

acyl-CoA dehydrogenase short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr12:120,725,826...120,740,008
Ensembl chr12:120,725,774...120,740,008

G

acyl-CoA dehydrogenase short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr10:123,009,006...123,058,290
Ensembl chr10:123,008,979...123,058,290

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

acetylcholinesterase (Yt blood group)

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

atypical chemokine receptor 1 (Duffy blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr 1:159,204,875...159,206,500
Ensembl chr 1:159,204,875...159,206,500

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 3:42,809,445...42,867,286
Ensembl chr 3:42,804,752...42,887,974

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 2:236,537,122...236,582,354
Ensembl chr 2:236,567,787...236,582,354

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 3:132,597,270...132,602,644
Ensembl chr 3:132,597,270...132,618,967

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr19:6,135,633...6,193,091
Ensembl chr19:6,135,247...6,193,094

G

acyl-CoA synthetase medium chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr16:20,623,235...20,697,680
Ensembl chr16:20,623,235...20,698,890

G

acyl-CoA synthetase medium chain family member 3

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr16:20,674,405...20,797,581
Ensembl chr16:20,610,243...20,797,581

G

acyl-CoA synthetase short chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr20:25,006,237...25,058,139
Ensembl chr20:25,006,230...25,058,980

G

acyl-CoA synthetase short chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962

G

actin like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 3:179,562,926...179,588,407
Ensembl chr 3:179,562,886...179,588,407

G

actinin alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr14:68,874,128...68,979,302
Ensembl chr14:68,874,123...68,979,440

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr 1:236,686,499...236,764,631
Ensembl chr 1:236,664,141...236,764,631

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr 2:65,227,831...65,271,253
Ensembl chr 2:65,227,788...65,271,253

G

actin related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596

G

activin A receptor type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 2:157,736,446...157,876,330
Ensembl chr 2:157,736,251...157,876,330

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 3:51,983,535...51,989,197
Ensembl chr 3:51,983,340...51,989,197

G

adenosine deaminase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252

G

ADAM metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:70,672,506...70,762,441
Ensembl chr10:70,672,506...70,762,441

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr 5:179,110,853...179,345,461
Ensembl chr 5:179,110,853...179,345,461

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:161,184,302...161,199,054
Ensembl chr 1:161,184,302...161,199,054

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr21:26,917,922...26,967,088
Ensembl chr21:26,917,922...26,967,088

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr 5:7,396,138...7,830,081
Ensembl chr 5:7,396,138...7,830,081

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr14:24,318,359...24,335,071
Ensembl chr14:24,318,349...24,335,093

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr12:48,766,194...48,789,974
Ensembl chr12:48,766,194...48,789,089

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr16:50,244,699...50,318,135
Ensembl chr16:50,246,137...50,318,135

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr18:904,411...912,172
Ensembl chr18:904,871...912,172

G

ADCYAP receptor type I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 7:31,052,308...31,111,474
Ensembl chr 7:31,052,308...31,111,474

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr 8:37,796,883...37,844,896
Ensembl chr 8:37,784,191...37,844,896

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr 8:142,449,649...142,545,007
Ensembl chr 8:142,449,430...142,545,009

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr19:6,887,579...6,940,450
Ensembl chr19:6,887,566...6,940,459

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr19:14,381,444...14,408,723
Ensembl chr19:14,380,501...14,408,725

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr 6:46,997,708...47,042,332
Ensembl chr 6:46,997,708...47,042,350

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr 6:46,852,522...46,954,939
Ensembl chr 6:46,852,522...46,954,943

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 4:99,070,978...99,088,788
Ensembl chr 4:99,070,978...99,088,801

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr22:24,423,597...24,442,357
Ensembl chr22:24,417,879...24,442,357

G

adenosine A2b receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr17:15,850,362...15,975,746
Ensembl chr17:15,945,130...15,975,746

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 1:111,499,429...111,503,633
Ensembl chr 1:111,499,429...111,503,633

G

adrenoceptor alpha 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907

G

adrenoceptor beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr11:62,433,544...62,546,806
Ensembl chr11:62,433,542...62,556,235

G

aryl hydrocarbon receptor

increases response to substance
multiple interactions

AHR gene mutant form results in increased susceptibility to Dextran Sulfate
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr16:31,527,900...31,528,803
Ensembl chr16:31,527,900...31,528,803

G

adenylate kinase 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein
Dextran Sulfate results in decreased expression of AK1 protein

NCBI chr 9:127,866,480...127,879,621
Ensembl chr 9:127,866,486...127,877,675

G

A-kinase anchoring protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559

G

A-kinase anchoring protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr14:64,465,499...64,474,503
Ensembl chr14:64,465,499...64,474,503

G

aldo-keto reductase family 1 member B

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of AKR1B1 protein
Dextran Sulfate results in increased expression of AKR1B1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284

G

aldo-keto reductase family 1 member C3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686

G

AKT serine/threonine kinase 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

aldehyde dehydrogenase 1 family member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

aldehyde dehydrogenase 1 family member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 9:38,392,702...38,398,661
Ensembl chr 9:38,392,702...38,398,661

G

aldehyde dehydrogenase 2 family member

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532

G

aldehyde dehydrogenase 3 family member A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760

G

aldehyde dehydrogenase 7 family member A1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ALDH7A1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr 5:126,541,841...126,595,219
Ensembl chr 5:126,531,200...126,595,362

G

aldolase, fructose-bisphosphate C

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948

G

arachidonate 12-lipoxygenase, 12S type

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr17:6,996,049...7,010,754
Ensembl chr17:6,996,049...7,010,754

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr17:8,072,636...8,087,716
Ensembl chr17:8,072,636...8,087,716

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr13:30,713,485...30,764,426
Ensembl chr13:30,713,478...30,764,426

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr20:869,900...916,334
Ensembl chr20:869,900...916,334

G

angiopoietin like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370

G

anoctamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 3:43,365,848...43,691,594
Ensembl chr 3:43,354,859...43,691,594

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr12:45,216,095...45,440,404
Ensembl chr12:45,215,987...45,482,280

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 2:241,188,677...241,240,308
Ensembl chr 2:241,188,509...241,225,976

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr11:417,938...442,011
Ensembl chr11:417,933...442,011

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,629

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr19:16,197,911...16,245,906
Ensembl chr19:16,197,854...16,245,906

G

adaptor related protein complex 1 subunit sigma 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr 7:101,154,476...101,161,276
Ensembl chr 7:101,154,456...101,161,596

G

APC regulator of WNT signaling pathway

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,518...112,846,239

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr 1:159,587,826...159,588,865
Ensembl chr 1:159,587,826...159,588,865

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:129,645,259...129,654,956
Ensembl chr X:129,645,259...129,654,956

G

apolipoprotein A2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr 1:161,222,292...161,223,628
Ensembl chr 1:161,222,290...161,223,631

G

apolipoprotein A4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of APOA4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr19:44,946,051...44,949,565
Ensembl chr19:44,946,035...44,949,565

G

apolipoprotein E

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

aquaporin 1 (Colton blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr11:77,589,953...77,610,356
Ensembl chr11:77,589,391...77,610,356

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878

G

aquaporin 3 (Gill blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr16:25,216,947...25,228,932
Ensembl chr16:25,215,731...25,228,932

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr15:58,138,169...58,185,911
Ensembl chr15:58,138,169...58,185,911

G

androgen receptor

increases expression
multiple interactions

Dextran Sulfate results in increased expression of AR mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ARF GTPase 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr12:48,935,723...48,957,487
Ensembl chr12:48,935,723...48,957,487

G

arginase 1

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr11:46,677,080...46,700,619
Ensembl chr11:46,677,080...46,700,619

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 2:143,129,419...143,768,352
Ensembl chr 2:143,091,362...143,768,352

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr11:110,577,043...110,713,189
Ensembl chr11:110,577,042...110,713,189

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 2:68,710,544...68,826,833
Ensembl chr 2:68,679,601...68,826,833

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr20:38,601,809...38,650,653
Ensembl chr20:38,601,809...38,651,035

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,719...81,871,378

G

Rho GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr12:14,942,015...14,961,601
Ensembl chr12:14,942,031...14,961,728

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr19:41,883,184...41,930,141
Ensembl chr19:41,883,173...41,930,150

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr11:120,336,413...120,489,937
Ensembl chr11:120,336,413...120,489,937

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:136,665,550...136,780,932
Ensembl chr X:136,665,547...136,780,932

G

ARF like GTPase 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr10:102,673,731...102,714,397
Ensembl chr10:102,673,731...102,714,397

G

ARF like GTPase 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr 4:56,505,209...56,524,453
Ensembl chr 4:56,505,209...56,524,959

G

actin related protein 2/3 complex subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 2:218,217,189...218,254,348
Ensembl chr 2:218,217,141...218,254,356

G

actin related protein 2/3 complex subunit 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein
Dextran Sulfate results in decreased expression of ARPC3 protein

NCBI chr12:110,434,823...110,450,337
Ensembl chr12:110,434,823...110,450,422

G

actin related protein 2/3 complex subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 3:9,792,518...9,807,101
Ensembl chr 3:9,792,495...9,807,101

G

arrestin beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr17:4,710,632...4,721,497
Ensembl chr17:4,710,596...4,721,499

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr 5:78,777,209...78,985,958
Ensembl chr 5:78,777,209...78,986,087

G

ankyrin repeat and SOCS box containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr14:93,934,166...93,976,570
Ensembl chr14:93,934,166...93,976,739

G

acid sensing ion channel subunit family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 2:219,507,093...219,538,772
Ensembl chr 2:219,514,170...219,538,772

G

argininosuccinate synthase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274

G

autophagy related 5

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ATG5 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791

G

autophagy related 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ATG7 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 2:215,312,059...215,368,592
Ensembl chr 2:215,311,956...215,349,773

G

ATPase phospholipid transporting 10A (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr15:25,672,237...25,865,088
Ensembl chr15:25,677,273...25,865,184

G

ATPase phospholipid transporting 11B (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 3:182,793,504...182,921,629
Ensembl chr 3:182,793,503...182,923,011

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr13:24,680,408...24,712,472
Ensembl chr13:24,680,408...24,712,472

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 1:116,373,244...116,404,774
Ensembl chr 1:116,372,668...116,410,261

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr19:41,966,582...41,994,230
Ensembl chr19:41,966,582...41,997,497

G

ATPase Na+/K+ transporting subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr 1:160,151,603...160,186,980
Ensembl chr 1:160,151,586...160,186,980

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992

G

ATPase Na+/K+ transporting subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 3:141,876,643...141,926,549
Ensembl chr 3:141,876,124...141,926,549

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr16:28,878,488...28,904,466
Ensembl chr16:28,878,405...28,904,466

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr17:3,923,873...3,964,437
Ensembl chr17:3,923,868...3,964,464

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr12:89,588,049...89,709,366
Ensembl chr12:89,588,049...89,709,366

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr16:84,368,538...84,464,187
Ensembl chr16:84,368,527...84,464,187

G

ATPase H+/K+ transporting subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr13:113,648,804...113,658,198
Ensembl chr13:113,648,804...113,658,198

G

ATPase H+ transporting V0 subunit a2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr12:123,712,353...123,761,755
Ensembl chr12:123,712,353...123,761,755

G

ATPase H+ transporting V0 subunit a4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 7:138,706,294...138,798,196
Ensembl chr 7:138,706,294...138,799,560

G

ATPase H+ transporting V0 subunit d2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 8:86,098,910...86,154,225
Ensembl chr 8:85,987,323...86,154,225

G

ATPase H+ transporting V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr 2:46,511,847...46,542,577
Ensembl chr 2:46,490,750...46,542,577

G

ATPase H+ transporting V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 7:128,862,856...128,865,847
Ensembl chr 7:128,862,856...128,865,847

G

ATPase H+ transporting V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr 1:198,523,222...198,540,945
Ensembl chr 1:198,523,222...198,540,945

G

ATPase copper transporting alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:77,910,693...78,050,395
Ensembl chr X:77,910,690...78,050,395

G

ATPase phospholipid transporting 8B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315

G

ATPase phospholipid transporting 8B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 1:154,325,525...154,351,304
Ensembl chr 1:154,325,525...154,351,304

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr12:63,142,759...63,151,201
Ensembl chr12:63,142,759...63,151,201

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr 1:206,106,936...206,117,388
Ensembl chr 1:206,106,936...206,117,699

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:153,902,625...153,907,166
Ensembl chr X:153,902,531...153,907,166

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr19:17,794,791...17,813,576
Ensembl chr19:17,794,828...17,813,576

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 2:231,395,710...231,401,164
Ensembl chr 2:231,395,671...231,408,799

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr19:41,425,359...41,428,730
Ensembl chr19:41,425,359...41,428,730

G

bile acid-CoA:amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400

G

barrier to autointegration nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr11:66,002,079...66,004,149
Ensembl chr11:66,002,228...66,004,149

G

B cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 4:101,790,730...102,074,812
Ensembl chr 4:101,411,286...102,074,812

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

butyrylcholinesterase

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of BCHE protein
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL6 transcription repressor

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr 3:187,721,377...187,745,468
Ensembl chr 3:187,721,377...187,745,725

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr16:30,833,626...30,894,077
Ensembl chr16:30,833,626...30,894,302

G

bradykinin receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

bradykinin receptor B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166

G

beclin 1

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr11:61,949,821...61,965,515
Ensembl chr11:61,950,063...61,965,515

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:153,494,980...153,509,546
Ensembl chr X:153,494,980...153,509,546

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr12:51,281,038...51,324,668
Ensembl chr12:51,281,038...51,324,668

G

baculoviral IAP repeat containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636

G

baculoviral IAP repeat containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr 2:32,357,023...32,618,878
Ensembl chr 2:32,357,023...32,619,571

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 2:68,860,909...68,871,397
Ensembl chr 2:68,860,909...68,871,397

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641

G

bone morphogenetic protein receptor type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 4:94,757,955...95,158,450
Ensembl chr 4:94,757,955...95,158,448

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 2:202,376,327...202,567,749
Ensembl chr 2:202,376,327...202,567,751

G

BPI fold containing family A member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr20:33,235,996...33,243,306
Ensembl chr20:33,235,995...33,243,311

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 9:113,349,541...113,371,222
Ensembl chr 9:113,349,541...113,371,233

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr 4:15,703,065...15,774,173
Ensembl chr 4:15,703,065...15,738,313

G

basic transcription factor 3 like 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 1:52,056,295...52,090,716
Ensembl chr 1:52,056,199...52,090,716

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 7:7,157,377...7,248,616
Ensembl chr 7:7,156,934...7,248,616

G

C1GALT1 specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:120,625,674...120,630,054
Ensembl chr X:120,625,674...120,630,054

G

complement C1q A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678

G

complement C1q B chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 1:22,653,236...22,661,637
Ensembl chr 1:22,652,762...22,661,637

G

C1q and TNF related 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr22:37,180,166...37,199,423
Ensembl chr22:37,180,166...37,199,385

G

complement C1s

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr12:7,060,718...7,071,032
Ensembl chr12:6,988,259...7,071,032

G

complement C3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562

G

complement C3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr12:8,056,844...8,066,359
Ensembl chr12:8,056,844...8,066,359

G

complement C4B (Chido/Rodgers blood group)

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418

G

complement component 4 binding protein alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein

NCBI chr 1:207,104,233...207,144,972
Ensembl chr 1:207,104,233...207,144,972

G

complement C5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr19:47,307,477...47,322,066
Ensembl chr19:47,290,023...47,322,066

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 8:85,464,007...85,481,493
Ensembl chr 8:85,463,968...85,481,493

G

carbonic anhydrase 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 8:85,438,859...85,449,040
Ensembl chr 8:85,373,436...85,449,040

G

carbonic anhydrase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CA4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr17:60,149,973...60,179,021
Ensembl chr17:60,149,942...60,170,899

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 2:230,712,842...230,821,075
Ensembl chr 2:230,712,842...230,821,075

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:49,205,063...49,233,340
Ensembl chr X:49,205,063...49,233,371

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr 1:201,039,512...201,112,426
Ensembl chr 1:201,039,512...201,112,451

G

calcitonin related polypeptide alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354

G

calcitonin related polypeptide beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr11:15,073,593...15,078,637
Ensembl chr11:14,904,997...15,082,342

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr14:90,396,502...90,408,268
Ensembl chr14:90,396,502...90,408,268

G

calmodulin 2

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein
Dextran Sulfate results in decreased expression of CALM2 protein

NCBI chr 2:47,160,082...47,176,936
Ensembl chr 2:47,160,084...47,176,921

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489

G

calcium/calmodulin dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr10:73,812,501...73,874,555
Ensembl chr10:73,812,501...73,874,591

G

calcium/calmodulin dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr 5:111,223,583...111,494,886
Ensembl chr 5:111,223,653...111,494,886

G

calcium/calmodulin dependent protein kinase kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr17:3,860,315...3,893,053
Ensembl chr17:3,860,315...3,894,891

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 1:40,040,240...40,072,648
Ensembl chr 1:40,040,233...40,072,649

G

calpain 13

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CAPN13 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr 2:30,722,771...30,807,446
Ensembl chr 2:30,722,771...30,820,542

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 1:19,338,775...19,485,539
Ensembl chr 1:19,338,775...19,485,539

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

increases cleavage
increases activity
multiple interactions

Dextran Sulfate results in increased cleavage of CASP3 protein
Dextran Sulfate results in increased activity of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CASP8 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

catalase

decreases activity
increases activity
multiple interactions

Dextran Sulfate results in decreased activity of CAT protein
Dextran Sulfate results in increased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolae associated protein 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 2:191,834,310...191,847,088
Ensembl chr 2:191,834,310...191,847,088

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 3:46,921,730...46,981,994
Ensembl chr 3:46,916,634...46,982,010

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr19:17,933,015...17,943,985
Ensembl chr19:17,933,015...17,943,991

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 3:42,704,118...42,773,253
Ensembl chr 3:42,705,756...42,773,253

G

coiled-coil domain containing 158

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CCDC158 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr 4:76,313,039...76,421,869
Ensembl chr 4:76,312,997...76,421,868

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr11:64,340,204...64,357,534
Ensembl chr11:64,340,204...64,357,534

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr19:47,256,525...47,275,723
Ensembl chr19:47,255,980...47,273,701

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr 6:31,142,439...31,158,197
Ensembl chr 6:31,142,439...31,158,238

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr11:6,259,838...6,272,127
Ensembl chr11:6,259,806...6,272,127

G

C-C motif chemokine ligand 11

multiple interactions
increases expression
increases secretion

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334

G

C-C motif chemokine ligand 15

decreases expression
increases expression

Dextran Sulfate results in decreased expression of CCL6 mRNA
Dextran Sulfate results in increased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr17:35,997,582...36,001,553
Ensembl chr17:35,996,440...36,001,553

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL2 protein
Dextran Sulfate results in increased expression of CCL2 mRNA
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 9:34,709,005...34,710,136
Ensembl chr 9:34,709,005...34,710,136

G

C-C motif chemokine ligand 23

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL9 mRNA
Dextran Sulfate results in increased expression of CCL9 mRNA

PMID:29950665 PMID:35093514

NCBI chr17:36,013,058...36,017,972
Ensembl chr17:36,013,056...36,017,972

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr 7:75,810,825...75,823,372
Ensembl chr 7:75,810,825...75,823,356

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr19:8,052,341...8,062,650
Ensembl chr19:8,052,318...8,062,660

G

C-C motif chemokine ligand 27

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 9:34,661,890...34,662,657
Ensembl chr 9:34,661,880...34,664,048

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr 5:43,356,975...43,412,391
Ensembl chr 5:43,376,645...43,412,391

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

C-C motif chemokine ligand 8

increases expression

Dextran Sulfate results in increased expression of CCL8 mRNA

PMID:19645018 PMID:23894361

NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,864...46,360,940

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 3:32,951,644...32,956,349
Ensembl chr 3:32,951,644...32,957,120

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 3:46,370,142...46,376,206
Ensembl chr 3:46,370,946...46,376,206

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr17:40,553,769...40,565,472
Ensembl chr17:40,551,081...40,565,472

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 3:39,329,709...39,333,680
Ensembl chr 3:39,329,709...39,333,680

G

C-C motif chemokine receptor like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 3:46,407,259...46,409,523
Ensembl chr 3:46,407,166...46,412,997

G

centriole, cilia and spindle associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr 1:229,321,015...229,343,047
Ensembl chr 1:229,321,011...229,343,294

G

CD14 molecule

affects response to substance
multiple interactions

Dextran Sulfate affects the susceptibility to CD14 protein
[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,700

G

CD163 molecule

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr12:7,470,811...7,503,777
Ensembl chr12:7,470,811...7,503,893

G

CD177 molecule

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr19:43,353,686...43,366,081
Ensembl chr19:43,353,686...43,363,172

G

CD180 molecule

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr 5:67,179,613...67,196,799
Ensembl chr 5:67,179,613...67,196,799

G

CD19 molecule

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr16:28,931,971...28,939,342
Ensembl chr16:28,931,965...28,939,342

G

CD200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr 3:112,332,573...112,362,812
Ensembl chr 3:112,332,235...112,363,181

G

CD247 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr 1:167,430,640...167,518,529
Ensembl chr 1:167,425,027...167,518,640

G

CD274 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566

G

CD28 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 2:203,706,482...203,738,912
Ensembl chr 2:203,706,517...203,739,756

G

CD34 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr 1:207,880,972...207,911,125
Ensembl chr 1:207,880,972...207,911,402

G

CD4 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr12:6,789,528...6,820,799
Ensembl chr12:6,786,858...6,820,799

G

CD44 molecule (IN blood group)

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402

G

CD52 molecule

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 1:26,317,958...26,320,523
Ensembl chr 1:26,317,958...26,320,523

G

CD53 molecule

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 1:110,871,210...110,899,922
Ensembl chr 1:110,871,188...110,899,936

G

CD55 molecule (Cromer blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804

G

CD68 molecule

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111

G

CD72 molecule

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 9:35,609,982...35,646,857
Ensembl chr 9:35,609,982...35,646,810

G

CD74 molecule

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969

G

CD79a molecule

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372

G

CD79b molecule

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr17:63,928,740...63,932,331
Ensembl chr17:63,928,738...63,932,336

G

CD81 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr11:2,376,180...2,397,397
Ensembl chr11:2,376,177...2,397,802

G

CD86 molecule

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 1:20,589,097...20,618,903
Ensembl chr 1:20,589,086...20,618,903

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784

G

cadherin related family member 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr 5:176,542,511...176,595,974
Ensembl chr 5:176,542,511...176,595,974

G

cyclin dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 1:1,635,225...1,659,004
Ensembl chr 1:1,635,225...1,659,012

G

cyclin dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr11:2,883,218...2,885,775
Ensembl chr11:2,883,213...2,885,775

G

caudal type homeobox 2

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of CDX2 protein
Dextran Sulfate results in decreased expression of CDX2 protein
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr13:27,960,918...27,969,315
Ensembl chr13:27,960,918...27,969,315

G

CCAAT enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr17:81,189,596...81,222,965
Ensembl chr17:81,189,593...81,222,999

G

carboxylesterase 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

cilia and flagella associated protein 184

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr 4:7,040,849...7,043,001
Ensembl chr 4:7,040,849...7,043,001

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr 1:159,872,364...159,900,165
Ensembl chr 1:159,872,364...159,900,165

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr19:859,664...863,641
Ensembl chr19:859,453...867,884

G

complement factor H

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr 1:196,652,043...196,747,504
Ensembl chr 1:196,651,754...196,752,476

G

cofilin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026

G

CASP8 and FADD like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687

G

CF transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971

G

cell growth regulator with EF-hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 2:27,099,353...27,119,128
Ensembl chr 2:27,098,889...27,119,128

G

chromatin assembly factor 1 subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr19:4,402,640...4,450,830
Ensembl chr19:4,402,640...4,445,018

G

calcium homeostasis endoplasmic reticulum protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHERP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr19:16,517,894...16,542,437
Ensembl chr19:16,517,894...16,542,437

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr19:58,551,566...58,555,105
Ensembl chr19:58,551,452...58,555,105

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr20:33,811,348...33,854,366
Ensembl chr20:33,811,348...33,854,366

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 7:29,146,591...29,514,328
Ensembl chr 7:29,146,547...29,514,328

G

chordin like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr11:74,696,429...74,731,426
Ensembl chr11:74,696,429...74,731,426

G

cholinergic receptor muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr11:46,383,789...46,391,776
Ensembl chr11:46,383,789...46,391,776

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr 8:27,459,756...27,479,261
Ensembl chr 8:27,459,756...27,479,883

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr 8:42,697,366...42,737,407
Ensembl chr 8:42,697,366...42,737,407

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr17:4,897,771...4,908,677
Ensembl chr17:4,897,771...4,934,438

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr12:104,456,948...104,762,014
Ensembl chr12:104,455,295...104,762,014

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596

G

creatine kinase B

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr14:103,519,667...103,522,830
Ensembl chr14:103,519,667...103,522,833

G

creatine kinase, M-type

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 1:86,468,927...86,500,259
Ensembl chr 1:86,468,368...86,500,259

G

chloride channel accessory 4

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 1:86,547,078...86,580,754
Ensembl chr 1:86,547,078...86,580,754

G

chloride voltage-gated channel 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr 3:184,346,185...184,361,605
Ensembl chr 3:184,346,185...184,361,650

G

chloride voltage-gated channel 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr 4:169,620,578...169,723,673
Ensembl chr 4:169,612,633...169,723,673

G

claudin 1

multiple interactions
increases expression
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 3:170,418,868...170,434,691
Ensembl chr 3:170,418,868...170,454,733

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:106,900,164...106,930,861
Ensembl chr X:106,900,164...106,930,861

G

C-type lectin domain containing 10A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr17:7,074,537...7,080,251
Ensembl chr17:7,074,537...7,080,307

G

chloride intracellular channel 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein
Dextran Sulfate results in decreased expression of CLIC1 protein

NCBI chr 6:31,730,581...31,737,318
Ensembl chr 6:31,730,581...31,739,763

G

chymase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr14:24,505,353...24,508,265
Ensembl chr14:24,505,353...24,508,265

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr12:22,046,218...22,065,668
Ensembl chr12:22,046,218...22,065,674

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 1:47,333,790...47,378,839
Ensembl chr 1:47,333,790...47,394,866

G

cyclic nucleotide gated channel subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr11:6,234,793...6,244,976
Ensembl chr11:6,234,765...6,244,479

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr19:1,026,608...1,039,065
Ensembl chr19:1,026,586...1,039,068

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

cannabinoid receptor 2

multiple interactions
increases response to substance
increases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 9:34,551,433...34,590,852
Ensembl chr 9:34,551,432...34,590,140

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr12:40,692,439...41,072,415
Ensembl chr12:40,692,439...41,072,415

G

component of oligomeric golgi complex 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr17:73,193,055...73,208,507
Ensembl chr17:73,193,055...73,208,507

G

collagen type XI alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872

G

collagen type XIV alpha 1 chain

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr 8:120,124,454...120,373,573
Ensembl chr 8:120,059,780...120,373,573

G

collagen type XVI alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 1:31,652,263...31,704,017
Ensembl chr 1:31,652,263...31,704,319

G

collagen type XVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type I alpha 2 chain

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

collagen type XXII alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr 8:138,588,235...138,914,041
Ensembl chr 8:138,588,235...138,914,041

G

collagen type XXIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr 5:178,237,618...178,590,393
Ensembl chr 5:178,237,476...178,590,393

G

collagen type XXVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 7:7,338,194...7,543,870
Ensembl chr 7:7,356,203...7,535,873

G

collagen type III alpha 1 chain

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

collagen type IV alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr13:110,148,963...110,307,157
Ensembl chr13:110,148,963...110,307,202

G

collagen type IV alpha 2 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr13:110,307,284...110,513,209
Ensembl chr13:110,305,812...110,513,209

G

collagen type V alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 9:134,641,803...134,844,843
Ensembl chr 9:134,641,803...134,844,843

G

collagen type V alpha 2 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 2:189,031,898...189,441,111
Ensembl chr 2:189,031,898...189,225,312

G

collagen type VI alpha 1 chain

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]
Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein

PMID:32272095 PMID:35093514

NCBI chr21:45,981,770...46,005,048
Ensembl chr21:45,981,770...46,005,050

G

collagen type VI alpha 2 chain

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr21:46,098,112...46,132,848
Ensembl chr21:46,098,112...46,132,848

G

collagen type VI alpha 4 pseudogene 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A4 protein]

NCBI chr 3:15,165,362...15,205,959
Ensembl chr 3:15,151,833...15,180,961
Ensembl chr 3:15,151,833...15,180,961

G

collagen type VIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr 3:99,638,594...99,799,217
Ensembl chr 3:99,638,475...99,799,226

G

coronin 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076

G

coronin 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr12:108,645,109...108,731,518
Ensembl chr12:108,645,109...108,731,526

G

coactosin like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr16:84,565,596...84,618,078
Ensembl chr16:84,565,596...84,618,078

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 2:97,646,062...97,648,383
Ensembl chr 2:97,646,062...97,648,383

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829

G

carboxypeptidase A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 7:130,380,494...130,388,108
Ensembl chr 7:130,380,339...130,388,114

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr13:46,053,186...46,105,033
Ensembl chr13:46,053,186...46,105,033

G

complement C3d receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr 1:207,454,328...207,489,892
Ensembl chr 1:207,453,024...207,489,895

G

capping protein inhibiting regulator of actin dynamics

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr 4:56,049,098...56,330,609
Ensembl chr 4:56,049,098...56,330,609

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr17:45,784,320...45,835,828
Ensembl chr17:45,784,277...45,835,828

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 7:30,651,942...30,700,103
Ensembl chr 7:30,651,942...30,700,129

G

cysteine rich secretory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 6:49,834,257...49,877,096
Ensembl chr 6:49,834,257...49,877,096

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 3:33,114,014...33,147,773
Ensembl chr 3:33,114,014...33,147,773

G

colony stimulating factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992

G

colony stimulating factor 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr22:36,913,628...36,940,439
Ensembl chr22:36,913,628...36,940,439

G

colony stimulating factor 3

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 1:36,466,043...36,483,314
Ensembl chr 1:36,466,043...36,483,278

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096

G

CTP synthase 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 1:40,979,696...41,012,565
Ensembl chr 1:40,979,300...41,012,565

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr11:88,293,592...88,337,736
Ensembl chr11:88,265,069...88,359,684

G

cathepsin D

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTSD protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469

G

cathepsin S

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr10:16,823,966...17,129,811
Ensembl chr10:16,823,966...17,129,811

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 3:39,263,494...39,292,966
Ensembl chr 3:39,263,495...39,281,735

G

CXADR Ig-like cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr21:17,513,043...17,636,262
Ensembl chr21:17,513,043...17,593,579

G

C-X-C motif chemokine ligand 1

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr 4:77,511,753...77,611,834
Ensembl chr 4:77,511,753...77,611,834

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr 5:135,570,679...135,578,991
Ensembl chr 5:135,570,679...135,579,279

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 6

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA
Dextran Sulfate results in increased expression of CXCL5 mRNA

PMID:19645018 PMID:29950665

NCBI chr 4:73,836,678...73,838,760
Ensembl chr 4:73,836,640...73,849,064

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL15 protein; Dextran Sulfate results in increased expression of CXCL8 protein
Dextran Sulfate results in increased expression of CXCL8 mRNA
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]

PMID:20637373 PMID:32272095 PMID:38423481

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 2:218,125,294...218,137,251
Ensembl chr 2:218,125,289...218,137,251

G

cytochrome b-245 alpha chain

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083

G

cytochrome b-245 beta chain

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr15:22,867,052...22,980,898
Ensembl chr15:22,867,052...22,981,063

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr 5:157,266,123...157,395,594
Ensembl chr 5:157,266,079...157,395,595

G

cytochrome P450 family 11 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

cytochrome P450 family 17 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP1A2 protein
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 21 subfamily A member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA

NCBI chr 6:32,038,415...32,041,644
Ensembl chr 6:32,038,327...32,041,644

G

cytochrome P450 family 24 subfamily A member 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986

G

cytochrome P450 family 26 subfamily B member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 2:72,129,238...72,147,862
Ensembl chr 2:72,129,238...72,147,862

G

cytochrome P450 family 27 subfamily B member 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr12:57,762,334...57,767,078
Ensembl chr12:57,762,334...57,768,986

G

cytochrome P450 family 2 subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 23, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA

NCBI chr10:100,105,754...100,140,151
Ensembl chr10:100,105,754...100,140,151

G

cytochrome P450 family 2 subfamily C member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 mRNA

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 2 subfamily J member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773

G

cytochrome P450 family 2 subfamily R member 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr11:14,877,440...14,892,443
Ensembl chr11:14,877,440...14,892,231

G

cytochrome P450 family 2 subfamily S member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr19:41,193,219...41,207,539
Ensembl chr19:41,193,210...41,207,539

G

cytochrome P450 family 3 subfamily A member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

cytochrome P450 family 4 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 1:46,799,046...46,819,413
Ensembl chr 1:46,757,838...46,819,413

G

cytochrome P450 family 4 subfamily F member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr19:15,673,087...15,697,174
Ensembl chr19:15,673,018...15,697,174

G

cytochrome P450 family 4 subfamily F member 22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr19:15,508,525...15,552,317
Ensembl chr19:15,508,525...15,552,317

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 1:100,186,919...100,249,834
Ensembl chr 1:100,186,919...100,249,834

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr12:91,140,484...91,182,817
Ensembl chr12:91,140,484...91,183,217

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr 1:162,630,863...162,787,405
Ensembl chr 1:162,631,373...162,787,405

G

DEPP autophagy regulator 1

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr10:44,976,128...44,978,809
Ensembl chr10:44,970,981...44,978,809

G

derlin 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr22:23,834,503...23,839,006
Ensembl chr22:23,834,503...23,839,128

G

diacylglycerol kinase beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr 7:14,145,049...14,974,858
Ensembl chr 7:14,145,049...14,974,777

G

diacylglycerol kinase iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 7:137,381,037...137,846,974
Ensembl chr 7:137,381,037...137,847,092

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167

G

dehydrogenase/reductase X-linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr  X:2,219,506...2,500,976
NCBI chr  Y:2,219,506...2,500,976
Ensembl chr  X:2,219,506...2,502,805
Ensembl chr  Y:2,219,506...2,502,805

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 4:106,921,802...107,036,313
Ensembl chr 4:106,921,802...107,283,806

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr14:100,726,892...100,738,224
Ensembl chr14:100,725,705...100,738,224

G

DM1 protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr19:45,769,717...45,782,490
Ensembl chr19:45,769,709...45,782,552

G

DMRT like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 9:22,446,824...22,455,740
Ensembl chr 9:22,446,824...22,455,740

G

DM1 locus, WD repeat containing

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr19:45,782,947...45,792,845
Ensembl chr19:45,782,947...45,792,845

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 9:128,203,379...128,255,244
Ensembl chr 9:128,191,655...128,255,248

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr 1:171,841,498...172,418,466
Ensembl chr 1:171,817,887...172,418,466

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr 8:21,908,873...21,913,690
Ensembl chr 8:21,908,873...21,913,690

G

dipeptidase 1

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr16:89,613,308...89,641,540
Ensembl chr16:89,613,308...89,638,456

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr16:67,987,390...68,000,619
Ensembl chr16:67,987,394...68,000,586

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000

G

DR1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr11:65,919,426...65,921,563
Ensembl chr11:65,919,274...65,921,563

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr11:637,269...640,706
Ensembl chr11:637,269...640,706

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr 4:9,781,634...9,784,009
Ensembl chr 4:9,781,634...9,784,009

G

deltex E3 ubiquitin ligase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr12:113,056,730...113,098,025
Ensembl chr12:113,056,730...113,098,028

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr15:45,114,326...45,118,421
Ensembl chr15:45,114,326...45,118,421

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

enoyl-CoA delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr16:2,239,402...2,251,587
Ensembl chr16:2,239,402...2,252,300

G

Ecm29 proteasome adaptor and scaffold

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 9:111,360,685...111,484,383
Ensembl chr 9:111,360,685...111,484,745

G

ectodysplasin A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:69,616,113...70,039,472
Ensembl chr X:69,616,067...70,039,472

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:66,595,637...66,639,269
Ensembl chr X:66,595,637...66,639,298

G

endothelial differentiation related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 9:136,862,119...136,866,308
Ensembl chr 9:136,862,119...136,866,308

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 1:41,478,775...41,484,683
Ensembl chr 1:41,478,775...41,484,683

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr11:62,559,596...62,573,891
Ensembl chr11:62,559,596...62,574,086

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr11:65,866,441...65,872,800
Ensembl chr11:65,866,441...65,873,592

G

EF-hand domain family member D2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 1:15,409,888...15,430,339
Ensembl chr 1:15,409,888...15,430,339

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899

G

egl-9 family hypoxia inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr19:40,799,191...40,808,434
Ensembl chr19:40,798,996...40,808,434

G

EH domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr11:64,851,642...64,879,693
Ensembl chr11:64,851,642...64,888,296

G

EH domain containing 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EHD4 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein

NCBI chr15:41,895,933...41,972,557
Ensembl chr15:41,895,933...41,972,557

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr 3:185,190,624...185,254,049
Ensembl chr 3:185,190,624...185,281,990

G

euchromatic histone lysine methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr 6:31,879,759...31,897,698
Ensembl chr 6:31,879,759...31,897,698

G

eukaryotic translation initiation factor 2 alpha kinase 2

increases phosphorylation
multiple interactions

Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr 2:37,099,210...37,156,980
Ensembl chr 2:37,099,210...37,157,522

G

eukaryotic translation initiation factor 3 subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr10:119,033,670...119,080,817
Ensembl chr10:119,033,670...119,080,817

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr17:7,306,999...7,312,463
Ensembl chr17:7,306,999...7,312,463

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 2:99,337,389...99,401,326
Ensembl chr 2:99,337,389...99,401,326

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr19:852,303...856,243
Ensembl chr19:851,014...856,247

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr20:46,366,050...46,406,615
Ensembl chr20:46,366,050...46,432,985

G

ER membrane protein complex subunit 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr 8:108,443,624...108,489,196
Ensembl chr 8:108,443,601...108,489,196

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr16:10,528,422...10,580,598
Ensembl chr16:10,528,422...10,580,632

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 9:127,815,016...127,854,658
Ensembl chr 9:127,811,130...127,854,773

G

enolase 1

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190

G

enolase 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr17:4,948,710...4,957,129
Ensembl chr17:4,948,092...4,957,131

G

glutamyl aminopeptidase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ENPEP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 4:110,476,155...110,565,285
Ensembl chr 4:110,365,733...110,565,285

G

ectonucleoside triphosphate diphosphohydrolase 5 (inactive)

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr14:73,955,329...74,019,288
Ensembl chr14:73,958,010...74,019,399

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,510...41,180,077

G

epoxide hydrolase 1

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 1:8,011,727...8,026,309
Ensembl chr 1:8,004,404...8,026,309

G

endothelial cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr11:124,753,126...124,762,290
Ensembl chr11:124,752,583...124,762,290

G

estrogen receptor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

Enah/Vasp-like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr14:99,971,422...100,144,236
Ensembl chr14:99,971,449...100,144,236

G

EWS RNA binding protein 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr22:29,268,268...29,300,521
Ensembl chr22:29,268,009...29,300,525

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr 4:186,266,189...186,289,681
Ensembl chr 4:186,266,189...186,289,681

G

coagulation factor XIII A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr 6:6,144,084...6,320,662
Ensembl chr 6:6,144,084...6,321,013

G

coagulation factor II thrombin receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 1:46,394,317...46,413,845
Ensembl chr 1:46,394,317...46,413,848

G

fatty acid binding protein 4

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354

G

family with sequence similarity 229 member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 1:32,361,270...32,362,485
Ensembl chr 1:32,361,270...32,364,278

G

family with sequence similarity 50 member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr 6:3,831,894...3,851,317
Ensembl chr 6:3,849,373...3,851,320

G

family with sequence similarity 98 member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr15:38,454,127...38,487,710
Ensembl chr15:38,454,127...38,487,710

G

FAU ubiquitin like and ribosomal protein S30 fusion

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAU protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr11:65,120,630...65,122,134
Ensembl chr11:65,120,630...65,122,177

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 3:13,549,125...13,638,404
Ensembl chr 3:13,549,125...13,638,422

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr14:91,869,411...91,947,694
Ensembl chr14:91,869,411...91,947,987

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr15:48,408,313...48,645,709
Ensembl chr15:48,408,313...48,645,721

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 1:11,648,387...11,654,429
Ensembl chr 1:11,637,018...11,655,785

G

Fc epsilon receptor Ig

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr 1:161,215,295...161,219,245
Ensembl chr 1:161,215,234...161,220,699

G

Fc gamma receptor Ia

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 1:149,782,694...149,800,609
Ensembl chr 1:149,782,671...149,791,675

G

Fc gamma receptor IIb

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr 1:161,647,243...161,678,654
Ensembl chr 1:161,663,143...161,678,654

G

Fc gamma receptor IIIa

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr 1:161,541,759...161,550,737
Ensembl chr 1:161,541,759...161,550,968

G

fucose kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA

NCBI chr16:70,454,595...70,480,274
Ensembl chr16:70,454,595...70,480,274

G

ferredoxin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FDX1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr11:110,429,331...110,464,884
Ensembl chr11:110,429,948...110,464,884

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr17:74,862,497...74,872,994
Ensembl chr17:74,862,497...74,873,031

G

FERM domain containing kindlin 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FERMT3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]

PMID:32272095 PMID:35999755

NCBI chr11:64,205,920...64,223,891
Ensembl chr11:64,205,926...64,223,896

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr19:35,448,257...35,451,767
Ensembl chr19:35,443,907...35,451,767

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr10:93,566,665...93,590,072
Ensembl chr10:93,566,665...93,604,480

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr 5:171,419,647...171,457,626
Ensembl chr 5:171,419,647...171,457,626

G

fibroblast growth factor 19

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr10:101,770,109...101,780,369
Ensembl chr10:101,770,109...101,780,371

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498

G

fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144

G

fibrinogen like 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr 8:17,864,389...17,895,538
Ensembl chr 8:17,864,380...17,910,365

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:136,146,702...136,211,359
Ensembl chr X:136,146,702...136,211,359

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 2:105,357,712...105,438,529
Ensembl chr 2:105,357,712...105,438,513

G

four and a half LIM domains 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FHL3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 1:37,996,770...38,005,514
Ensembl chr 1:37,996,764...38,005,606

G

filamin A

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:154,348,531...154,374,634
Ensembl chr X:154,348,524...154,374,634

G

flotillin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FLOT2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr17:28,879,339...28,897,733
Ensembl chr17:28,879,335...28,897,733

G

fms related receptor tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145

G

fms related receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr 5:180,601,506...180,650,298
Ensembl chr 5:180,601,506...180,649,624

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr 1:203,340,628...203,351,122
Ensembl chr 1:203,340,628...203,351,758

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr20:22,580,998...22,585,490
Ensembl chr20:22,580,998...22,585,455

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr19:45,864,326...45,873,797
Ensembl chr19:45,863,989...45,873,797

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:71,095,851...71,103,532
Ensembl chr X:71,095,851...71,103,535

G

forkhead box P3

increases methylation
increases expression
multiple interactions

Dextran Sulfate results in increased methylation of FOXP3 gene
Dextran Sulfate results in increased expression of FOXP3 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 1:74,198,242...74,208,702
Ensembl chr 1:74,198,238...74,234,086

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr19:51,745,172...51,751,878
Ensembl chr19:51,745,172...51,804,115

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr19:51,761,180...51,770,531
Ensembl chr19:51,752,026...51,770,531

G

formyl peptide receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr19:51,795,157...51,826,190
Ensembl chr19:51,795,157...51,826,190

G

FRAT regulator of WNT signaling pathway 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr10:97,332,497...97,334,729
Ensembl chr10:97,332,497...97,334,729

G

follicle stimulating hormone subunit beta

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FSHB protein
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr 2:48,962,157...49,154,515
Ensembl chr 2:48,962,157...49,154,527

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134

G

follistatin like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr19:676,392...683,385
Ensembl chr19:676,392...683,392

G

FUS RNA binding protein

increases expression

Dextran Sulfate results in increased expression of FUS mRNA

NCBI chr16:31,180,110...31,194,871
Ensembl chr16:31,180,138...31,196,963

G

FXYD domain containing ion transport regulator 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA
Dextran Sulfate results in decreased expression of FXYD1 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:35,137,188...35,143,109
Ensembl chr19:35,138,824...35,143,109

G

FXYD domain containing ion transport regulator 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr19:35,115,823...35,124,324
Ensembl chr19:35,115,823...35,124,324

G

FXYD domain containing ion transport regulator 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr10:43,371,636...43,376,335
Ensembl chr10:43,371,636...43,376,335

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452

G

frizzled class receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 7:91,264,433...91,271,326
Ensembl chr 7:91,264,433...91,271,326

G

frizzled class receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr11:86,945,679...86,955,395
Ensembl chr11:86,945,679...86,955,395

G

frizzled class receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 2:207,762,598...207,769,906
Ensembl chr 2:207,762,598...207,769,906

G

frizzled class receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr 8:103,298,494...103,332,866
Ensembl chr 8:103,298,433...103,332,866

G

frizzled class receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 2:202,033,855...202,038,441
Ensembl chr 2:202,033,855...202,038,441

G

frizzled class receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr10:35,638,247...35,642,296
Ensembl chr10:35,638,247...35,642,296

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr 6:29,602,238...29,633,183
Ensembl chr 6:29,555,629...29,633,976

G

gamma-aminobutyric acid type A receptor subunit alpha2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230

G

gamma-aminobutyric acid type A receptor subunit alpha5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr15:26,866,719...26,949,208
Ensembl chr15:26,866,911...26,949,208

G

gamma-aminobutyric acid type A receptor subunit beta2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr 5:161,288,436...161,548,404
Ensembl chr 5:161,288,429...161,549,044

G

gamma-aminobutyric acid type A receptor subunit delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 1:2,019,345...2,030,758
Ensembl chr 1:2,019,329...2,030,758

G

glutamate decarboxylase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 2:170,813,210...170,861,151
Ensembl chr 2:170,813,213...170,861,151

G

UDP-galactose-4-epimerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781

G

galactokinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr15:49,155,774...49,367,740
Ensembl chr15:49,155,656...49,367,869

G

galactose mutarotase

increases expression

Dextran Sulfate results in increased expression of GALM mRNA

NCBI chr 2:38,666,114...38,734,765
Ensembl chr 2:38,666,081...38,741,237

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr 5:154,190,733...154,420,984
Ensembl chr 5:154,190,730...154,420,984

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 9:98,807,670...98,850,081
Ensembl chr 9:98,807,670...98,850,081

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr 3:16,174,680...16,248,224
Ensembl chr 3:16,174,680...16,231,992

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr14:69,259,631...69,386,337
Ensembl chr14:69,259,277...69,357,033

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr11:11,270,877...11,622,005
Ensembl chr11:11,270,877...11,622,005

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr 1:230,057,789...230,282,122
Ensembl chr 1:230,057,990...230,282,122

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr12:89,519,412...89,524,796
Ensembl chr12:89,519,412...89,524,796

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 2:157,257,705...157,318,491
Ensembl chr 2:157,257,705...157,318,491

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr12:51,351,252...51,391,673
Ensembl chr12:51,351,247...51,392,867

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr 4:173,168,811...173,323,967
Ensembl chr 4:173,168,811...173,323,967

G

polypeptide N-acetylgalactosaminyltransferase like 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr 4:171,813,404...173,041,559
Ensembl chr 4:171,812,254...173,041,559

G

GAR1 ribonucleoprotein

increases expression

Dextran Sulfate results in increased expression of GAR1 mRNA

NCBI chr 4:109,815,510...109,824,737
Ensembl chr 4:109,815,510...109,824,740

G

growth arrest specific 8

increases expression

Dextran Sulfate results in increased expression of GAS8 mRNA

NCBI chr16:90,019,633...90,044,960
Ensembl chr16:90,019,629...90,044,975

G

gastrin

decreases response to substance
multiple interactions

GAST protein modified form results in decreased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

PMID:16618411 PMID:29950665

NCBI chr17:41,712,331...41,715,969
Ensembl chr17:41,712,331...41,715,969

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA

NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201

G

guanylate binding protein family member 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GBP9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]

NCBI chr 1:89,364,059...89,388,160
Ensembl chr 1:89,364,059...89,388,160

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr15:59,611,783...59,622,723
Ensembl chr15:59,594,875...59,640,239

G

GDP dissociation inhibitor 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein

NCBI chr X:154,437,154...154,443,467
Ensembl chr X:154,436,913...154,443,467

G

glutamine--fructose-6-phosphate transaminase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 2:69,319,780...69,387,227
Ensembl chr 2:69,319,780...69,387,250

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA

NCBI chr 5:180,300,698...180,353,336
Ensembl chr 5:180,300,698...180,353,336

G

GDP-L-fucose synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA

NCBI chr 8:143,612,618...143,618,048
Ensembl chr 8:143,612,618...143,618,048

G

golgi associated olfactory signaling regulator

increases expression

Dextran Sulfate results in increased expression of GFY mRNA

NCBI chr19:49,423,747...49,428,987
Ensembl chr19:49,423,749...49,428,987

G

gamma-glutamylcyclotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA

NCBI chr 7:30,496,621...30,504,829
Ensembl chr 7:30,496,621...30,504,841

G

gametogenetin binding protein 1 (pseudogene)

increases expression

Dextran Sulfate results in increased expression of GGNBP1 mRNA

NCBI chr 6:33,583,699...33,589,026
Ensembl chr 6:33,583,699...33,589,026

G

growth hormone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA

NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839

G

ghrelin and obestatin prepropeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA

NCBI chr 3:10,285,666...10,292,947
Ensembl chr 3:10,285,666...10,292,947

G

galactosidase beta 1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein]

NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202

G

galactosidase beta 1 like 2

decreases expression

Dextran Sulfate results in decreased expression of GLB1L2 mRNA

NCBI chr11:134,331,988...134,376,324
Ensembl chr11:134,331,988...134,378,341

G

GLI family zinc finger 1

decreases expression

Dextran Sulfate results in decreased expression of GLI1 mRNA

NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268

G

GLI family zinc finger 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA

NCBI chr 7:41,960,949...42,264,268
Ensembl chr 7:41,960,949...42,264,100

G

glucagon like peptide 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA

NCBI chr 6:39,048,781...39,091,303
Ensembl chr 6:39,048,781...39,091,303

G

glutaminase

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein]

NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552

G

GDP-mannose 4,6-dehydratase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA

NCBI chr 6:1,623,806...2,245,605
Ensembl chr 6:1,623,806...2,245,605

G

G protein subunit alpha 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA

NCBI chr19:3,094,362...3,123,999
Ensembl chr19:3,094,362...3,123,999

G

G protein subunit alpha 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA

NCBI chr 7:2,728,105...2,844,308
Ensembl chr 7:2,721,822...2,870,786

G

G protein subunit alpha 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA

NCBI chr 9:77,423,079...77,648,322
Ensembl chr 9:77,423,079...77,648,322

G

G protein subunit alpha 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA

NCBI chr19:3,136,033...3,163,749
Ensembl chr19:3,136,033...3,163,749

G

G protein subunit alpha z

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA

NCBI chr22:23,070,519...23,125,032
Ensembl chr22:23,070,519...23,125,032

G

G protein subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA

NCBI chr12:6,840,925...6,847,393
Ensembl chr12:6,839,954...6,847,393

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA

NCBI chr 9:36,214,441...36,276,978
Ensembl chr 9:36,214,441...36,277,042

G

G protein subunit gamma 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA

NCBI chr 1:235,547,685...235,650,608
Ensembl chr 1:235,547,685...235,650,754

G

G protein subunit gamma 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA

NCBI chr19:2,511,219...2,702,694
Ensembl chr19:2,511,219...2,702,694

G

G protein subunit gamma 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA

NCBI chr19:46,633,953...46,639,326
Ensembl chr19:46,633,953...46,636,541

G

G protein subunit gamma transducin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA

NCBI chr17:49,206,234...49,210,574
Ensembl chr17:49,202,791...49,210,574

G

G protein nucleolar 1 (putative)

increases expression

Dextran Sulfate results in increased expression of GNL1 mRNA

NCBI chr 6:30,541,381...30,556,489
Ensembl chr 6:30,541,381...30,556,489

G

glucosamine-phosphate N-acetyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA

NCBI chr14:52,775,193...52,791,607
Ensembl chr14:52,775,193...52,791,668

G

glutamic-oxaloacetic transaminase 1

increases activity
multiple interactions

Dextran Sulfate results in increased activity of GOT1 protein
Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of GOT1 protein]

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

glycoprotein Ib platelet subunit beta

increases expression

Dextran Sulfate results in increased expression of GP1BB mRNA

NCBI chr22:19,723,539...19,724,771
Ensembl chr22:19,723,539...19,724,771

G

glycoprotein VI platelet

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GP6 protein

NCBI chr19:55,013,705...55,038,264
Ensembl chr19:55,013,705...55,038,264

G

G protein-coupled bile acid receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA

NCBI chr 2:218,259,496...218,263,861
Ensembl chr 2:218,259,496...218,263,861

G

glypican 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA

NCBI chr X:133,300,103...133,415,489
Ensembl chr X:133,300,103...133,415,489

G

glucose-6-phosphate isomerase

decreases expression

Dextran Sulfate results in decreased expression of GPI protein

NCBI chr19:34,359,718...34,402,413
Ensembl chr19:34,359,480...34,402,413

G

glycoprotein nmb

increases expression

Dextran Sulfate results in increased expression of GPNMB mRNA

NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108

G

G protein-coupled receptor 119

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA

NCBI chr X:130,379,449...130,385,674
Ensembl chr X:130,379,449...130,385,674

G

G protein-coupled receptor 137B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA

NCBI chr 1:236,142,539...236,208,907
Ensembl chr 1:236,142,505...236,221,865

G

G protein-coupled receptor 149

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA

NCBI chr 3:154,334,943...154,430,190
Ensembl chr 3:154,334,943...154,430,190

G

G protein-coupled receptor 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA

NCBI chr 3:98,531,978...98,534,681
Ensembl chr 3:98,531,978...98,534,681

G

G protein-coupled receptor 152

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA

NCBI chr11:67,451,301...67,452,729
Ensembl chr11:67,451,301...67,452,729

G

G protein-coupled receptor 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA

NCBI chr 2:127,646,153...127,652,639
Ensembl chr 2:127,645,864...127,652,639

G

G protein-coupled receptor 176

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA

NCBI chr15:39,799,008...39,920,266
Ensembl chr15:39,799,008...39,920,936

G

G protein-coupled receptor 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA

NCBI chr 8:141,356,470...141,367,286
Ensembl chr 8:141,356,470...141,367,286

G

G protein-coupled receptor 27

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA

NCBI chr 3:71,753,855...71,756,496
Ensembl chr 3:71,753,855...71,756,496

G

G protein-coupled receptor 37 like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA

NCBI chr 1:202,122,917...202,133,592
Ensembl chr 1:202,122,886...202,133,592

G

G protein-coupled receptor 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA

NCBI chr 2:132,416,805...132,646,582
Ensembl chr 2:132,416,805...132,646,582

G

G protein-coupled receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA

NCBI chr19:45,589,764...45,602,212
Ensembl chr19:45,589,764...45,602,212

G

G protein-coupled receptor 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA

NCBI chr X:151,176,584...151,182,856
Ensembl chr X:151,176,584...151,181,465

G

G protein-coupled receptor 68

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA

NCBI chr14:91,232,532...91,270,790
Ensembl chr14:91,232,532...91,253,925

G

G protein-coupled receptor 83

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA

NCBI chr11:94,377,316...94,401,419
Ensembl chr11:94,377,316...94,401,419

G

G protein-coupled receptor 85

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA

NCBI chr 7:113,082,285...113,087,724
Ensembl chr 7:113,078,331...113,087,778

G

G protein-coupled receptor 88

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA

NCBI chr 1:100,538,139...100,542,021
Ensembl chr 1:100,538,139...100,542,021

G

G protein-coupled receptor class C group 5 member B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA

NCBI chr16:19,856,691...19,885,634
Ensembl chr16:19,856,691...19,886,167

G

G protein-coupled receptor class C group 5 member D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA

NCBI chr12:12,940,575...12,952,170
Ensembl chr12:12,940,575...12,952,170

G

glutamic--pyruvic transaminase

decreases activity

Dextran Sulfate results in decreased activity of GPT protein

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

glutamic--pyruvic transaminase 2

decreases expression

Dextran Sulfate results in decreased expression of GPT2 mRNA

NCBI chr16:46,884,362...46,931,289
Ensembl chr16:46,884,362...46,931,289

G

glutathione peroxidase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA

NCBI chr 5:151,020,591...151,028,988
Ensembl chr 5:151,020,591...151,028,988

G

glutathione peroxidase 4

decreases expression
multiple interactions
decreases activity

Dextran Sulfate results in decreased expression of GPX4 mRNA; Dextran Sulfate results in decreased expression of GPX4 protein
gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 mRNA]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 protein]
Dextran Sulfate results in decreased activity of GPX4 protein

NCBI chr19:1,103,994...1,106,779
Ensembl chr19:1,103,982...1,106,791

G

glutathione peroxidase 6

decreases expression

Dextran Sulfate results in decreased expression of GPX6 mRNA

NCBI chr 6:28,503,296...28,515,793
Ensembl chr 6:28,503,296...28,528,215

G

glutathione peroxidase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA

NCBI chr 1:52,602,371...52,609,051
Ensembl chr 1:52,602,371...52,609,051

G

glutathione peroxidase 8 (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA

NCBI chr 5:55,160,171...55,167,297
Ensembl chr 5:55,160,167...55,167,297

G

growth factor receptor bound protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA

NCBI chr17:75,318,076...75,405,678
Ensembl chr17:75,318,076...75,405,709

G

growth factor receptor bound protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA

NCBI chr17:39,737,938...39,747,285
Ensembl chr17:39,737,927...39,747,291

G

gremlin 1, DAN family BMP antagonist

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GREM1 protein]

NCBI chr15:32,718,004...32,745,106
Ensembl chr15:32,718,004...32,745,106

G

glutamate ionotropic receptor kainate type subunit 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA

NCBI chr11:120,511,748...120,988,906
Ensembl chr11:120,511,746...120,988,906

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA

NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA

NCBI chr19:48,393,668...48,444,931
Ensembl chr19:48,393,668...48,444,931

G

G protein-coupled receptor kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA

NCBI chr22:25,564,675...25,729,294
Ensembl chr22:25,564,675...25,729,294

G

G protein-coupled receptor kinase 6

multiple interactions
decreases response to substance

GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
GRK6 results in decreased susceptibility to Dextran Sulfate

NCBI chr 5:177,425,523...177,442,891
Ensembl chr 5:177,403,204...177,442,901

G

glutamate metabotropic receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA

NCBI chr 6:34,018,643...34,155,622
Ensembl chr 6:34,018,643...34,155,622

G

gastrin releasing peptide receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA

NCBI chr X:16,123,565...16,153,518
Ensembl chr X:16,123,565...16,153,518

G

gasdermin D

increases cleavage
multiple interactions

Dextran Sulfate results in increased cleavage of GSDMD protein
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]

NCBI chr 8:143,553,387...143,563,062
Ensembl chr 8:143,553,207...143,563,062

G

gelsolin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA

NCBI chr 9:121,201,483...121,332,842
Ensembl chr 9:121,207,794...121,332,843

G

glutathione-disulfide reductase

multiple interactions
decreases activity

Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of GSR protein]

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

glutathione synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA

NCBI chr20:34,928,432...34,956,027
Ensembl chr20:34,928,432...34,956,027

G

glutathione S-transferase kappa 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA

NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854

G

glutathione S-transferase mu 1

decreases expression

Dextran Sulfate results in decreased expression of GSTM1 mRNA

NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039

G

glutathione S-transferase mu 2

decreases expression

Dextran Sulfate results in decreased expression of GSTM2 mRNA

NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551

G

glutathione S-transferase mu 3

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GSTM3 protein]

NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038

G

glutathione S-transferase omega 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO1 mRNA

NCBI chr10:104,254,173...104,267,455
Ensembl chr10:104,235,356...104,267,459

G

glutathione S-transferase omega 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO2 mRNA

NCBI chr10:104,269,184...104,304,950
Ensembl chr10:104,268,873...104,304,950

G

glutathione S-transferase theta 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTT2 mRNA

NCBI chr22:23,957,414...23,961,206
Ensembl chr22:23,957,414...23,961,195

G

glutathione S-transferase theta 3, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTT3 mRNA

G

general transcription factor IIF subunit 1

increases expression

Dextran Sulfate results in increased expression of GTF2F1 mRNA

NCBI chr19:6,379,572...6,393,164
Ensembl chr19:6,379,572...6,393,981

G

guanylate cyclase activator 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GUCA1A mRNA

NCBI chr 6:42,173,364...42,180,056
Ensembl chr 6:42,173,364...42,181,338

G

guanylate cyclase activator 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCA1B mRNA

NCBI chr 6:42,183,284...42,194,956
Ensembl chr 6:42,183,284...42,194,956

G

guanylate cyclase activator 2B

increases expression

Dextran Sulfate results in increased expression of GUCA2B protein

NCBI chr 1:42,153,410...42,155,820
Ensembl chr 1:42,153,410...42,155,820

G

guanylate cyclase 2F, retinal

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCY2F mRNA

NCBI chr X:109,372,906...109,482,086
Ensembl chr X:109,372,906...109,482,086

G

guanylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GUK1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GUK1 protein]

NCBI chr 1:228,140,084...228,148,955
Ensembl chr 1:228,139,962...228,148,984

G

gulonolactone (L-) oxidase, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GULO mRNA

NCBI chr 8:27,577,611...27,589,073
Ensembl chr 8:27,560,274...27,589,073

G

granzyme A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GZMA mRNA

NCBI chr 5:55,102,646...55,110,252
Ensembl chr 5:55,102,646...55,110,252

G

H1.10 linker histone

increases expression

Dextran Sulfate results in increased expression of H1F10 mRNA

NCBI chr 3:129,314,771...129,316,286
Ensembl chr 3:129,314,771...129,316,286

G

hydroxyacyl-CoA dehydrogenase

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of HADH protein]

NCBI chr 4:107,989,889...108,035,171
Ensembl chr 4:107,989,714...108,035,241

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HADHB mRNA

NCBI chr 2:26,244,939...26,290,465
Ensembl chr 2:26,243,170...26,290,465

G

hemoglobin subunit alpha 1

increases expression

Dextran Sulfate results in increased expression of HBA-A1 mRNA

NCBI chr16:176,680...177,522
Ensembl chr16:176,680...177,522

G

hemoglobin subunit beta

increases expression

Dextran Sulfate results in increased expression of HBB-B1 mRNA

NCBI chr11:5,225,464...5,227,071
Ensembl chr11:5,225,464...5,229,395

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN2 mRNA

NCBI chr19:589,881...617,159
Ensembl chr19:589,881...617,159

G

hyperpolarization activated cyclic nucleotide gated potassium channel 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN3 mRNA

NCBI chr 1:155,277,463...155,289,848
Ensembl chr 1:155,277,463...155,289,848

G

hyperpolarization activated cyclic nucleotide gated potassium channel 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN4 mRNA

NCBI chr15:73,319,859...73,368,958
Ensembl chr15:73,319,859...73,368,958

G

HDGF like 2

increases expression

Dextran Sulfate results in increased expression of HDGFL2 mRNA

NCBI chr19:4,472,297...4,502,207
Ensembl chr19:4,472,297...4,502,208

G

hephaestin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HEPH mRNA

NCBI chr X:66,162,671...66,268,863
Ensembl chr X:66,162,671...66,268,867

G

hes family bHLH transcription factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HES1 mRNA

NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HIF1A protein
resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of HIF1A protein]

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

HIRA interacting protein 3

increases expression

Dextran Sulfate results in increased expression of HIRIP3 mRNA

NCBI chr16:29,992,321...29,996,096
Ensembl chr16:29,992,330...29,996,074

G

hexokinase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HK1 protein
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]

NCBI chr10:69,270,000...69,401,882
Ensembl chr10:69,269,984...69,401,884

G

hexokinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HK3 mRNA

NCBI chr 5:176,880,869...176,899,346
Ensembl chr 5:176,880,869...176,899,346

G

major histocompatibility complex, class II, DM alpha

increases expression

Dextran Sulfate results in increased expression of H2-DMA mRNA

NCBI chr 6:32,948,618...32,953,097
Ensembl chr 6:32,948,613...32,969,094

G

major histocompatibility complex, class II, DO beta

increases expression

Dextran Sulfate results in increased expression of H2-OB mRNA

NCBI chr 6:32,812,763...32,817,002
Ensembl chr 6:32,812,763...32,820,466

G

major histocompatibility complex, class II, DQ alpha 1

increases expression

Dextran Sulfate results in increased expression of H2-AA mRNA

NCBI chr 6:32,637,406...32,655,272
Ensembl chr 6:32,628,179...32,647,062

G

major histocompatibility complex, class II, DQ beta 1

increases expression

Dextran Sulfate results in increased expression of H2-AB1 mRNA

NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383

G

major histocompatibility complex, class II, DR beta 1

increases expression

Dextran Sulfate results in increased expression of H2-EB1 mRNA

NCBI chr 6:32,578,775...32,589,848
Ensembl chr 6:32,577,902...32,589,848

G

major histocompatibility complex, class I, G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-M3 mRNA

NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125

G

high mobility group box 1

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein]

NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597

G

heme oxygenase 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HMOX1 mRNA; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]
Dextran Sulfate results in decreased expression of HMOX1 mRNA; Dextran Sulfate results in decreased expression of HMOX1 protein

PMID:29950665 PMID:30142311 PMID:33974900 PMID:36135333

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

HNF1 homeobox A

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of HNF1A protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1A mRNA

PMID:29680209 PMID:29950665

NCBI chr12:120,978,543...121,002,512
Ensembl chr12:120,978,543...121,002,512

G

HNF1 homeobox B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1B mRNA

NCBI chr17:37,686,431...37,745,059
Ensembl chr17:37,686,431...37,745,059

G

hepatocyte nuclear factor 4 alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4A mRNA

NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845

G

hepatocyte nuclear factor 4 gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4G mRNA

NCBI chr 8:75,407,649...75,566,834
Ensembl chr 8:75,407,914...75,566,834

G

heterogeneous nuclear ribonucleoprotein A0

increases expression

Dextran Sulfate results in increased expression of HNRNPA0 mRNA

NCBI chr 5:137,745,651...137,754,363
Ensembl chr 5:137,745,651...137,754,363

G

hook microtubule tethering protein 2

increases expression

Dextran Sulfate results in increased expression of HOOK2 mRNA

NCBI chr19:12,763,003...12,792,350
Ensembl chr19:12,763,003...12,872,740

G

haptoglobin

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HP protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of HP protein; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of HP protein]

PMID:31807802 PMID:35999755

NCBI chr16:72,054,505...72,061,055
Ensembl chr16:72,054,505...72,061,055

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HPGD mRNA

NCBI chr 4:174,490,175...174,522,893
Ensembl chr 4:174,490,175...174,523,154

G

heparanase

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of HPSE protein

NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153

G

histamine receptor H3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HRH3 mRNA

NCBI chr20:62,214,960...62,220,278
Ensembl chr20:62,214,960...62,220,278

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD11B1 mRNA
Dextran Sulfate results in increased expression of HSD11B1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD11B2 mRNA

NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553

G

hydroxysteroid 17-beta dehydrogenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD17B1 mRNA

NCBI chr17:42,552,923...42,555,214
Ensembl chr17:42,552,922...42,555,214

G

hydroxysteroid 17-beta dehydrogenase 3

decreases expression

Dextran Sulfate results in decreased expression of HSD17B3 mRNA

NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176

G

hydroxysteroid 17-beta dehydrogenase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD17B6 mRNA

NCBI chr12:56,763,324...56,787,790
Ensembl chr12:56,752,161...56,787,790

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases expression

Dextran Sulfate results in decreased expression of HSD3B1 mRNA

NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054

G

heat shock protein 90 alpha family class A member 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSP90AA1 mRNA
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA]

NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699

G

heat shock protein 90 alpha family class B member 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSP90AB1 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein]

NCBI chr 6:44,246,194...44,253,883
Ensembl chr 6:44,246,166...44,253,888

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1A mRNA

NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1B mRNA

NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254

G

heat shock protein family A (Hsp70) member 8

decreases expression

Dextran Sulfate results in decreased expression of HSPA8 protein

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

heat shock protein family B (small) member 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSPB1 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of HSPB1 mRNA]

NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,305,813

G

heparan sulfate proteoglycan 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSPG2 mRNA

NCBI chr 1:21,822,244...21,937,310
Ensembl chr 1:21,822,244...21,937,310

G

5-hydroxytryptamine receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR1B mRNA

NCBI chr 6:77,460,924...77,463,491
Ensembl chr 6:77,460,924...77,463,491

G

5-hydroxytryptamine receptor 1D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HTR1D mRNA

NCBI chr 1:23,191,895...23,217,502
Ensembl chr 1:23,191,895...23,217,502

G

5-hydroxytryptamine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HTR4 mRNA

NCBI chr 5:148,451,032...148,654,527
Ensembl chr 5:148,446,042...148,677,235

G

5-hydroxytryptamine receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR7 mRNA

NCBI chr10:90,740,823...90,858,039
Ensembl chr10:90,740,823...90,858,039

G

HtrA serine peptidase 1

decreases expression

Dextran Sulfate results in decreased expression of HTRA1 mRNA

NCBI chr10:122,461,553...122,514,907
Ensembl chr10:122,458,551...122,514,907

G

intercellular adhesion molecule 1

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM1 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]

PMID:21724996 PMID:24038091 PMID:25448682 PMID:25472953 PMID:29950665 More...

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM4 mRNA

NCBI chr19:10,286,955...10,288,520
Ensembl chr19:10,286,955...10,288,522

G

inducible T cell costimulator ligand

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICOSL mRNA

NCBI chr21:44,216,981...44,240,943
Ensembl chr21:44,215,382...44,241,446

G

isocitrate dehydrogenase (NADP(+)) 1

decreases expression

Dextran Sulfate results in decreased expression of IDH1 mRNA

NCBI chr 2:208,236,227...208,255,071
Ensembl chr 2:208,236,229...208,266,074

G

indoleamine 2,3-dioxygenase 1

increases expression

Dextran Sulfate results in increased expression of IDO1 mRNA

NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790

G

immediate early response 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IER3 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IER3 mRNA]

NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548

G

interferon gamma inducible protein 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFI204 mRNA

NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155

G

interferon induced transmembrane protein 3

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFITM3 protein]

PMID:26271895 PMID:32272095

NCBI chr11:319,676...320,860
Ensembl chr11:319,676...329,475

G

interferon alpha and beta receptor subunit 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNAR2 mRNA

NCBI chr21:33,229,938...33,265,664
Ensembl chr21:33,205,282...33,265,675

G

interferon gamma

multiple interactions
increases expression
increases secretion

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNG protein; [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of IFNG protein]
Dextran Sulfate results in increased expression of IFNG mRNA; Dextran Sulfate results in increased expression of IFNG protein

PMID:12105854 PMID:19940103 PMID:20637373 PMID:21068411 PMID:21359540 More...

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interferon kappa

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNK mRNA

NCBI chr 9:27,524,290...27,526,498
Ensembl chr 9:27,524,290...27,526,498

G

insulin like growth factor 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IGF1 protein

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor 2 mRNA binding protein 3

multiple interactions

[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein; Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein]

NCBI chr 7:23,310,209...23,470,491
Ensembl chr 7:23,310,209...23,470,491

G

insulin like growth factor binding protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP2 mRNA

NCBI chr 2:216,632,828...216,664,436
Ensembl chr 2:216,632,828...216,664,436

G

insulin like growth factor binding protein 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA

NCBI chr17:40,443,450...40,457,725
Ensembl chr17:40,443,450...40,457,725

G

insulin like growth factor binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP6 mRNA

NCBI chr12:53,097,667...53,102,340
Ensembl chr12:53,097,436...53,102,345

G

Indian hedgehog signaling molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IHH mRNA

NCBI chr 2:219,054,424...219,060,921
Ensembl chr 2:219,054,424...219,060,921

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions
increases expression
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IKBKB mRNA; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]

PMID:20155626 PMID:25472953 PMID:29950665

NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460

G

inhibitor of nuclear factor kappa B kinase subunit epsilon

increases phosphorylation
multiple interactions

Dextran Sulfate results in increased phosphorylation of IKBKE protein
GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of IKBKE protein]

NCBI chr 1:206,470,476...206,496,889
Ensembl chr 1:206,470,476...206,496,889

G

IKAROS family zinc finger 3

increases expression

Dextran Sulfate results in increased expression of IKZF3 mRNA

NCBI chr17:39,757,715...39,864,312
Ensembl chr17:39,757,715...39,864,312

G

interleukin 10

multiple interactions
decreases expression
increases expression

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester promotes the reaction [Dextran Sulfate results in increased expression of IL10 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; celastrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL10 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Resveratrol promotes the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]
Dextran Sulfate results in decreased expression of IL10 mRNA; Dextran Sulfate results in decreased expression of IL10 protein
Dextran Sulfate results in increased expression of IL10 mRNA; Dextran Sulfate results in increased expression of IL10 protein
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]

PMID:20132809 PMID:20881082 PMID:21068411 PMID:21359540 PMID:21724996 More...

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11 mRNA; Melatonin inhibits the reaction [Dextran Sulfate results in decreased expression of IL11 protein]

PMID:29950665 PMID:36265525

NCBI chr19:55,364,382...55,370,463
Ensembl chr19:55,364,382...55,370,463

G

interleukin 11 receptor subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11RA1 mRNA

NCBI chr 9:34,652,185...34,661,902
Ensembl chr 9:34,652,162...34,661,902

G

interleukin 12A

affects response to substance

IL12A protein affects the susceptibility to Dextran Sulfate

NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019

G

interleukin 12B

multiple interactions
increases expression

ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]

NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863

G

interleukin 15

increases response to substance
multiple interactions
decreases expression

IL15 protein results in increased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL15 mRNA
Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of IL15 mRNA]

PMID:16162679 PMID:16375993 PMID:29950665

NCBI chr 4:141,636,583...141,733,987
Ensembl chr 4:141,636,583...141,733,987

G

interleukin 17A

multiple interactions
affects response to substance
increases expression

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL17A mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]
Dextran Sulfate results in increased expression of IL17A mRNA; Dextran Sulfate results in increased expression of IL17A protein
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]

PMID:20881082 PMID:21068411 PMID:24384223 PMID:24548422 PMID:26074695 More...

NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638

G

interleukin 18

affects response to substance
increases expression
multiple interactions
increases secretion

IL18 protein affects the susceptibility to Dextran Sulfate
Dextran Sulfate results in increased expression of IL18 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]
Dextran Sulfate results in increased secretion of IL18 protein
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL18 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL18 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased secretion of IL18 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]
Dextran Sulfate results in increased expression of IL18 mRNA; Dextran Sulfate results in increased expression of IL18 protein

PMID:12940437 PMID:25448682 PMID:29950665 PMID:30270565 PMID:32470352 More...

NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096

G

interleukin 18 receptor 1

affects response to substance

IL18R1 protein affects the susceptibility to Dextran Sulfate

NCBI chr 2:102,355,796...102,398,776
Ensembl chr 2:102,311,529...102,398,777

G

interleukin 18 receptor accessory protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL18RAP mRNA

NCBI chr 2:102,418,621...102,452,565
Ensembl chr 2:102,418,689...102,452,565

G

interleukin 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL19 mRNA

NCBI chr 1:206,770,773...206,842,981
Ensembl chr 1:206,770,764...206,842,981

G

interleukin 1 alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL1A mRNA; Dextran Sulfate results in increased expression of IL1A protein
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1A protein; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA]

PMID:23894361 PMID:25472953 PMID:29672155 PMID:34273909 PMID:36265525

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 1 beta

multiple interactions
increases expression
increases cleavage
increases secretion

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL1B protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1B mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; phenethyl isothiocyanate inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Quercetin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]
Dextran Sulfate results in increased expression of IL1B mRNA; Dextran Sulfate results in increased expression of IL1B protein
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]

PMID:15652231 PMID:16774945 PMID:19028472 PMID:19285099 PMID:19645018 More...

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 1 receptor type 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1R1 mRNA]

PMID:29950665 PMID:32033881

NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874

G

interleukin 1 receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R2 mRNA

NCBI chr 2:101,991,960...102,028,544
Ensembl chr 2:101,991,960...102,028,544

G

interleukin 1 receptor antagonist

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein]

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 2

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of IL2 mRNA
Dextran Sulfate results in decreased expression of IL2 protein
5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]

PMID:21068411 PMID:25472953 PMID:32272095 PMID:35889507

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 20 receptor subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RA mRNA

NCBI chr 6:136,999,971...137,044,965
Ensembl chr 6:136,999,971...137,045,180

G

interleukin 20 receptor subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RB mRNA

NCBI chr 3:136,957,983...137,011,085
Ensembl chr 3:136,946,230...137,011,085

G

interleukin 22

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL22 mRNA
[Azoxymethane co-treated with Dextran Sulfate] results in increased secretion of IL22 protein; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL22 mRNA]; Dronabinol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased secretion of IL22 protein]

PMID:27920257 PMID:32942172 PMID:34998820 PMID:37385329

NCBI chr12:68,248,242...68,253,604
Ensembl chr12:68,248,242...68,253,604

G

interleukin 22 receptor subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL22RA1 mRNA

NCBI chr 1:24,119,771...24,143,140
Ensembl chr 1:24,119,771...24,143,140

G

interleukin 22 receptor subunit alpha 2

decreases expression

Dextran Sulfate results in decreased expression of IL22RA2 mRNA

NCBI chr 6:137,143,820...137,173,644
Ensembl chr 6:137,143,820...137,173,648

G

interleukin 23 subunit alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL23A protein
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL23A mRNA]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]

PMID:20881082 PMID:24384223 PMID:36265525

NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410

G

interleukin 27 receptor subunit alpha

decreases response to substance

IL27RA protein results in decreased susceptibility to Dextran Sulfate

NCBI chr19:14,031,762...14,053,218
Ensembl chr19:14,031,762...14,053,218

G

interleukin 2 receptor subunit gamma

increases expression

Dextran Sulfate results in increased expression of IL2RG mRNA

NCBI chr X:71,107,404...71,111,577
Ensembl chr X:71,107,404...71,112,108

G

interleukin 33

multiple interactions
increases expression

flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL33 mRNA]

NCBI chr 9:6,215,149...6,257,983
Ensembl chr 9:6,215,786...6,257,983

G

interleukin 3 receptor subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL3RA mRNA

NCBI chr  X:1,336,785...1,382,689
NCBI chr  Y:1,336,785...1,382,689
Ensembl chr  Y:1,336,616...1,382,689
Ensembl chr  X:1,336,616...1,382,689

G

interleukin 4

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of IL4 mRNA
Dextran Sulfate results in increased expression of IL4 protein
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA]

PMID:12105854 PMID:21068411 PMID:25777935 PMID:28438436

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 4 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL4RA mRNA

NCBI chr16:27,313,756...27,364,778
Ensembl chr16:27,313,668...27,364,778

G

interleukin 6

multiple interactions
increases secretion
affects expression
increases expression

(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of IL6 protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]
Dextran Sulfate results in increased expression of IL6 mRNA; Dextran Sulfate results in increased expression of IL6 protein
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]

PMID:15652231 PMID:16774945 PMID:19285099 PMID:19940103 PMID:20079348 More...

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

interleukin 6 cytokine family signal transducer

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL6ST mRNA

NCBI chr 5:55,935,095...55,994,963
Ensembl chr 5:55,935,095...55,995,022

G

interleukin 7 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL7R mRNA

NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603

G

integrin linked kinase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ILK protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ILK protein

NCBI chr11:6,603,774...6,610,870
Ensembl chr11:6,603,708...6,610,874

G

inhibin subunit beta A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA

NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834

G

inhibin subunit beta B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBB mRNA

NCBI chr 2:120,346,136...120,351,803
Ensembl chr 2:120,346,136...120,351,803

G

INO80 complex subunit B

increases expression

Dextran Sulfate results in increased expression of INO80B mRNA

NCBI chr 2:74,455,087...74,457,944
Ensembl chr 2:74,455,087...74,457,944

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INPP5D mRNA

NCBI chr 2:233,060,342...233,207,903
Ensembl chr 2:233,059,967...233,207,903

G

insulin like 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INSL5 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of INSL5 protein]

PMID:29950665 PMID:32272095

NCBI chr 1:66,797,740...66,801,276
Ensembl chr 1:66,797,740...66,801,276

G

IQ motif and ankyrin repeat containing 1

increases expression

Dextran Sulfate results in increased expression of IQANK1 mRNA

NCBI chr 8:143,734,139...143,790,645
Ensembl chr 8:143,734,139...143,790,645

G

IQ motif containing D

increases expression

Dextran Sulfate results in increased expression of IQCD mRNA

NCBI chr12:113,195,446...113,221,094
Ensembl chr12:113,195,441...113,221,094

G

inositol 1,4,5-triphosphate receptor associated 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IRAG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IRAG1 protein]

NCBI chr11:10,573,095...10,693,755
Ensembl chr11:10,573,091...10,693,988

G

interleukin 1 receptor associated kinase 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK1 protein

NCBI chr X:154,010,507...154,019,902
Ensembl chr X:154,010,506...154,019,902

G

interleukin 1 receptor associated kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRAK2 mRNA

NCBI chr 3:10,164,919...10,243,745
Ensembl chr 3:10,164,919...10,243,745

G

interleukin 1 receptor associated kinase 4

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK4 protein

NCBI chr12:43,758,951...43,789,541
Ensembl chr12:43,758,944...43,798,307

G

interferon regulatory factor 4

multiple interactions

IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443

G

insulin receptor substrate 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRS1 mRNA

NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820

G

iroquois homeobox 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRX6 mRNA

NCBI chr16:55,324,203...55,330,756
Ensembl chr16:55,324,203...55,330,756

G

integrin subunit alpha 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGA10 mRNA

NCBI chr 1:145,891,208...145,910,050
Ensembl chr 1:145,891,208...145,910,111

G

integrin subunit alpha 2b

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA2B mRNA

NCBI chr17:44,372,181...44,389,649
Ensembl chr17:44,372,180...44,389,649

G

integrin subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA4 mRNA

NCBI chr 2:181,457,205...181,538,940
Ensembl chr 2:181,457,202...181,538,940

G

integrin subunit alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA5 mRNA

NCBI chr12:54,395,261...54,419,266
Ensembl chr12:54,395,261...54,419,266

G

integrin subunit alpha 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA6 mRNA

NCBI chr 2:172,427,336...172,506,459
Ensembl chr 2:172,234,216...172,506,459

G

integrin subunit alpha L

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]

NCBI chr16:30,472,742...30,523,185
Ensembl chr16:30,472,658...30,523,567

G

integrin subunit beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB1 mRNA

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

integrin subunit beta 2

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITGB2 protein]

PMID:29950665 PMID:32272095

NCBI chr21:44,885,953...44,928,815
Ensembl chr21:44,885,953...44,931,989

G

integrin subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB3 mRNA

NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743

G

integrin subunit beta 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGB6 mRNA

NCBI chr 2:160,099,671...160,200,272
Ensembl chr 2:160,099,667...160,271,888

G

integrin subunit beta 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB8 mRNA

NCBI chr 7:20,329,766...20,415,754
Ensembl chr 7:20,330,702...20,415,754

G

inter-alpha-trypsin inhibitor heavy chain 1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH1 protein]

NCBI chr 3:52,777,599...52,792,068
Ensembl chr 3:52,777,595...52,792,068

G

inter-alpha-trypsin inhibitor heavy chain 3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH3 protein

NCBI chr 3:52,794,796...52,808,797
Ensembl chr 3:52,794,768...52,808,799

G

inter-alpha-trypsin inhibitor heavy chain 4

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ITIH4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH4 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH4 protein]

PMID:32272095 PMID:35999755

NCBI chr 3:52,812,962...52,830,672
Ensembl chr 3:52,812,962...52,830,688

G

inter-alpha-trypsin inhibitor heavy chain 5

decreases expression

Dextran Sulfate results in decreased expression of ITIH5 mRNA

NCBI chr10:7,559,270...7,666,966
Ensembl chr10:7,559,270...7,666,998

G

inositol-trisphosphate 3-kinase A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPKA mRNA

NCBI chr15:41,493,874...41,503,551
Ensembl chr15:41,493,393...41,503,551

G

inositol 1,4,5-trisphosphate receptor type 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPR3 mRNA

NCBI chr 6:33,621,322...33,696,562
Ensembl chr 6:33,620,365...33,696,574

G

Janus kinase 2

multiple interactions
increases phosphorylation

BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of JAK2 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of JAK2 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]

PMID:32272095 PMID:38164749 PMID:38437956 PMID:38663798

NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948

G

junctional adhesion molecule 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM2 mRNA

NCBI chr21:25,639,258...25,717,562
Ensembl chr21:25,639,258...25,717,562

G

junctional adhesion molecule 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM3 mRNA

NCBI chr11:134,069,072...134,152,001
Ensembl chr11:134,069,071...134,152,001

G

junction adhesion molecule like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAML mRNA

NCBI chr11:118,193,725...118,225,011
Ensembl chr11:118,193,725...118,225,092

G

joining chain of multimeric IgA and IgM

decreases expression

Dextran Sulfate results in decreased expression of JCHAIN mRNA

NCBI chr 4:70,655,541...70,666,508
Ensembl chr 4:70,655,541...70,681,817

G

Josephin domain containing 2

increases expression

Dextran Sulfate results in increased expression of JOSD2 mRNA

NCBI chr19:50,505,998...50,511,191
Ensembl chr19:50,505,998...50,511,220

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Dextran Sulfate results in increased expression of and affects the localization of JUN protein; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

kalirin RhoGEF kinase

decreases expression

Dextran Sulfate results in decreased expression of KALRN protein

NCBI chr 3:124,033,369...124,726,325
Ensembl chr 3:124,033,369...124,726,325

G

KASH domain containing 5

increases expression

Dextran Sulfate results in increased expression of KASH5 mRNA

NCBI chr19:49,388,249...49,417,990
Ensembl chr19:49,388,219...49,417,990

G

potassium voltage-gated channel subfamily A regulatory beta subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNAB1 mRNA

NCBI chr 3:156,118,211...156,539,138
Ensembl chr 3:156,037,701...156,538,756

G

potassium voltage-gated channel subfamily E regulatory subunit 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNE3 mRNA

NCBI chr11:74,454,841...74,467,549
Ensembl chr11:74,454,841...74,467,729

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNH2 mRNA

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

G

potassium inwardly rectifying channel subfamily J member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNJ9 mRNA

NCBI chr 1:160,081,538...160,090,563
Ensembl chr 1:160,081,538...160,090,563

G

potassium two pore domain channel subfamily K member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNK4 mRNA

NCBI chr11:64,291,302...64,300,031
Ensembl chr11:64,291,302...64,300,031

G

potassium two pore domain channel subfamily K member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNK5 mRNA

NCBI chr 6:39,188,971...39,229,475
Ensembl chr 6:39,188,971...39,229,475

G

KH domain containing 1

increases expression

Dextran Sulfate results in increased expression of KHDC1A mRNA

NCBI chr 6:73,241,314...73,310,378
Ensembl chr 6:73,241,314...73,310,365

G

KiSS-1 metastasis suppressor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KISS1 mRNA

NCBI chr 1:204,190,341...204,196,491
Ensembl chr 1:204,190,341...204,196,491

G

KIT proto-oncogene, receptor tyrosine kinase

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KIT mRNA
Dextran Sulfate results in decreased expression of KIT mRNA

PMID:29950665 PMID:35093514

NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783

G

KIT ligand

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KITL mRNA

NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851

G

klotho beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KLB mRNA

NCBI chr 4:39,406,930...39,451,533
Ensembl chr 4:39,406,930...39,451,533

G

kinesin light chain 3

increases expression

Dextran Sulfate results in increased expression of KLC3 mRNA

NCBI chr19:45,340,750...45,351,519
Ensembl chr19:45,333,434...45,351,520

G

kallikrein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1 mRNA

NCBI chr19:50,819,146...50,823,787
Ensembl chr19:50,819,146...50,823,787

G

kallikrein related peptidase 3

multiple interactions

Dextran Sulfate affects the reaction [SEMG2 protein binds to KLK3 protein]

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

karyopherin subunit alpha 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of KPNA1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of KPNA1 protein]

NCBI chr 3:122,421,902...122,514,939
Ensembl chr 3:122,421,902...122,514,945

G

KRAS proto-oncogene, GTPase

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of KRAS protein]

PMID:29950665 PMID:32272095

NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936

G

keratin 16

decreases expression

Dextran Sulfate results in decreased expression of KRT16 protein

NCBI chr17:41,609,778...41,612,767
Ensembl chr17:41,609,778...41,615,899

G

L1 cell adhesion molecule

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of L1CAM mRNA
Dextran Sulfate results in decreased expression of L1CAM protein

PMID:29950665 PMID:35999755

NCBI chr X:153,861,514...153,886,173
Ensembl chr X:153,861,514...153,886,173

G

laminin subunit alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMA5 mRNA

NCBI chr20:62,309,065...62,367,312
Ensembl chr20:62,307,955...62,367,312

G

laminin subunit beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMB2 mRNA

NCBI chr 3:49,121,114...49,133,050
Ensembl chr 3:49,121,114...49,133,118

G

laminin subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LAMB3 mRNA

NCBI chr 1:209,614,870...209,652,425
Ensembl chr 1:209,614,870...209,652,425

G

laminin subunit gamma 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMC1 mRNA

NCBI chr 1:183,023,420...183,145,592
Ensembl chr 1:183,023,420...183,145,592

G

laminin subunit gamma 3

decreases expression

Dextran Sulfate results in decreased expression of LAMC3 mRNA

NCBI chr 9:131,009,174...131,094,473
Ensembl chr 9:131,009,174...131,094,473

G

lysosomal protein transmembrane 5

increases expression

Dextran Sulfate results in increased expression of LAPTM5 mRNA

NCBI chr 1:30,732,469...30,757,774
Ensembl chr 1:30,732,469...30,757,774

G

La ribonucleoprotein 1, translational regulator

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LARP1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of LARP1 protein]

NCBI chr 5:154,682,979...154,817,605
Ensembl chr 5:154,682,986...154,817,605

G

LIM and SH3 protein 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LASP1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LASP1 protein

NCBI chr17:38,870,058...38,921,770
Ensembl chr17:38,869,859...38,921,770

G

linker for activation of T cells family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAT2 mRNA

NCBI chr 7:74,210,006...74,229,834
Ensembl chr 7:74,199,652...74,229,834

G

layilin

decreases expression

Dextran Sulfate results in decreased expression of LAYN protein

NCBI chr11:111,540,280...111,561,745
Ensembl chr11:111,540,280...111,561,745

G

lipocalin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of LCN2 mRNA
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]

PMID:23894361 PMID:36519841

NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453

G

lactase

multiple interactions
decreases activity

Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of LCT protein]

NCBI chr 2:135,787,850...135,837,184
Ensembl chr 2:135,787,850...135,837,184

G

lactate dehydrogenase A

decreases expression

Dextran Sulfate results in decreased expression of LDHA protein

NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425

G

lactate dehydrogenase A like 6B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LDHAL6B mRNA

NCBI chr15:59,206,843...59,208,588
Ensembl chr15:59,206,843...59,208,588

G

lactate dehydrogenase B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LDHB mRNA

NCBI chr12:21,635,342...21,657,842
Ensembl chr12:21,635,342...21,757,857

G

lactate dehydrogenase C

increases activity
multiple interactions

Dextran Sulfate results in increased activity of LDHC protein
gingerol inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]

NCBI chr11:18,412,318...18,452,063
Ensembl chr11:18,412,318...18,452,063

G

lymphoid enhancer binding factor 1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein]

NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956

G

leukocyte receptor cluster member 1

increases expression

Dextran Sulfate results in increased expression of LENG1 mRNA

NCBI chr19:54,155,161...54,159,721
Ensembl chr19:54,155,161...54,159,721

G

leptin

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP protein

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

leucine rich repeat containing G protein-coupled receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LGR4 mRNA

NCBI chr11:27,365,961...27,472,790
Ensembl chr11:27,365,961...27,472,790

G

leucine rich repeat containing G protein-coupled receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LGR6 mRNA

NCBI chr 1:202,193,799...202,319,761
Ensembl chr 1:202,193,799...202,319,781

G

luteinizing hormone subunit beta

multiple interactions
decreases expression

gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]

NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of LHCGR mRNA
Dextran Sulfate results in decreased expression of LHCGR mRNA

PMID:29950665 PMID:35093514

NCBI chr 2:48,686,774...48,755,724
Ensembl chr 2:48,686,774...48,755,730

G

LIM domain kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LIMK1 mRNA

NCBI chr 7:74,083,804...74,122,525
Ensembl chr 7:74,082,933...74,122,525

G

LIM zinc finger domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of LIMS1 protein

NCBI chr 2:108,533,671...108,687,246
Ensembl chr 2:108,533,671...108,687,246

G

lamin B2

increases expression

Dextran Sulfate results in increased expression of LMNB2 mRNA

NCBI chr19:2,428,166...2,456,959
Ensembl chr19:2,427,638...2,456,959

G

lysyl oxidase

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOX mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of LOX mRNA]

PMID:29950665 PMID:32033881 PMID:35093514

NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413

G

lysyl oxidase like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOXL1 mRNA

NCBI chr15:73,926,462...73,952,136
Ensembl chr15:73,925,989...73,952,137

G

lysophosphatidic acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR2 mRNA

NCBI chr19:19,623,655...19,628,220
Ensembl chr19:19,623,655...19,628,930

G

lysophosphatidic acid receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LPAR3 mRNA

NCBI chr 1:84,811,602...84,893,206
Ensembl chr 1:84,811,602...84,893,206

G

lysophosphatidic acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR4 mRNA

NCBI chr X:78,747,720...78,758,714
Ensembl chr X:78,747,709...78,758,714

G

leucine rich alpha-2-glycoprotein 1

increases expression

Dextran Sulfate results in increased expression of LRG1 mRNA

PMID:23894361 PMID:35093514

NCBI chr19:4,536,402...4,540,036
Ensembl chr19:4,536,402...4,540,036

G

LDL receptor related protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LRP1 mRNA

NCBI chr12:57,128,483...57,213,361
Ensembl chr12:57,128,483...57,213,361

G

LDL receptor related protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LRP2 mRNA

NCBI chr 2:169,127,109...169,362,534
Ensembl chr 2:169,127,109...169,362,534

G

LDL receptor related protein 5

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA]

NCBI chr11:68,298,412...68,449,275
Ensembl chr11:68,312,591...68,449,275

G

leucine rich repeat containing 61

increases expression

Dextran Sulfate results in increased expression of LRRC61 mRNA

NCBI chr 7:150,309,499...150,338,156
Ensembl chr 7:150,323,263...150,338,156

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

Dextran Sulfate results in increased expression of LSM4 mRNA

NCBI chr19:18,306,236...18,323,076
Ensembl chr19:18,306,236...18,323,112

G

lymphotoxin alpha

increases expression

Dextran Sulfate results in increased expression of LTA mRNA

NCBI chr 6:31,560,610...31,574,324
Ensembl chr 6:31,572,054...31,574,324

G

leukotriene A4 hydrolase

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LTA4H protein

NCBI chr12:96,000,753...96,043,520
Ensembl chr12:96,000,753...96,043,520

G

leukotriene B4 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTB4R1 mRNA

NCBI chr14:24,311,502...24,318,036
Ensembl chr14:24,311,450...24,318,036

G

latent transforming growth factor beta binding protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP3 mRNA

NCBI chr11:65,538,559...65,558,359
Ensembl chr11:65,538,559...65,558,930

G

latent transforming growth factor beta binding protein 4

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP4 mRNA
Dextran Sulfate results in decreased expression of LTBP4 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:40,593,166...40,629,820
Ensembl chr19:40,592,883...40,629,818

G

lactotransferrin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LTF protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of LTF protein

NCBI chr 3:46,435,645...46,485,234
Ensembl chr 3:46,435,645...46,485,234

G

lymphocyte antigen 6 family member D

decreases expression

Dextran Sulfate results in decreased expression of LY6D mRNA

NCBI chr 8:142,784,882...142,786,539
Ensembl chr 8:142,784,882...142,786,539

G

lymphocyte antigen 6 family member E

decreases expression

Dextran Sulfate results in decreased expression of LY6E mRNA

NCBI chr 8:143,018,529...143,022,409
Ensembl chr 8:143,017,982...143,023,832

G

lymphocyte antigen 86

increases expression

Dextran Sulfate results in increased expression of LY86 mRNA

NCBI chr 6:6,588,720...6,654,982
Ensembl chr 6:6,588,108...6,654,983

G

lysozyme

increases expression

Dextran Sulfate results in increased expression of LYZ2 mRNA

NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234

G

MAF bZIP transcription factor F

increases expression

Dextran Sulfate results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

myelin associated glycoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAG mRNA

NCBI chr19:35,292,161...35,313,807
Ensembl chr19:35,292,125...35,313,807

G

mesencephalic astrocyte derived neurotrophic factor

decreases expression

Dextran Sulfate results in decreased expression of MANF protein

NCBI chr 3:51,385,291...51,389,397
Ensembl chr 3:51,385,291...51,389,397

G

monoamine oxidase A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MAOA mRNA

NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817

G

microtubule associated protein 1 light chain 3 beta

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of and results in increased lipidation of MAP1LC3B protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mitogen-activated protein kinase kinase kinase 7

increases phosphorylation
multiple interactions

Dextran Sulfate results in increased phosphorylation of MAP3K7 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAP3K7 protein]

NCBI chr 6:90,513,579...90,587,072
Ensembl chr 6:90,513,573...90,587,086

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK1 protein; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]

PMID:19931517 PMID:20155626 PMID:35889507 PMID:36806191

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAPK10 mRNA

NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK3 protein; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]

PMID:19931517 PMID:20155626 PMID:35889507 PMID:36806191

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

microtubule associated protein RP/EB family member 1

decreases expression

Dextran Sulfate results in decreased expression of MAPRE1 protein

NCBI chr20:32,819,777...32,850,405
Ensembl chr20:32,819,954...32,850,405

G

MBL associated serine protease 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MASP1 mRNA

NCBI chr 3:187,217,282...187,291,737
Ensembl chr 3:187,217,282...187,291,980

G

matrilin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MATN4 mRNA

NCBI chr20:45,293,450...45,308,684
Ensembl chr20:45,293,445...45,308,529

G

mitochondrial antiviral signaling protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MAVS protein]

NCBI chr20:3,846,834...3,876,118
Ensembl chr20:3,846,799...3,876,123

G

methyl-CpG binding domain protein 3

increases expression

Dextran Sulfate results in increased expression of MBD3 mRNA

NCBI chr19:1,573,596...1,592,865
Ensembl chr19:1,573,596...1,592,865

G

melanocortin 4 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MC4R mRNA

NCBI chr18:60,371,062...60,372,775
Ensembl chr18:60,371,062...60,372,775

G

minichromosome maintenance complex component 3

increases expression

Dextran Sulfate results in increased expression of MCM3 protein

NCBI chr 6:52,264,015...52,284,742
Ensembl chr 6:52,264,014...52,284,881

G

malate dehydrogenase 1

decreases expression

Dextran Sulfate results in decreased expression of MDH1 protein

NCBI chr 2:63,588,963...63,607,197
Ensembl chr 2:63,588,609...63,607,197

G

midkine

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MDK mRNA

NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837

G

malic enzyme 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ME1 protein

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

meprin A subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1A mRNA

NCBI chr 6:46,793,389...46,845,984
Ensembl chr 6:46,793,389...46,839,778

G

meprin A subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1B mRNA

NCBI chr18:32,190,039...32,220,404
Ensembl chr18:32,185,069...32,220,404

G

mesoderm posterior bHLH transcription factor 1

increases expression

Dextran Sulfate results in increased expression of MESP1 mRNA

NCBI chr15:89,732,446...89,751,249
Ensembl chr15:89,749,875...89,751,249

G

microfibril associated protein 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP4 mRNA

NCBI chr17:19,383,445...19,387,190
Ensembl chr17:19,383,442...19,387,190

G

microfibril associated protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP5 mRNA

NCBI chr12:8,645,943...8,662,826
Ensembl chr12:8,637,346...8,662,888

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of MFGE8 mRNA

NCBI chr15:88,898,683...88,913,379
Ensembl chr15:88,898,683...88,913,468

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression
decreases expression

Dextran Sulfate results in increased expression of MFSD2A mRNA
Dextran Sulfate results in decreased expression of MFSD2A mRNA

PMID:23894361 PMID:35093514

NCBI chr 1:39,955,145...39,969,956
Ensembl chr 1:39,955,112...39,969,968

G

matrix Gla protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MGP mRNA

NCBI chr12:14,880,864...14,885,854
Ensembl chr12:14,880,864...14,885,857

G

microsomal glutathione S-transferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST2 mRNA

NCBI chr 4:139,665,819...139,754,618
Ensembl chr 4:139,665,768...139,740,745

G

microsomal glutathione S-transferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST3 mRNA

NCBI chr 1:165,631,234...165,656,136
Ensembl chr 1:165,631,213...165,661,796

G

macrophage migration inhibitory factor

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MIF mRNA
MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr22:23,894,383...23,895,223
Ensembl chr22:23,894,383...23,895,227

G

myo-inositol oxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MIOX mRNA

NCBI chr22:50,486,859...50,490,648
Ensembl chr22:50,486,784...50,490,648

G

marker of proliferation Ki-67

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein]
Dextran Sulfate results in decreased expression of MKI67 protein
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein; berberrubine inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of MKI67 protein]

PMID:19028472 PMID:34273909 PMID:37871880 PMID:38648921

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

mixed lineage kinase domain like pseudokinase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MLKL protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MLKL protein]

NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960

G

membrane metalloendopeptidase

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MME mRNA
Dextran Sulfate results in decreased expression of MME mRNA

PMID:29950665 PMID:35093514

NCBI chr 3:155,024,202...155,183,729
Ensembl chr 3:155,024,124...155,183,704

G

matrix metallopeptidase 10

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MMP10 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP10 mRNA

PMID:20824662 PMID:29950665

NCBI chr11:102,770,502...102,780,628
Ensembl chr11:102,770,502...102,780,628

G

matrix metallopeptidase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP12 mRNA

NCBI chr11:102,862,736...102,874,982
Ensembl chr11:102,862,736...102,874,982

G

matrix metallopeptidase 13

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP13 mRNA; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]

PMID:12105854 PMID:19285099 PMID:20824662 PMID:23894361 PMID:29950665

NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732

G

matrix metallopeptidase 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP14 mRNA

NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041

G

matrix metallopeptidase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMP15 mRNA

NCBI chr16:58,025,754...58,046,901
Ensembl chr16:58,025,754...58,046,901

G

matrix metallopeptidase 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP19 mRNA

NCBI chr12:55,835,433...55,842,936
Ensembl chr12:55,835,433...55,842,966

G

matrix metallopeptidase 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MMP2 mRNA; Dextran Sulfate results in increased expression of MMP2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP2 mRNA; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 protein]

PMID:19285099 PMID:29950665

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 23B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP23 mRNA

NCBI chr 1:1,632,173...1,634,654
Ensembl chr 1:1,632,163...1,635,263

G

matrix metallopeptidase 3

multiple interactions
increases expression

Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]

PMID:19285099 PMID:20824662 PMID:32033881

NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609

G

matrix metallopeptidase 7

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA]

NCBI chr11:102,520,508...102,530,747
Ensembl chr11:102,520,508...102,530,750

G

matrix metallopeptidase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP8 mRNA

NCBI chr11:102,711,796...102,724,954
Ensembl chr11:102,711,796...102,727,050

G

matrix metallopeptidase 9

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP9 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]
Dextran Sulfate results in increased expression of MMP9 mRNA; Dextran Sulfate results in increased expression of MMP9 protein

PMID:19285099 PMID:27125760 PMID:29950665 PMID:30972795 PMID:32033881

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

methylmalonyl-CoA mutase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMUT mRNA

NCBI chr 6:49,430,360...49,463,253
Ensembl chr 6:49,430,360...49,463,253

G

myeloid cell nuclear differentiation antigen

increases expression

Dextran Sulfate results in increased expression of PYHIN1 mRNA

NCBI chr 1:158,831,351...158,849,502
Ensembl chr 1:158,831,351...158,849,506

G

meiosis specific nuclear structural 1

increases expression

Dextran Sulfate results in increased expression of MNS1 mRNA

NCBI chr15:56,428,724...56,465,137
Ensembl chr15:56,421,544...56,465,137

G

MORN repeat containing 2

increases expression

Dextran Sulfate results in increased expression of MORN2 mRNA

NCBI chr 2:38,875,976...38,882,709
Ensembl chr 2:38,875,976...38,929,072

G

macrophage expressed 1

increases expression

Dextran Sulfate results in increased expression of MPEG1 mRNA

NCBI chr11:59,208,510...59,212,927
Ensembl chr11:59,208,510...59,212,927

G

mannose phosphate isomerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MPI mRNA

NCBI chr15:74,890,042...74,902,219
Ensembl chr15:74,890,005...74,902,219

G

megakaryocyte and platelet inhibitory receptor G6b

decreases expression

Dextran Sulfate results in decreased expression of MPIG6B protein

NCBI chr 6:31,720,296...31,726,714
Ensembl chr 6:31,718,594...31,726,714

G

myeloperoxidase

multiple interactions
increases secretion
increases activity
increases expression

Capsaicin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; lafutidine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Oligosaccharides inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; zileuton inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]
Dextran Sulfate results in increased secretion of MPO protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of MPO protein; [Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [Streptozocin co-treated with Dextran Sulfate] results in increased activity of MPO protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; icilin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; morphiceptin analog inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Tropisetron inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]

PMID:11766996 PMID:15339030 PMID:15573930 PMID:16375993 PMID:20637373 More...

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

mannose receptor C-type 1

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein]
Dextran Sulfate results in decreased expression of MRC1 mRNA; Dextran Sulfate results in decreased expression of MRC1 protein

PMID:25026504 PMID:38164749

NCBI chr10:17,809,348...17,911,164
Ensembl chr10:17,809,348...17,911,164

G

mitochondrial ribosomal protein L20

increases expression

Dextran Sulfate results in increased expression of MRPL20 mRNA

NCBI chr 1:1,401,909...1,407,293
Ensembl chr 1:1,401,909...1,407,293

G

membrane spanning 4-domains A1

increases expression

Dextran Sulfate results in increased expression of MS4A1 mRNA

NCBI chr11:60,455,847...60,470,752
Ensembl chr11:60,455,846...60,470,752

G

methylsterol monooxygenase 1

decreases expression

Dextran Sulfate results in decreased expression of MSMO1 mRNA

NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164

G

moesin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MSN mRNA

NCBI chr X:65,588,377...65,741,931
Ensembl chr X:65,588,377...65,741,931

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

increases expression

Dextran Sulfate results in increased expression of ND6 mRNA

NCBI chr MT:14,149...14,673
Ensembl chr MT:14,149...14,673

G

metallothionein 1X

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MT1 mRNA
Dextran Sulfate results in increased expression of MT1 mRNA

PMID:29950665 PMID:35093514

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

metallothionein 2A

increases expression

Dextran Sulfate results in increased expression of MT2 mRNA

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

melatonin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1A mRNA

NCBI chr 4:186,533,655...186,555,567
Ensembl chr 4:186,526,792...186,555,567

G

melatonin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1B mRNA

NCBI chr11:92,969,651...92,984,960
Ensembl chr11:92,969,651...92,985,066

G

mechanistic target of rapamycin kinase

increases expression
increases phosphorylation
multiple interactions
decreases phosphorylation

Dextran Sulfate results in increased expression of MTOR protein
Dextran Sulfate results in increased phosphorylation of MTOR protein
Dextran Sulfate results in increased expression of MTOR protein modified form
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein modified form]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]
biochanin A inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein]

PMID:26074695 PMID:27611972 PMID:31926917 PMID:32470352 PMID:38648921

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

myotrophin

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MTPN protein]

NCBI chr 7:135,926,760...135,977,359
Ensembl chr 7:135,926,760...135,977,359

G

mucin 13, cell surface associated

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC13 mRNA

NCBI chr 3:124,905,442...124,934,751
Ensembl chr 3:124,905,442...124,953,819

G

mucin 2, oligomeric mucus/gel-forming

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MUC2 mRNA; Dextran Sulfate results in decreased expression of MUC2 protein
biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of MUC2 protein]

PMID:37385329 PMID:38648921

NCBI chr11:1,074,874...1,110,508
Ensembl chr11:1,074,875...1,110,511

G

mucin 4, cell surface associated

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC4 mRNA

NCBI chr 3:195,746,771...195,811,929
Ensembl chr 3:195,746,765...195,811,973

G

muscle associated receptor tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MUSK mRNA

NCBI chr 9:110,668,791...110,806,558
Ensembl chr 9:110,668,779...110,806,558

G

myosin binding protein C1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC1 mRNA

NCBI chr12:101,594,971...101,695,841
Ensembl chr12:101,568,353...101,686,028

G

myosin binding protein C2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC2 mRNA

NCBI chr19:50,432,892...50,466,321
Ensembl chr19:50,432,892...50,466,321

G

myosin binding protein C3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC3 mRNA

NCBI chr11:47,331,406...47,352,702
Ensembl chr11:47,331,406...47,352,702

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein]

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

MYD88 innate immune signal transduction adaptor

multiple interactions

Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]; flavokawain B inhibits the reaction [Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]]

NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024

G

myosin heavy chain 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYH8 mRNA

NCBI chr17:10,390,322...10,421,950
Ensembl chr17:10,390,322...10,421,950

G

myosin heavy chain 9

decreases expression

Dextran Sulfate results in decreased expression of MYH9 protein

NCBI chr22:36,281,280...36,387,967
Ensembl chr22:36,281,280...36,388,010

G

myosin light chain 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL1 mRNA

NCBI chr 2:210,290,150...210,315,174
Ensembl chr 2:210,290,150...210,315,174

G

myosin light chain 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL3 mRNA

NCBI chr 3:46,857,872...46,882,182
Ensembl chr 3:46,835,110...46,882,178

G

myosin light chain 4

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of MYL4 protein]

NCBI chr17:47,189,433...47,227,650
Ensembl chr17:47,200,446...47,223,679

G

myosin light chain 6

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MYL6 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL6 protein

NCBI chr12:56,158,359...56,161,579
Ensembl chr12:56,158,346...56,163,496

G

myosin light chain 7

increases expression

Dextran Sulfate results in increased expression of MYL7 mRNA

NCBI chr 7:44,138,864...44,141,332
Ensembl chr 7:44,138,864...44,141,332

G

myosin light chain 9

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MYL9 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL9 protein

NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447

G

myosin light chain kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYLK2 mRNA

NCBI chr20:31,819,356...31,834,684
Ensembl chr20:31,819,308...31,834,689

G

myosin IB

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MYO1B protein]

NCBI chr 2:191,245,404...191,425,386
Ensembl chr 2:191,245,185...191,425,389

G

myosin VB

decreases expression

Dextran Sulfate results in decreased expression of MYO5B mRNA

NCBI chr18:49,822,789...50,195,147
Ensembl chr18:49,822,789...50,195,164

G

myosin VIIA

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYO7A mRNA

NCBI chr11:77,128,246...77,215,241
Ensembl chr11:77,128,246...77,215,241

G

NEDD4 binding protein 3

increases expression

Dextran Sulfate results in increased expression of N4BP3 mRNA

NCBI chr 5:178,113,532...178,127,034
Ensembl chr 5:178,113,532...178,126,081

G

sodium leak channel, non-selective

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of NALCN mRNA

NCBI chr13:101,053,776...101,417,179
Ensembl chr13:101,053,776...101,416,508

G

N-acetylneuraminate synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NANS mRNA

NCBI chr 9:98,056,732...98,083,077
Ensembl chr 9:98,056,732...98,083,077

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions
decreases expression

GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]

NCBI chr 7:103,099,776...103,150,001
Ensembl chr 7:103,099,776...103,149,560

G

N-acetyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA

NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218

G

neurocan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCAN mRNA

NCBI chr19:19,211,958...19,252,233
Ensembl chr19:19,211,958...19,252,233

G

neutral cholesterol ester hydrolase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCEH1 mRNA

NCBI chr 3:172,630,249...172,711,067
Ensembl chr 3:172,630,249...172,711,218

G

NCK interacting protein with SH3 domain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCKIPSD mRNA

NCBI chr 3:48,673,844...48,685,915
Ensembl chr 3:48,673,844...48,686,364

G

nuclear receptor corepressor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCOR2 mRNA

NCBI chr12:124,324,415...124,567,612
Ensembl chr12:124,324,415...124,567,612

G

NDRG family member 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NDRG2 protein]

NCBI chr14:21,016,763...21,070,872
Ensembl chr14:21,016,763...21,070,872

G

NADH:ubiquinone oxidoreductase complex assembly factor 3

increases expression

Dextran Sulfate results in increased expression of NDUFAF3 mRNA

NCBI chr 3:49,020,452...49,023,495
Ensembl chr 3:49,020,459...49,023,495

G

nebulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NEB mRNA

NCBI chr 2:151,485,339...151,734,476
Ensembl chr 2:151,485,336...151,734,487

G

NEDD4 E3 ubiquitin protein ligase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NEDD4 mRNA

NCBI chr15:55,826,917...55,993,612
Ensembl chr15:55,826,922...55,993,660

G

neuronal differentiation 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NEUROD1 mRNA

NCBI chr 2:181,668,295...181,680,517
Ensembl chr 2:181,668,295...181,680,827

G

nuclear factor of activated T cells 5

increases activity
decreases expression

Dextran Sulfate results in increased activity of NFAT5 protein
Dextran Sulfate results in decreased expression of NFAT5 mRNA

PMID:27920257 PMID:35093514

NCBI chr16:69,565,966...69,704,654
Ensembl chr16:69,565,094...69,704,666

G

NFE2 like bZIP transcription factor 2

affects response to substance
multiple interactions
decreases expression

NFE2L2 affects the susceptibility to Dextran Sulfate
[asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [Cholecalciferol co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; NFE2L2 results in decreased susceptibility to [Dextran Sulfate co-treated with Azoxymethane]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]
Dextran Sulfate results in decreased expression of NFE2L2 mRNA; Dextran Sulfate results in decreased expression of NFE2L2 protein

PMID:20404090 PMID:23056183 PMID:23261717 PMID:30142311 PMID:30844440 More...

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor kappa B subunit 1

multiple interactions
affects localization

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein]
Dextran Sulfate affects the localization of NFKB1 protein
monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]

PMID:19028472 PMID:23261679

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation
decreases expression
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Dextran Sulfate results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]

PMID:19940103 PMID:21724996 PMID:23261679 PMID:25472953 PMID:26190278 More...

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NFKB inhibitor like 1

increases expression

Dextran Sulfate results in increased expression of NFKBIL1 mRNA

NCBI chr 6:31,546,851...31,558,829
Ensembl chr 6:31,546,870...31,558,829

G

niban apoptosis regulator 1

decreases expression

Dextran Sulfate results in decreased expression of NIBAN1 mRNA

NCBI chr 1:184,791,032...184,974,508
Ensembl chr 1:184,790,724...184,974,508

G

nidogen 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NID2 mRNA

NCBI chr14:52,004,809...52,069,059
Ensembl chr14:52,004,809...52,069,059

G

NKD inhibitor of WNT signaling pathway 1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA]

NCBI chr16:50,548,396...50,649,249
Ensembl chr16:50,548,396...50,649,249

G

NK2 homeobox 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NKX2-2 mRNA

NCBI chr20:21,511,017...21,522,689
Ensembl chr20:21,511,017...21,514,064

G

neuroligin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN1 mRNA

NCBI chr 3:173,395,952...174,294,372
Ensembl chr 3:173,396,284...174,294,372

G

neuroligin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN3 mRNA

NCBI chr X:71,144,841...71,175,307
Ensembl chr X:71,144,821...71,175,255

G

neurolysin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NLN protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NLN protein]

NCBI chr 5:65,722,205...65,829,283
Ensembl chr 5:65,722,205...65,871,725

G

NLR family CARD domain containing 5

increases expression

Dextran Sulfate results in increased expression of NLRC5 mRNA

NCBI chr16:56,989,557...57,083,520
Ensembl chr16:56,989,485...57,083,531

G

NLR family pyrin domain containing 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLRP1A mRNA

NCBI chr17:5,501,396...5,584,509
Ensembl chr17:5,499,415...5,619,424

G

NLR family pyrin domain containing 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]]
[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of NLRP3 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]

PMID:27611972 PMID:30270565 PMID:32470352 PMID:37001609

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108

G

neuromedin B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NMB mRNA

NCBI chr15:84,655,132...84,658,199
Ensembl chr15:84,655,129...84,658,563

G

NME/NM23 nucleoside diphosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of NME1 protein

NCBI chr17:51,153,559...51,162,168
Ensembl chr17:51,153,559...51,162,428

G

NME/NM23 nucleoside diphosphate kinase 2

decreases expression

Dextran Sulfate results in decreased expression of NME2 protein

NCBI chr17:51,165,536...51,171,744
Ensembl chr17:51,165,435...51,171,744

G

neuromedin U receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NMUR2 mRNA

NCBI chr 5:152,391,546...152,405,279
Ensembl chr 5:152,391,546...152,433,368

G

nitric oxide synthase 2

multiple interactions
increases activity
increases expression
affects response to substance

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA]
Dextran Sulfate results in increased expression of NOS2 mRNA; Dextran Sulfate results in increased expression of NOS2 protein
NOS2 protein affects the susceptibility to Dextran Sulfate

PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:17449036 More...

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS3 mRNA

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

notum, palmitoleoyl-protein carboxylesterase

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA]

NCBI chr17:81,952,507...81,961,187
Ensembl chr17:81,952,507...81,961,840

G

NADPH oxidase 4

increases expression

Dextran Sulfate results in increased expression of NOX4 mRNA; Dextran Sulfate results in increased expression of NOX4 protein

NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187

G

N-acetylneuraminate pyruvate lyase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NPL protein]

NCBI chr 1:182,789,773...182,830,384
Ensembl chr 1:182,789,293...182,830,384

G

neuronal pentraxin 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NPTX1 mRNA

NCBI chr17:80,466,834...80,476,607
Ensembl chr17:80,466,834...80,477,843

G

neuropeptide Y

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY mRNA

NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862

G

neuropeptide Y receptor Y1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY1R mRNA

NCBI chr 4:163,323,962...163,344,689
Ensembl chr 4:163,323,962...163,344,832

G

neuropeptide Y receptor Y2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NPY2R mRNA

NCBI chr 4:155,173,723...155,217,076
Ensembl chr 4:155,208,636...155,217,078

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NQO1 mRNA; Dextran Sulfate results in decreased expression of NQO1 protein
gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NQO1 protein]

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group H member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1H4 mRNA

NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414

G

nuclear receptor subfamily 1 group I member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1I2 mRNA

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

G

nuclear receptor subfamily 5 group A member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR5A2 mRNA

NCBI chr 1:200,027,710...200,177,415
Ensembl chr 1:200,027,614...200,177,420

G

Nik related kinase

decreases expression

Dextran Sulfate results in decreased expression of NRK mRNA

NCBI chr X:105,821,786...105,958,610
Ensembl chr X:105,822,539...105,958,610

G

neuropilin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NRP1 mRNA

NCBI chr10:33,177,493...33,334,667
Ensembl chr10:33,177,492...33,336,262

G

netrin G1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NTNG1 mRNA

NCBI chr 1:107,140,088...107,484,923
Ensembl chr 1:107,140,007...107,484,923

G

neurotensin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NTS mRNA

NCBI chr12:85,874,295...85,882,992
Ensembl chr12:85,874,295...85,882,992

G

nucleobindin 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of NUCB1 protein

NCBI chr19:48,900,312...48,923,372
Ensembl chr19:48,900,050...48,923,473

G

nuclear distribution C, dynein complex regulator

increases expression

Dextran Sulfate results in increased expression of NUDC mRNA

NCBI chr 1:26,900,161...26,946,871
Ensembl chr 1:26,900,238...26,946,871

G

nudix hydrolase 16

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NUDT16 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NUDT16 protein]

NCBI chr 3:131,381,671...131,388,830
Ensembl chr 3:131,381,671...131,388,830

G

nucleoporin 205

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NUP205 protein]

NCBI chr 7:135,557,917...135,648,753
Ensembl chr 7:135,557,917...135,648,757

G

nuclear protein 2, transcriptional regulator

increases expression

Dextran Sulfate results in increased expression of NUPR2 mRNA

NCBI chr 7:56,114,681...56,116,417
Ensembl chr 7:56,114,681...56,116,417

G

occludin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of OCLN mRNA; Dextran Sulfate results in decreased expression of OCLN protein
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein]

PMID:23261717 PMID:27995407 PMID:35439472 PMID:35670535 PMID:36281492 More...

NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104

G

O-GlcNAcase

multiple interactions
decreases expression

Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of OGA protein]; thiamet G inhibits the reaction [Dextran Sulfate results in decreased expression of OGA protein]

NCBI chr10:101,784,450...101,818,444
Ensembl chr10:101,784,443...101,818,465

G

O-linked N-acetylglucosamine (GlcNAc) transferase

multiple interactions
increases expression

Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of OGT protein]; thiamet G inhibits the reaction [Dextran Sulfate results in increased expression of OGT protein]

NCBI chr X:71,533,104...71,575,892
Ensembl chr X:71,533,087...71,575,892

G

opsin 1, medium wave sensitive

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPN1MW mRNA

NCBI chr X:154,182,596...154,196,861
Ensembl chr X:154,182,596...154,196,861

G

opioid receptor delta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPRD1 mRNA

NCBI chr 1:28,812,170...28,871,267
Ensembl chr 1:28,812,170...28,871,267

G

opioid receptor kappa 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OPRK1 mRNA

NCBI chr 8:53,225,724...53,251,637
Ensembl chr 8:53,225,724...53,251,637

G

olfactory receptor family 10 subfamily AD member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AD1 mRNA

NCBI chr12:48,202,339...48,203,292
Ensembl chr12:48,202,339...48,203,292

G

olfactory receptor family 10 subfamily H member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10H28 mRNA

NCBI chr19:15,949,008...15,949,958
Ensembl chr19:15,944,299...15,950,350

G

olfactory receptor family 10 subfamily J member 3 (gene/pseudogene)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10J3 mRNA

NCBI chr 1:159,313,570...159,314,759
Ensembl chr 1:159,313,720...159,314,659

G

olfactory receptor family 10 subfamily R member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10B1 mRNA

NCBI chr 1:158,472,220...158,480,936
Ensembl chr 1:158,472,220...158,480,936

G

olfactory receptor family 11 subfamily A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11A4 mRNA

NCBI chr 6:29,425,504...29,457,071
Ensembl chr 6:29,425,504...29,457,071

G

olfactory receptor family 13 subfamily C member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13C25 mRNA

NCBI chr 9:104,569,168...104,570,130
Ensembl chr 9:104,569,168...104,570,130

G

olfactory receptor family 1 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1B1 mRNA

NCBI chr 9:122,628,125...122,657,627
Ensembl chr 9:122,628,125...122,657,627

G

olfactory receptor family 1 subfamily F member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1F19 mRNA

NCBI chr16:3,188,204...3,206,556
Ensembl chr16:3,188,204...3,224,779

G

olfactory receptor family 1 subfamily M member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1M1 mRNA

NCBI chr19:9,087,061...9,095,669
Ensembl chr19:9,087,061...9,095,669

G

olfactory receptor family 1 subfamily Q member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1Q1 mRNA

NCBI chr 9:122,614,738...122,615,682
Ensembl chr 9:122,614,738...122,615,682

G

olfactory receptor family 1 subfamily R member 1 pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR1R1 mRNA

NCBI chr17:3,385,930...3,386,874
Ensembl chr17:3,385,930...3,386,874

G

olfactory receptor family 1 subfamily S member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1S2 mRNA

NCBI chr11:58,203,204...58,204,142
Ensembl chr11:58,203,204...58,204,142

G

olfactory receptor family 2 subfamily AG member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AG2 mRNA

NCBI chr11:6,765,626...6,771,976
Ensembl chr11:6,765,626...6,771,976

G

olfactory receptor family 2 subfamily AP member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C8 mRNA

NCBI chr12:55,572,468...55,575,612
Ensembl chr12:55,572,468...55,575,612

G

olfactory receptor family 2 subfamily D member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR2D2B mRNA

NCBI chr11:6,891,574...6,892,500
Ensembl chr11:6,891,574...6,892,500

G

olfactory receptor family 2 subfamily F member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2F2 mRNA

NCBI chr 7:143,935,233...143,936,186
Ensembl chr 7:143,935,233...143,936,186

G

olfactory receptor family 2 subfamily L member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2L13 mRNA

NCBI chr 1:247,937,177...248,101,163
Ensembl chr 1:248,095,184...248,101,163

G

olfactory receptor family 2 subfamily V member 1

increases expression

Dextran Sulfate results in increased expression of OR2V1 mRNA

NCBI chr 5:181,123,122...181,131,169
Ensembl chr 5:181,123,122...181,131,169

G

olfactory receptor family 2 subfamily V member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2V2 mRNA

NCBI chr 5:181,147,586...181,159,285
Ensembl chr 5:181,147,586...181,159,285

G

olfactory receptor family 2 subfamily Z member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Z9 mRNA

NCBI chr19:8,721,634...8,732,160
Ensembl chr19:8,721,634...8,732,160

G

olfactory receptor family 3 subfamily A member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR3A1D mRNA

NCBI chr17:3,411,370...3,424,070
Ensembl chr17:3,411,370...3,424,070

G

olfactory receptor family 3 subfamily A member 4 pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR3A4 mRNA

NCBI chr17:3,310,245...3,311,446
Ensembl chr17:3,310,311...3,311,216

G

olfactory receptor family 4 subfamily C member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C10B mRNA

NCBI chr11:49,952,391...49,953,419
Ensembl chr11:49,952,391...49,953,419

G

olfactory receptor family 4 subfamily C member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C15 mRNA

NCBI chr11:55,554,469...55,555,419
Ensembl chr11:55,554,307...55,555,419

G

olfactory receptor family 4 subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C123 mRNA

NCBI chr11:55,662,201...55,666,096
Ensembl chr11:55,662,201...55,666,195

G

olfactory receptor family 4 subfamily E member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4E2 mRNA

NCBI chr14:21,653,835...21,667,642
Ensembl chr14:21,653,835...21,667,642

G

olfactory receptor family 4 subfamily F member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F15 mRNA

NCBI chr15:101,812,202...101,820,197
Ensembl chr15:101,812,202...101,820,197

G

olfactory receptor family 4 subfamily N member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4N5 mRNA

NCBI chr14:20,138,820...20,145,471
Ensembl chr14:20,138,820...20,145,471

G

olfactory receptor family 4 subfamily Q member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4Q3 mRNA

NCBI chr14:19,743,571...19,752,334
Ensembl chr14:19,743,571...19,749,469

G

olfactory receptor family 51 subfamily A member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A8 mRNA

NCBI chr11:4,942,831...4,947,605
Ensembl chr11:4,942,831...4,947,605

G

olfactory receptor family 51 subfamily A member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A7 mRNA

NCBI chr11:4,903,783...4,909,462
Ensembl chr11:4,903,783...4,909,462

G

olfactory receptor family 51 subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51B6 mRNA

NCBI chr11:5,351,508...5,352,446
Ensembl chr11:5,351,508...5,352,446

G

olfactory receptor family 51 subfamily D member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51D1 mRNA

NCBI chr11:4,637,477...4,643,060
Ensembl chr11:4,637,477...4,643,060

G

olfactory receptor family 51 subfamily E member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51E2 mRNA

NCBI chr11:4,680,171...4,697,853
Ensembl chr11:4,680,171...4,697,854

G

olfactory receptor family 51 subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51G1 mRNA

NCBI chr11:4,923,374...4,924,339
Ensembl chr11:4,923,374...4,924,339

G

olfactory receptor family 51 subfamily G member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51G2 mRNA

NCBI chr11:4,912,588...4,919,350
Ensembl chr11:4,912,588...4,919,350

G

olfactory receptor family 51 subfamily M member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51M1 mRNA

NCBI chr11:5,383,812...5,393,263
Ensembl chr11:5,383,812...5,393,263

G

olfactory receptor family 52 subfamily B member 1 pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR52B1 mRNA

NCBI chr11:6,151,595...6,152,549
Ensembl chr11:6,151,641...6,152,549

G

olfactory receptor family 52 subfamily E member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR52E8 mRNA

NCBI chr11:5,856,749...5,857,690
Ensembl chr11:5,856,749...5,857,690

G

olfactory receptor family 5 subfamily B member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5B12B mRNA

NCBI chr11:58,438,994...58,442,236
Ensembl chr11:58,438,994...58,442,236

G

olfactory receptor family 5 subfamily C member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5C1 mRNA

NCBI chr 9:122,788,933...122,789,895
Ensembl chr 9:122,788,933...122,789,895

G

olfactory receptor family 5 subfamily E member 1 pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5E1 mRNA

NCBI chr11:7,849,051...7,849,571
Ensembl chr11:7,848,700...7,849,626

G

olfactory receptor family 5 subfamily H member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5H26 mRNA

NCBI chr 3:98,282,505...98,284,070
Ensembl chr 3:98,282,505...98,284,070

G

olfactory receptor family 5 subfamily H member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5H19 mRNA

NCBI chr 3:98,264,244...98,265,356
Ensembl chr 3:98,263,252...98,265,356

G

olfactory receptor family 5 subfamily K member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5K3 mRNA

NCBI chr 3:98,390,666...98,391,631
Ensembl chr 3:98,390,666...98,391,631

G

olfactory receptor family 5 subfamily P member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P76 mRNA

NCBI chr11:7,795,974...7,796,942
Ensembl chr11:7,795,974...7,796,942

G

olfactory receptor family 6 subfamily B member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6B3 mRNA

NCBI chr 2:240,044,571...240,053,521
Ensembl chr 2:240,044,571...240,053,521

G

olfactory receptor family 6 subfamily C member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C1B mRNA

NCBI chr12:55,314,343...55,322,364
Ensembl chr12:55,314,343...55,322,364

G

olfactory receptor family 6 subfamily C member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C2 mRNA

NCBI chr12:55,444,076...55,453,347
Ensembl chr12:55,444,069...55,453,347

G

olfactory receptor family 6 subfamily C member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C3 mRNA

NCBI chr12:55,330,043...55,332,636
Ensembl chr12:55,330,043...55,332,687

G

olfactory receptor family 6 subfamily C member 68

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR6C68 mRNA

NCBI chr12:55,492,378...55,493,316
Ensembl chr12:55,492,378...55,493,316

G

olfactory receptor family 6 subfamily C member 74

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C74 mRNA

NCBI chr12:55,244,609...55,256,625
Ensembl chr12:55,244,609...55,256,625

G

olfactory receptor family 6 subfamily K member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6K4 mRNA

NCBI chr 1:158,716,327...158,725,120
Ensembl chr 1:158,716,327...158,720,720

G

olfactory receptor family 6 subfamily K member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6K6 mRNA

NCBI chr 1:158,754,720...158,755,891
Ensembl chr 1:158,754,720...158,755,891

G

olfactory receptor family 6 subfamily N member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6N2 mRNA

NCBI chr 1:158,774,222...158,781,204
Ensembl chr 1:158,774,222...158,781,204

G

olfactory receptor family 7 subfamily E member 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7E178 mRNA

NCBI chr19:9,206,488...9,252,625
Ensembl chr19:9,247,344...9,252,625

G

olfactory receptor family 8 subfamily B member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR8B12 mRNA

NCBI chr11:124,542,722...124,543,654
Ensembl chr11:124,539,635...124,545,333

G

olfactory receptor family 8 subfamily D member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8D2B mRNA

NCBI chr11:124,319,262...124,320,197
Ensembl chr11:124,319,262...124,320,197

G

olfactory receptor family 8 subfamily G member 2 pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G2 mRNA

NCBI chr11:124,224,732...124,225,607
Ensembl chr11:124,224,732...124,225,666

G

olfactory receptor family 9 subfamily A member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR9A4 mRNA

NCBI chr 7:141,916,399...141,920,625
Ensembl chr 7:141,916,399...141,920,625

G

olfactory receptor family 9 subfamily G member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9G4 mRNA

NCBI chr11:56,741,223...56,748,697
Ensembl chr11:56,741,223...56,748,697

G

oncostatin M

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSM mRNA

NCBI chr22:30,262,829...30,266,851
Ensembl chr22:30,262,829...30,266,851

G

oncostatin M receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSMR mRNA

NCBI chr 5:38,846,012...38,945,579
Ensembl chr 5:38,845,858...38,945,596

G

oviductal glycoprotein 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of OVGP1 protein

NCBI chr 1:111,414,319...111,427,735
Ensembl chr 1:111,414,319...111,427,735

G

oxytocin receptor

decreases expression

Dextran Sulfate results in decreased expression of OXTR mRNA

NCBI chr 3:8,741,269...8,769,613
Ensembl chr 3:8,750,381...8,769,628

G

purinergic receptor P2X 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX5 mRNA

NCBI chr17:3,673,227...3,723,835
Ensembl chr17:3,672,199...3,696,240

G

purinergic receptor P2X 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX7 mRNA

NCBI chr12:121,132,876...121,188,032
Ensembl chr12:121,132,819...121,188,032

G

pyrimidinergic receptor P2Y4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of P2RY4 mRNA

NCBI chr X:70,258,166...70,260,204
Ensembl chr X:70,258,166...70,260,204

G

pyrimidinergic receptor P2Y6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RY6 mRNA

NCBI chr11:73,264,506...73,298,625
Ensembl chr11:73,264,498...73,305,103

G

P2Y receptor family member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R103 mRNA

NCBI chr  X:1,462,581...1,537,185
NCBI chr  Y:1,462,581...1,537,185
Ensembl chr  Y:1,462,581...1,537,185
Ensembl chr  X:1,462,581...1,537,185

G

prolyl 3-hydroxylase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P3H3 mRNA

NCBI chr12:6,828,407...6,839,847
Ensembl chr12:6,828,407...6,839,847

G

prolyl 4-hydroxylase subunit beta

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P4HB mRNA
Dextran Sulfate results in decreased expression of P4HB protein

PMID:29950665 PMID:35999755

NCBI chr17:81,843,166...81,860,535
Ensembl chr17:81,843,159...81,860,856

G

poly(A) binding protein nuclear 1

increases expression

Dextran Sulfate results in increased expression of PABPN1 mRNA

NCBI chr14:23,321,457...23,326,163
Ensembl chr14:23,321,457...23,326,163

G

phosphoprotein membrane anchor with glycosphingolipid microdomains 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAG1 mRNA

NCBI chr 8:80,967,810...81,112,068
Ensembl chr 8:80,967,810...81,112,068

G

p21 (RAC1) activated kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAK4 mRNA

NCBI chr19:39,125,786...39,182,816
Ensembl chr19:39,125,770...39,182,816

G

pantothenate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of PANK1 mRNA

NCBI chr10:89,579,495...89,645,242
Ensembl chr10:89,579,497...89,645,242

G

polyamine oxidase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAOX mRNA

NCBI chr10:133,379,262...133,391,694
Ensembl chr10:133,379,261...133,391,694

G

pappalysin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAPPA mRNA

NCBI chr 9:116,153,791...116,402,321
Ensembl chr 9:116,153,791...116,402,321

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAPSS2 mRNA

NCBI chr10:87,659,878...87,747,705
Ensembl chr10:87,659,613...87,747,705

G

poly(ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Dextran Sulfate results in increased cleavage of PARP1 protein
[Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [Plant Extracts co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of PARP1 protein]

PMID:21989142 PMID:25449198

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

parvin beta

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PARVB protein
Dextran Sulfate results in decreased expression of PARVB protein

NCBI chr22:43,999,211...44,172,939
Ensembl chr22:43,999,211...44,172,939

G

pro-apoptotic WT1 regulator

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PAWR protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PAWR protein]

NCBI chr12:79,584,879...79,690,964
Ensembl chr12:79,574,979...79,690,964

G

paired box 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX4 mRNA

NCBI chr 7:127,610,292...127,618,142
Ensembl chr 7:127,610,292...127,618,142

G

paired box 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX6 mRNA

NCBI chr11:31,789,026...31,817,961
Ensembl chr11:31,784,779...31,817,961

G

propionyl-CoA carboxylase subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCCB mRNA

NCBI chr 3:136,250,340...136,330,169
Ensembl chr 3:136,250,340...136,337,896

G

protocadherin gamma subfamily B, 1

decreases expression

Dextran Sulfate results in decreased expression of PCDHGB1 mRNA

NCBI chr 5:141,350,099...141,512,975
Ensembl chr 5:141,350,099...141,512,975

G

proliferating cell nuclear antigen

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PCNA protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of PCNA protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]

PMID:17438113 PMID:19028472 PMID:34964214 PMID:38648921

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

PEST proteolytic signal containing nuclear protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PCNP protein]

NCBI chr 3:101,574,094...101,594,465
Ensembl chr 3:101,574,180...101,594,465

G

procollagen C-endopeptidase enhancer

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PCOLCE mRNA
Dextran Sulfate results in decreased expression of PCOLCE mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:100,602,363...100,608,175
Ensembl chr 7:100,602,363...100,608,175

G

Purkinje cell protein 4 like 1

decreases expression

Dextran Sulfate results in decreased expression of PCP4L1 mRNA

NCBI chr 1:161,258,745...161,285,450
Ensembl chr 1:161,258,745...161,285,450

G

PDGFA associated protein 1

increases expression

Dextran Sulfate results in increased expression of PDAP1 mRNA

NCBI chr 7:99,394,673...99,408,597
Ensembl chr 7:99,392,048...99,408,597

G

programmed cell death 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDCD4 protein]

NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006

G

phosphodiesterase 10A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE10A mRNA

NCBI chr 6:165,327,289...165,988,052
Ensembl chr 6:165,327,287...165,988,117

G

phosphodiesterase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE1A mRNA

NCBI chr 2:182,140,041...182,716,797
Ensembl chr 2:182,139,968...182,523,359

G

phosphodiesterase 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE1C mRNA

NCBI chr 7:31,616,777...32,428,224
Ensembl chr 7:31,751,179...32,428,131

G

phosphodiesterase 2A

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE2A mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDE2A protein]

PMID:29950665 PMID:32272095

NCBI chr11:72,576,141...72,674,422
Ensembl chr11:72,576,141...72,674,591

G

phosphodiesterase 3A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE3A mRNA

NCBI chr12:20,368,537...20,688,583
Ensembl chr12:20,368,537...20,688,583

G

phosphodiesterase 4A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4A mRNA

NCBI chr19:10,416,773...10,469,631
Ensembl chr19:10,416,773...10,469,630

G

phosphodiesterase 4B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4B mRNA; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]

PMID:29950665 PMID:30188895

NCBI chr 1:65,792,510...66,374,579
Ensembl chr 1:65,792,514...66,374,579

G

phosphodiesterase 7A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE7A mRNA

NCBI chr 8:65,714,334...65,842,064
Ensembl chr 8:65,714,334...65,842,322

G

phosphodiesterase 7B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE7B mRNA

NCBI chr 6:135,851,701...136,195,574
Ensembl chr 6:135,851,701...136,195,574

G

platelet derived growth factor subunit B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFB mRNA

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

platelet derived growth factor receptor alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRA mRNA

NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245

G

platelet derived growth factor receptor beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRB mRNA

NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872

G

protein disulfide isomerase family A member 3

decreases expression

Dextran Sulfate results in decreased expression of PDIA3 protein

NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279

G

prodynorphin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDYN mRNA

NCBI chr20:1,978,756...1,994,285
Ensembl chr20:1,978,757...1,994,285

G

PDZK1 interacting protein 1

increases expression

Dextran Sulfate results in increased expression of PDZK1IP1 mRNA

NCBI chr 1:47,183,582...47,190,036
Ensembl chr 1:47,183,582...47,191,044

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PECAM1 protein

NCBI chr17:64,319,415...64,390,860
Ensembl chr17:64,319,415...64,413,776

G

platelet factor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PF4 mRNA

NCBI chr 4:73,980,811...73,982,124
Ensembl chr 4:73,980,811...73,982,027

G

profilin 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PFN1 protein
Dextran Sulfate results in decreased expression of PFN1 protein

NCBI chr17:4,945,652...4,948,530
Ensembl chr17:4,945,652...4,949,061

G

profilin 3

increases expression

Dextran Sulfate results in increased expression of PFN3 mRNA

NCBI chr 5:177,400,109...177,400,661
Ensembl chr 5:177,400,109...177,400,661

G

phosphoglycerate mutase 1

decreases expression

Dextran Sulfate results in decreased expression of PGAM1 protein

NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444

G

phosphoglycerate mutase 2

decreases expression

Dextran Sulfate results in decreased expression of PGAM2 protein

NCBI chr 7:44,062,727...44,065,567
Ensembl chr 7:44,062,727...44,065,567

G

placental growth factor

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PGF mRNA
Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of PGF mRNA]

NCBI chr14:74,941,830...74,955,764
Ensembl chr14:74,941,834...74,955,626

G

phosphoglycerate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of PGK1 protein

NCBI chr X:78,104,248...78,129,295
Ensembl chr X:77,910,739...78,129,295

G

6-phosphogluconolactonase

decreases expression

Dextran Sulfate results in decreased expression of PGLS protein

NCBI chr19:17,511,649...17,521,288
Ensembl chr19:17,511,636...17,521,288

G

phosphoglucomutase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM1 mRNA

NCBI chr 1:63,593,411...63,660,245
Ensembl chr 1:63,593,411...63,660,245

G

phosphoglucomutase 2

decreases expression

Dextran Sulfate results in decreased expression of PGM2 protein

NCBI chr 4:37,826,686...37,862,937
Ensembl chr 4:37,826,660...37,862,937

G

phosphoglucomutase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM3 mRNA

NCBI chr 6:83,148,705...83,193,900
Ensembl chr 6:83,147,324...83,193,936

G

phosphoglycolate phosphatase

increases expression

Dextran Sulfate results in increased expression of PGP mRNA

NCBI chr16:2,211,593...2,214,840
Ensembl chr16:2,211,593...2,214,840

G

phosphate regulating endopeptidase X-linked

increases expression

Dextran Sulfate results in increased expression of PHEX protein

NCBI chr X:22,032,325...22,251,310
Ensembl chr X:22,032,325...22,494,713

G

phosphorylase kinase regulatory subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKA1 mRNA

NCBI chr X:72,578,814...72,714,306
Ensembl chr X:72,578,814...72,714,319

G

phosphorylase kinase regulatory subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKB mRNA

NCBI chr16:47,461,299...47,701,523
Ensembl chr16:47,461,123...47,701,523

G

phosphoinositide-3-kinase adaptor protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PIK3AP1 mRNA

NCBI chr10:96,593,315...96,720,514
Ensembl chr10:96,593,315...96,720,514

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PIK3CA mRNA

NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093

G

phosphoinositide-3-kinase regulatory subunit 5

increases expression

Dextran Sulfate results in increased expression of PIK3R5 protein

NCBI chr17:8,878,916...8,965,707
Ensembl chr17:8,878,911...8,965,712

G

protein kinase domain containing, cytoplasmic

decreases expression

Dextran Sulfate results in decreased expression of PKDCC mRNA

NCBI chr 2:42,048,021...42,058,517
Ensembl chr 2:42,048,021...42,058,517

G

pyruvate kinase L/R

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PKLR mRNA

NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438

G

plakophilin 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PKP2 protein]

NCBI chr12:32,790,755...32,896,777
Ensembl chr12:32,790,745...32,896,798

G

phospholipase A2 group X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G10 mRNA

NCBI chr16:14,672,548...14,701,850
Ensembl chr16:14,672,548...14,694,308

G

phospholipase A2 group XIIA

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G12A mRNA

NCBI chr 4:109,709,989...109,730,070
Ensembl chr 4:109,709,989...109,730,070

G

phospholipase A2 group XIIB

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G12B mRNA

NCBI chr10:72,934,762...72,954,806
Ensembl chr10:72,934,762...72,954,806

G

phospholipase A2 group IIA

increases expression

Dextran Sulfate results in increased expression of PLA2G2A mRNA

NCBI chr 1:19,975,431...19,980,434
Ensembl chr 1:19,975,431...19,980,416

G

phospholipase A2 group IIC

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G2C mRNA

NCBI chr 1:20,163,055...20,186,518
Ensembl chr 1:20,161,253...20,186,518

G

phospholipase A2 group IIE

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2E mRNA

NCBI chr 1:19,920,009...19,923,617
Ensembl chr 1:19,920,009...19,923,617

G

phospholipase A2 group IIF

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2F mRNA

NCBI chr 1:20,139,323...20,150,381
Ensembl chr 1:20,139,323...20,150,381

G

phospholipase A2 group IVA

multiple interactions
increases phosphorylation

tussilagone inhibits the reaction [Dextran Sulfate results in increased phosphorylation of PLA2G4A protein]

NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981

G

phospholipase A2 group IVC

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PLA2G4C protein]

NCBI chr19:48,047,846...48,110,817
Ensembl chr19:48,047,843...48,110,817

G

phospholipase A2 group IVF

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G4F mRNA

NCBI chr15:42,139,034...42,156,636
Ensembl chr15:42,139,034...42,156,636

G

plasminogen activator, tissue type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAT mRNA

NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709

G

plasminogen activator, urokinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAU mRNA

NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496

G

plasminogen activator, urokinase receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAUR mRNA

NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547

G

phospholipase C beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLCB2 mRNA

NCBI chr15:40,284,256...40,307,935
Ensembl chr15:40,278,176...40,307,935

G

phospholipase C beta 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCB4 mRNA

NCBI chr20:9,068,678...9,480,808
Ensembl chr20:9,067,825...9,504,593

G

phospholipase C epsilon 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCE1 mRNA

NCBI chr10:93,993,931...94,332,823
Ensembl chr10:93,993,931...94,332,823

G

phospholipase D family member 3

decreases expression

Dextran Sulfate results in decreased expression of PLD3 mRNA

NCBI chr19:40,348,695...40,378,485
Ensembl chr19:40,348,456...40,389,472

G

pleckstrin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLEK mRNA

NCBI chr 2:68,365,282...68,397,453
Ensembl chr 2:68,365,282...68,397,453

G

plasminogen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLG mRNA

NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097

G

procollagen-lysine,2-oxoglutarate 5-dioxygenase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA

NCBI chr 3:146,069,440...146,161,184
Ensembl chr 3:146,035,139...146,163,725

G

plastin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PLS1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PLS1 protein

NCBI chr 3:142,596,393...142,713,664
Ensembl chr 3:142,596,393...142,713,664

G

phospholipid transfer protein

decreases expression

Dextran Sulfate results in decreased expression of PLTP mRNA

NCBI chr20:45,898,620...45,912,155
Ensembl chr20:45,898,621...45,912,155

G

plexin A1

decreases expression

Dextran Sulfate results in decreased expression of PLXNA1 mRNA

NCBI chr 3:126,983,115...127,037,389
Ensembl chr 3:126,982,693...127,037,389

G

plexin C1

decreases expression

Dextran Sulfate results in decreased expression of PLXNC1 mRNA

NCBI chr12:94,148,577...94,307,675
Ensembl chr12:94,148,577...94,307,675

G

plexin D1

decreases expression

Dextran Sulfate results in decreased expression of PLXND1 mRNA

NCBI chr 3:129,555,214...129,606,676
Ensembl chr 3:129,555,214...129,606,676

G

premelanosome protein

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PMEL protein

NCBI chr12:55,954,105...55,966,709
Ensembl chr12:55,954,105...55,973,317

G

phosphomannomutase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PMM2 mRNA

NCBI chr16:8,797,839...8,849,325
Ensembl chr16:8,788,823...8,862,534

G

pancreatic lipase related protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PNLIPRP1 mRNA

NCBI chr10:116,590,959...116,609,175
Ensembl chr10:116,590,385...116,609,175

G

purine nucleoside phosphorylase

decreases expression

Dextran Sulfate results in decreased expression of PNP2 mRNA

NCBI chr14:20,469,406...20,477,089
Ensembl chr14:20,461,992...20,477,094

G

polyribonucleotide nucleotidyltransferase 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PNPT1 protein]

NCBI chr 2:55,634,061...55,693,844
Ensembl chr 2:55,634,061...55,693,863

G

podocalyxin like

decreases expression

Dextran Sulfate results in decreased expression of PODXL mRNA

NCBI chr 7:131,500,271...131,556,628
Ensembl chr 7:131,500,262...131,558,217

G

paraoxonase 3

decreases expression

Dextran Sulfate results in decreased expression of PON3 mRNA

NCBI chr 7:95,359,872...95,396,375
Ensembl chr 7:95,359,872...95,396,375

G

periostin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of POSTN protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of POSTN protein]

NCBI chr13:37,562,585...37,598,768
Ensembl chr13:37,562,583...37,598,844

G

peroxisome proliferator activated receptor alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARA mRNA

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARD mRNA

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

peroxisome proliferator activated receptor gamma

increases expression
affects localization
multiple interactions

Dextran Sulfate results in increased expression of PPARG protein
Dextran Sulfate affects the localization of PPARG protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARG mRNA; ligustilide inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]; Mesalamine inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]

PMID:23261717 PMID:29950665 PMID:33130971

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

Hesperidin inhibits the reaction [Dextran Sulfate results in decreased expression of PPARGC1A protein]

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

peptidylprolyl isomerase A

decreases expression

Dextran Sulfate results in decreased expression of PPIA protein

NCBI chr 7:44,796,681...44,803,117
Ensembl chr 7:44,796,680...44,824,564

G

peptidylprolyl isomerase H

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PPIH protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPIH protein]

NCBI chr 1:42,658,423...42,681,654
Ensembl chr 1:42,658,335...42,676,758

G

protein phosphatase 1 catalytic subunit gamma

increases expression

Dextran Sulfate results in increased expression of PPP1CC mRNA

NCBI chr12:110,708,376...110,742,891
Ensembl chr12:110,719,680...110,742,939

G

protein phosphatase 1 regulatory inhibitor subunit 14A

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of PPP1R14A protein]

NCBI chr19:38,251,237...38,256,374
Ensembl chr19:38,251,237...38,256,532

G

protein phosphatase 1 regulatory inhibitor subunit 1B

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PPP1R1B protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPP1R1B protein]

NCBI chr17:39,626,707...39,636,624
Ensembl chr17:39,626,740...39,636,626

G

protein phosphatase 3 catalytic subunit gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPP3CC mRNA

NCBI chr 8:22,441,078...22,541,125
Ensembl chr 8:22,440,819...22,541,142

G

pancreatic polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPY mRNA

NCBI chr17:43,940,804...43,944,215
Ensembl chr17:43,940,804...43,942,476

G

peroxiredoxin 1

decreases expression

Dextran Sulfate results in decreased expression of PRDX1 protein

NCBI chr 1:45,511,051...45,522,890
Ensembl chr 1:45,510,914...45,542,732

G

protein kinase AMP-activated catalytic subunit alpha 1

decreases phosphorylation
multiple interactions

Dextran Sulfate results in decreased phosphorylation of PRKAA1 protein
biochanin A inhibits the reaction [Dextran Sulfate results in decreased phosphorylation of PRKAA1 protein]

NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374

G

protein kinase cAMP-activated catalytic subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKACB mRNA

NCBI chr 1:84,078,079...84,238,498
Ensembl chr 1:84,078,062...84,238,498

G

protein kinase AMP-activated non-catalytic subunit gamma 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKAG2 mRNA

NCBI chr 7:151,556,127...151,877,115
Ensembl chr 7:151,556,124...151,877,214

G

protein kinase C alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKCA mRNA

NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743

G

protein kinase C beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCB mRNA

NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611

G

protein kinase C theta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCQ mRNA

NCBI chr10:6,394,097...6,580,646
Ensembl chr10:6,427,143...6,580,301

G

protein kinase cGMP-dependent 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKG2 mRNA

NCBI chr 4:81,087,370...81,217,836
Ensembl chr 4:81,087,370...81,215,222

G

prolactin receptor

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRLR mRNA
Dextran Sulfate results in decreased expression of PRLR mRNA

PMID:29950665 PMID:35093514

NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487

G

protamine 3

increases expression

Dextran Sulfate results in increased expression of PRM3 mRNA

NCBI chr16:11,273,199...11,273,629
Ensembl chr16:11,273,199...11,273,629

G

protein C, inactivator of coagulation factors Va and VIIIa

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PROC mRNA

NCBI chr 2:127,418,427...127,429,242
Ensembl chr 2:127,418,427...127,429,242

G

protein S

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PROS1 mRNA

NCBI chr 3:93,873,051...93,973,896
Ensembl chr 3:93,873,051...93,980,003

G

prospero homeobox 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PROX1 mRNA

NCBI chr 1:213,983,151...214,041,510
Ensembl chr 1:213,983,181...214,041,510

G

pre-mRNA processing factor 38B

increases expression

Dextran Sulfate results in increased expression of PRPF38B mRNA

NCBI chr 1:108,692,310...108,702,928
Ensembl chr 1:108,692,310...108,702,928

G

proline rich coiled-coil 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PRRC1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PRRC1 protein]

NCBI chr 5:127,517,640...127,555,085
Ensembl chr 5:127,517,617...127,555,085

G

proline rich coiled-coil 2C

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PRRC2C mRNA

NCBI chr 1:171,485,530...171,593,511
Ensembl chr 1:171,485,530...171,593,511

G

serine protease 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS2 mRNA

NCBI chr 7:142,770,970...142,774,560
Ensembl chr 7:142,760,398...142,774,564

G

serine protease 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS3 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY4 mRNA

NCBI chr 9:33,750,679...33,799,231
Ensembl chr 9:33,750,679...33,799,231

G

peroxiredoxin like 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRXL2B mRNA

NCBI chr 1:2,586,523...2,591,468
Ensembl chr 1:2,586,491...2,591,469

G

presenilin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PSEN1 mRNA

NCBI chr14:73,136,417...73,223,691
Ensembl chr14:73,136,418...73,223,691

G

proteasome 20S subunit beta 8

increases expression

Dextran Sulfate results in increased expression of PSMB8 mRNA

NCBI chr 6:32,840,717...32,844,679
Ensembl chr 6:32,840,717...32,844,679

G

proline-serine-threonine phosphatase interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PSTPIP1 mRNA

NCBI chr15:76,994,680...77,037,475
Ensembl chr15:76,993,359...77,037,475

G

platelet activating factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTAFR mRNA

NCBI chr 1:28,147,166...28,193,856
Ensembl chr 1:28,147,166...28,193,936

G

phosphatase and tensin homolog

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]

NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930

G

prostaglandin D2 receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDR2 mRNA

NCBI chr11:60,850,933...60,855,950
Ensembl chr11:60,850,933...60,855,950

G

prostaglandin D2 synthase

multiple interactions
increases expression
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDS mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGDS protein]
Dextran Sulfate results in decreased expression of PTGDS protein

PMID:29950665 PMID:30489199 PMID:35999755

NCBI chr 9:136,977,504...136,981,742
Ensembl chr 9:136,975,092...136,981,742

G

prostaglandin E receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER2 mRNA

NCBI chr14:52,314,312...52,328,598
Ensembl chr14:52,314,305...52,329,822

G

prostaglandin E receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGER3 mRNA

NCBI chr 1:70,852,358...71,047,816
Ensembl chr 1:70,852,353...71,047,816

G

prostaglandin E receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER4 mRNA

NCBI chr 5:40,679,915...40,746,800
Ensembl chr 5:40,679,915...40,693,735

G

prostaglandin E synthase

multiple interactions
increases expression

resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGES mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]

PMID:19228061 PMID:20132809 PMID:29950665 PMID:30489199 PMID:36543318

NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042

G

prostaglandin E synthase 3

decreases expression

Dextran Sulfate results in decreased expression of PTGES3 protein

NCBI chr12:56,663,349...56,688,284
Ensembl chr12:56,663,341...56,688,408

G

prostaglandin F receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGFR mRNA

NCBI chr 1:78,490,974...78,540,701
Ensembl chr 1:78,303,884...78,540,701

G

prostaglandin I2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIR mRNA

NCBI chr19:46,610,687...46,625,089
Ensembl chr19:46,618,550...46,625,089

G

prostaglandin I2 synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIS mRNA

NCBI chr20:49,503,874...49,568,137
Ensembl chr20:49,503,874...49,568,137

G

prostaglandin reductase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGR1 mRNA

NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGS2 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]
Dextran Sulfate results in increased expression of PTGS2 mRNA; Dextran Sulfate results in increased expression of PTGS2 protein
resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]

PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:19228061 More...

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

parathyroid hormone 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTH1R mRNA

NCBI chr 3:46,877,721...46,903,799
Ensembl chr 3:46,877,721...46,903,799

G

parathyroid hormone like hormone

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTHLH mRNA

NCBI chr12:27,958,084...27,972,733
Ensembl chr12:27,958,084...27,972,733

G

pleiotrophin

decreases expression

Dextran Sulfate results in decreased expression of PTN mRNA

NCBI chr 7:137,227,341...137,343,733
Ensembl chr 7:137,227,341...137,343,774

G

protein tyrosine phosphatase receptor type C

increases expression

Dextran Sulfate results in increased expression of PTPRC mRNA

NCBI chr 1:198,638,713...198,757,476
Ensembl chr 1:198,638,457...198,759,342

G

protein tyrosine phosphatase receptor type H

decreases expression

Dextran Sulfate results in decreased expression of PTPRH mRNA

NCBI chr19:55,181,247...55,209,501
Ensembl chr19:55,181,247...55,209,506

G

protein tyrosine phosphatase receptor type M

decreases expression

Dextran Sulfate results in decreased expression of PTPRM protein

NCBI chr18:7,567,316...8,406,856
Ensembl chr18:7,566,782...8,406,861

G

protein tyrosine phosphatase receptor type U

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTPRU mRNA

NCBI chr 1:29,236,522...29,326,800
Ensembl chr 1:29,236,516...29,326,813

G

protein tyrosine phosphatase receptor type V, pseudogene

decreases expression

Dextran Sulfate results in decreased expression of PTPRV mRNA

NCBI chr 1:202,168,051...202,189,449
Ensembl chr 1:202,168,051...202,189,455
Ensembl chr 1:202,168,051...202,189,455

G

PYD and CARD domain containing

increases expression
multiple interactions

Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PYCARD protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD protein]

PMID:30270565 PMID:34964214

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

glycogen phosphorylase B

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PYGB protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PYGB protein

NCBI chr20:25,248,085...25,298,012
Ensembl chr20:25,248,085...25,298,012

G

glycogen phosphorylase L

decreases expression

Dextran Sulfate results in decreased expression of PYGL protein

NCBI chr14:50,905,217...50,944,483
Ensembl chr14:50,857,891...50,944,483

G

peptide YY

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PYY mRNA

NCBI chr17:43,952,733...44,004,445
Ensembl chr17:43,952,733...44,004,469

G

R3H domain and coiled-coil containing 1

increases expression

Dextran Sulfate results in increased expression of R3HCC1 mRNA

NCBI chr 8:23,288,092...23,296,279
Ensembl chr 8:23,270,120...23,296,279

G

RAB11B, member RAS oncogene family

decreases expression

Dextran Sulfate results in decreased expression of RAB11B protein

NCBI chr19:8,390,360...8,404,434
Ensembl chr19:8,389,981...8,404,434

G

RAB1B, member RAS oncogene family

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RAB1B protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB1B protein]

NCBI chr11:66,268,639...66,277,492
Ensembl chr11:66,268,590...66,277,492

G

RAB21, member RAS oncogene family

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB21 protein

NCBI chr12:71,754,863...71,800,286
Ensembl chr12:71,754,863...71,800,286

G

RAB27A, member RAS oncogene family

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB27A protein]

NCBI chr15:55,202,966...55,289,813
Ensembl chr15:55,202,966...55,319,113

G

RAB27B, member RAS oncogene family

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB27B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RAB27B mRNA
Dextran Sulfate results in decreased expression of RAB27B protein

PMID:29950665 PMID:35999755

NCBI chr18:54,717,857...54,895,516
Ensembl chr18:54,717,860...54,895,516

G

RAB39B, member RAS oncogene family

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB39B protein

NCBI chr X:155,258,235...155,264,491
Ensembl chr X:155,258,235...155,264,491

G

Rac family small GTPase 3

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA]

NCBI chr17:82,031,678...82,034,204
Ensembl chr17:82,031,678...82,034,204

G

receptor activity modifying protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP1 mRNA

NCBI chr 2:237,858,880...237,912,106
Ensembl chr 2:237,858,893...237,912,106

G

receptor activity modifying protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP2 mRNA

NCBI chr17:42,761,227...42,763,041
Ensembl chr17:42,758,447...42,763,041

G

receptor activity modifying protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP3 mRNA

NCBI chr 7:45,157,791...45,184,250
Ensembl chr 7:45,157,791...45,186,302

G

RAP1B, member of RAS oncogene family

decreases expression

Dextran Sulfate results in decreased expression of RAP1B protein

NCBI chr12:68,610,899...68,671,901
Ensembl chr12:68,610,855...68,671,901

G

Rap guanine nucleotide exchange factor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAPGEF4 mRNA

NCBI chr 2:172,735,318...173,052,893
Ensembl chr 2:172,735,274...173,052,893

G

retinoic acid receptor gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RARG mRNA

NCBI chr12:53,210,569...53,232,209
Ensembl chr12:53,210,567...53,232,980

G

retinoic acid receptor responder 1

decreases expression

Dextran Sulfate results in decreased expression of RARRES1 mRNA

NCBI chr 3:158,696,892...158,732,457
Ensembl chr 3:158,696,892...158,732,489

G

RAS guanyl releasing protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RASGRP3 mRNA

NCBI chr 2:33,436,348...33,564,731
Ensembl chr 2:33,436,324...33,586,669

G

Ras association domain family member 1

increases response to substance
multiple interactions

RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein

NCBI chr 3:50,329,788...50,340,836
Ensembl chr 3:50,329,782...50,340,980

G

retinol binding protein 4

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RBP4 protein

NCBI chr10:93,591,694...93,601,744
Ensembl chr10:93,591,687...93,601,744

G

RCC1 and BTB domain containing protein 2

increases expression

Dextran Sulfate results in increased expression of RCBTB2 mRNA

NCBI chr13:48,488,963...48,535,895
Ensembl chr13:48,488,963...48,533,256

G

radixin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RDX protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RDX protein]

NCBI chr11:110,174,922...110,296,614
Ensembl chr11:109,864,295...110,296,712

G

regenerating family member 1 alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of REG1 protein

NCBI chr 2:79,120,488...79,123,409
Ensembl chr 2:79,120,362...79,123,409

G

regenerating family member 3 alpha

increases expression

Dextran Sulfate results in increased expression of REG3B mRNA

NCBI chr 2:79,157,006...79,159,753
Ensembl chr 2:79,157,003...79,159,753

G

regenerating family member 3 gamma

increases expression

Dextran Sulfate results in increased expression of REG3G mRNA

NCBI chr 2:79,025,702...79,028,501
Ensembl chr 2:79,025,686...79,028,505

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression
increases phosphorylation
affects localization
increases activity

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; [Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RELA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased phosphorylation of RELA protein; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of RELA protein; Dextran Sulfate results in increased phosphorylation of and affects the localization of RELA protein; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of RELA protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]
Dextran Sulfate results in increased expression of RELA protein; Dextran Sulfate results in increased expression of RELA protein modified form

PMID:21724996 PMID:23261679 PMID:24038091 PMID:25449198 PMID:25472953 More...

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

renin binding protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RENBP mRNA

NCBI chr X:153,935,269...153,944,643
Ensembl chr X:153,935,269...153,944,687

G

resistin like beta

increases expression

Dextran Sulfate results in increased expression of RETNLB mRNA

NCBI chr 3:108,755,638...108,757,410
Ensembl chr 3:108,743,424...108,757,410

G

retinol saturase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RETSAT mRNA

NCBI chr 2:85,341,955...85,354,528
Ensembl chr 2:85,341,955...85,354,531

G

retinal G protein coupled receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGR mRNA

NCBI chr10:84,245,053...84,259,960
Ensembl chr10:84,230,666...84,259,960

G

regulator of G protein signaling 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS19 mRNA

NCBI chr20:64,073,181...64,079,964
Ensembl chr20:64,073,181...64,079,988

G

regulator of G protein signaling 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS7 mRNA

NCBI chr 1:240,774,742...241,357,230
Ensembl chr 1:240,767,636...241,357,374

G

Rh family B glycoprotein

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RHBG mRNA
Dextran Sulfate results in decreased expression of RHBG mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:156,369,211...156,385,219
Ensembl chr 1:156,369,211...156,385,219

G

ras homolog family member J

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RHOJ mRNA

NCBI chr14:63,204,443...63,293,508
Ensembl chr14:63,204,114...63,293,508

G

reactive intermediate imine deaminase A homolog

decreases expression

Dextran Sulfate results in decreased expression of RIDA protein

NCBI chr 8:98,102,344...98,117,171
Ensembl chr 8:98,102,344...98,117,171

G

receptor interacting serine/threonine kinase 1

multiple interactions
increases expression

dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK1 protein]

NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187

G

receptor interacting serine/threonine kinase 3

multiple interactions
increases expression

dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK3 protein]

NCBI chr14:24,336,025...24,339,991
Ensembl chr14:24,336,025...24,340,022

G

ring finger protein 213

decreases expression

Dextran Sulfate results in decreased expression of RNF213 mRNA

NCBI chr17:80,260,852...80,398,794
Ensembl chr17:80,260,852...80,398,794

G

RAR related orphan receptor C

multiple interactions
increases expression

Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA alternative form]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA]
Dextran Sulfate results in increased expression of RORC mRNA; Dextran Sulfate results in increased expression of RORC mRNA alternative form

PMID:31737179 PMID:31807802

NCBI chr 1:151,806,071...151,831,802
Ensembl chr 1:151,806,071...151,831,845

G

ribosomal protein L39 like

increases expression

Dextran Sulfate results in increased expression of RPL39L mRNA

NCBI chr 3:187,120,948...187,139,496
Ensembl chr 3:187,120,948...187,180,908

G

ribosomal protein L41

increases expression

Dextran Sulfate results in increased expression of RPL41 mRNA

NCBI chr12:56,116,633...56,117,967
Ensembl chr12:56,116,590...56,117,967

G

ribosomal protein S14

increases expression

Dextran Sulfate results in increased expression of RPS14 mRNA

NCBI chr 5:150,442,635...150,449,739
Ensembl chr 5:150,442,635...150,449,739

G

ribosomal protein S15

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15 protein]

NCBI chr19:1,438,396...1,440,495
Ensembl chr19:1,438,358...1,440,495

G

ribosomal protein S15a

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15A protein]

NCBI chr16:18,781,295...18,790,334
Ensembl chr16:18,781,295...18,790,383

G

ribosomal protein S29

increases expression

Dextran Sulfate results in increased expression of RPS29 mRNA

NCBI chr14:49,570,988...49,598,710
Ensembl chr14:49,570,984...49,599,164

G

ribosomal protein S6

multiple interactions
increases phosphorylation

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of RPS6 protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]

PMID:19931517 PMID:31676321

NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236

G

ribosomal protein S6 kinase B1

multiple interactions
decreases phosphorylation
increases phosphorylation

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574

G

RAS related 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RRAS2 protein]

NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506

G

ribosome binding protein 1

increases expression

Dextran Sulfate results in increased expression of RRBP1 mRNA

NCBI chr20:17,613,679...17,682,242
Ensembl chr20:17,613,678...17,682,295

G

ribosomal RNA processing 1

increases expression

Dextran Sulfate results in increased expression of RRP1 mRNA

NCBI chr21:43,789,577...43,805,293
Ensembl chr21:43,789,513...43,805,293

G

radial spoke head component 1

increases expression

Dextran Sulfate results in increased expression of RSPH1 mRNA

NCBI chr21:42,472,486...42,496,224
Ensembl chr21:42,472,486...42,496,246

G

Ras suppressor protein 1

decreases expression

Dextran Sulfate results in decreased expression of RSU1 protein

NCBI chr10:16,590,611...16,817,424
Ensembl chr10:16,590,611...16,817,463

G

relaxin family peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP1 mRNA

NCBI chr 4:158,521,714...158,653,372
Ensembl chr 4:158,315,311...158,653,372

G

relaxin family peptide/INSL5 receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP4 mRNA

NCBI chr 1:155,941,638...155,943,087
Ensembl chr 1:155,941,638...155,943,087

G

retinoid X receptor alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RXRA mRNA

NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585

G

ryanodine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RYR1 mRNA

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

S100 calcium binding protein A11

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of S100A11 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of S100A11 protein]

NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907

G

S100 calcium binding protein A4

increases expression
multiple interactions

Dextran Sulfate results in increased expression of S100A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A4 protein]

NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136

G

S100 calcium binding protein A8

increases expression

Dextran Sulfate results in increased expression of S100A8 mRNA

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

increases expression
multiple interactions

Dextran Sulfate results in increased expression of S100A9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A9 protein]

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

S100 calcium binding protein G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of S100G mRNA

NCBI chr X:16,650,158...16,654,670
Ensembl chr X:16,650,158...16,654,670

G

sphingosine-1-phosphate receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of S1PR2 mRNA

NCBI chr19:10,221,433...10,231,331
Ensembl chr19:10,221,433...10,231,331

G

serum amyloid A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SAA1 mRNA

NCBI chr11:18,266,264...18,269,967
Ensembl chr11:18,266,260...18,269,977

G

serum amyloid A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SAA2 mRNA

NCBI chr11:18,238,236...18,248,668
Ensembl chr11:18,239,223...18,248,668

G

serum amyloid A3, pseudogene

increases expression

Dextran Sulfate results in increased expression of SAA3 mRNA

NCBI chr11:18,112,472...18,116,132
Ensembl chr11:18,112,472...18,116,132
Ensembl chr11:18,112,472...18,116,132

G

scaffold attachment factor B

increases expression

Dextran Sulfate results in increased expression of SAFB mRNA

NCBI chr19:5,623,083...5,668,478
Ensembl chr19:5,623,035...5,668,478

G

scaffold attachment factor B2

increases expression

Dextran Sulfate results in increased expression of SAFB2 mRNA

NCBI chr19:5,586,999...5,622,776
Ensembl chr19:5,586,981...5,624,046

G

Sin3A associated protein 30

increases expression

Dextran Sulfate results in increased expression of SAP30 mRNA

NCBI chr 4:173,370,954...173,377,532
Ensembl chr 4:173,369,969...173,377,532

G

sarcosine dehydrogenase

decreases expression

Dextran Sulfate results in decreased expression of SARDH mRNA

NCBI chr 9:133,659,418...133,739,955
Ensembl chr 9:133,663,560...133,739,955

G

SAP domain containing ribonucleoprotein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SARNP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SARNP protein]

NCBI chr12:55,752,463...55,817,724
Ensembl chr12:55,752,463...55,817,724

G

spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP

increases expression

Dextran Sulfate results in increased expression of SART1 mRNA

NCBI chr11:65,961,734...65,980,137
Ensembl chr11:65,961,728...65,980,137

G

sterol-C5-desaturase

decreases expression

Dextran Sulfate results in decreased expression of SC5D mRNA

NCBI chr11:121,292,771...121,313,410
Ensembl chr11:121,292,681...121,313,410

G

secretory carrier membrane protein 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SCAMP1 protein]

NCBI chr 5:78,360,617...78,480,739
Ensembl chr 5:78,360,611...78,480,739

G

stearoyl-CoA desaturase

decreases expression

Dextran Sulfate results in decreased expression of SCD2 mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

secretoglobin family 1A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SCGB1A1 mRNA

NCBI chr11:62,419,033...62,423,195
Ensembl chr11:62,405,103...62,423,195

G

secretoglobin family 3A member 1

increases expression

Dextran Sulfate results in increased expression of SCGB3A1 mRNA

NCBI chr 5:180,590,105...180,591,499
Ensembl chr 5:180,590,105...180,591,499

G

scinderin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCIN mRNA

NCBI chr 7:12,570,720...12,660,182
Ensembl chr 7:12,570,577...12,660,182

G

sodium channel epithelial 1 subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1A mRNA

NCBI chr12:6,346,847...6,377,359
Ensembl chr12:6,346,843...6,377,730

G

sodium channel epithelial 1 subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1B mRNA

NCBI chr16:23,278,231...23,381,294
Ensembl chr16:23,278,231...23,381,294

G

secretin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCT mRNA

NCBI chr11:626,309...627,181
Ensembl chr11:626,309...627,181

G

syndecan 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SDC3 mRNA

NCBI chr 1:30,869,466...30,909,735
Ensembl chr 1:30,869,466...30,908,758

G

SEC62 homolog, preprotein translocation factor

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SEC62 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SEC62 protein]

NCBI chr 3:169,966,807...169,998,373
Ensembl chr 3:169,966,635...169,998,373

G

selectin P

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SELP mRNA

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

semenogelin 2

multiple interactions

Dextran Sulfate affects the reaction [SEMG2 protein binds to KLK3 protein]; Dextran Sulfate affects the reaction [SEMG2 protein binds to SERPINA5 protein]

NCBI chr20:45,221,373...45,224,458
Ensembl chr20:45,221,373...45,224,458

G

serpin family A member 5

multiple interactions

Dextran Sulfate affects the reaction [SEMG2 protein binds to SERPINA5 protein]

NCBI chr14:94,581,426...94,593,118
Ensembl chr14:94,561,442...94,593,118

G

serpin family B member 1

decreases expression

Dextran Sulfate results in decreased expression of SERPINB1A protein

NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959

G

serpin family E member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

serpin family G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPING1 mRNA

NCBI chr11:57,597,685...57,614,848
Ensembl chr11:57,597,387...57,619,171

G

splicing factor 3a subunit 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SF3A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SF3A2 protein]

NCBI chr19:2,236,824...2,248,655
Ensembl chr19:2,236,824...2,248,655

G

serum/glucocorticoid regulated kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SGK2 mRNA

NCBI chr20:43,559,027...43,585,627
Ensembl chr20:43,558,968...43,588,237

G

sphingomyelin synthase 2

increases expression

Dextran Sulfate results in increased expression of SGMS2 mRNA

NCBI chr 4:107,824,563...107,915,047
Ensembl chr 4:107,824,563...107,915,047

G

sphingosine-1-phosphate phosphatase 2

multiple interactions
increases expression

Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SGPP2 mRNA]

NCBI chr 2:222,423,988...222,562,621
Ensembl chr 2:222,424,543...222,562,621

G

SH3 domain binding glutamate rich protein like

decreases expression

Dextran Sulfate results in decreased expression of SH3BGRL protein

NCBI chr X:81,202,102...81,298,547
Ensembl chr X:81,202,102...81,298,547

G

SH3 domain binding glutamate rich protein like 3

decreases expression

Dextran Sulfate results in decreased expression of SH3BGRL3 protein

NCBI chr 1:26,280,086...26,281,522
Ensembl chr 1:26,280,086...26,281,522

G

SH3 domain containing GRB2 like 2, endophilin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SH3GL2 mRNA

NCBI chr 9:17,579,066...17,797,124
Ensembl chr 9:17,579,066...17,797,124

G

SH3 domain containing kinase binding protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SH3KBP1 mRNA

NCBI chr X:19,533,977...19,887,600
Ensembl chr X:19,533,977...19,887,600

G

serine hydroxymethyltransferase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SHMT1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SHMT1 protein]

NCBI chr17:18,327,873...18,363,550
Ensembl chr17:18,327,873...18,363,550

G

sialic acid acetylesterase

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SIAE protein]

NCBI chr11:124,633,113...124,676,303
Ensembl chr11:124,633,113...124,695,707

G

signal-induced proliferation-associated 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SIPA1 mRNA

NCBI chr11:65,638,101...65,650,912
Ensembl chr11:65,638,101...65,650,918

G

sirtuin 1

multiple interactions
decreases expression

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 protein]
Dextran Sulfate results in decreased expression of SIRT1 mRNA; Dextran Sulfate results in decreased expression of SIRT1 protein

PMID:19940103 PMID:24548422

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

solute carrier family 10 member 1

decreases expression

Dextran Sulfate results in decreased expression of SLC10A1 mRNA; Dextran Sulfate results in decreased expression of SLC10A1 protein

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 10 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC10A2 mRNA

NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417

G

solute carrier family 10 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC10A6 mRNA

NCBI chr 4:86,823,468...86,849,384
Ensembl chr 4:86,823,468...86,849,384

G

solute carrier family 11 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC11A1 mRNA

NCBI chr 2:218,382,273...218,396,894
Ensembl chr 2:218,382,029...218,396,894

G

solute carrier family 12 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC12A4 mRNA

NCBI chr16:67,943,474...67,968,694
Ensembl chr16:67,943,474...67,969,601

G

solute carrier family 12 member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC12A7 mRNA

NCBI chr 5:1,050,384...1,155,899
Ensembl chr 5:1,050,384...1,112,063

G

solute carrier family 13 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A1 mRNA

NCBI chr 7:123,113,531...123,199,971
Ensembl chr 7:123,113,531...123,199,972

G

solute carrier family 13 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A2 mRNA

NCBI chr17:28,473,644...28,497,781
Ensembl chr17:28,473,293...28,497,781

G

solute carrier family 13 member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A5 mRNA

NCBI chr17:6,684,719...6,713,369
Ensembl chr17:6,684,719...6,713,377

G

solute carrier family 15 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC15A1 mRNA

NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672

G

solute carrier family 15 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC15A4 mRNA

NCBI chr12:128,793,194...128,823,958
Ensembl chr12:128,793,194...128,823,958

G

solute carrier family 16 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A3 mRNA

NCBI chr17:82,217,934...82,240,086
Ensembl chr17:82,217,934...82,261,129

G

solute carrier family 16 member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A8 mRNA

NCBI chr22:38,078,137...38,084,184
Ensembl chr22:38,078,134...38,084,184

G

solute carrier family 17 member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A5 mRNA

NCBI chr 6:73,593,379...73,653,992
Ensembl chr 6:73,593,379...73,653,992

G

solute carrier family 17 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC17A6 mRNA

NCBI chr11:22,338,381...22,379,503
Ensembl chr11:22,338,381...22,379,503

G

solute carrier family 17 member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A8 mRNA

NCBI chr12:100,357,074...100,422,055
Ensembl chr12:100,357,074...100,422,055

G

solute carrier family 18 member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC18A1 mRNA

NCBI chr 8:20,144,855...20,183,136
Ensembl chr 8:20,144,855...20,183,206

G

solute carrier family 1 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A2 mRNA

NCBI chr11:35,251,205...35,420,507
Ensembl chr11:35,251,205...35,420,063

G

solute carrier family 1 member 5

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SLC1A5 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SLC1A5 protein]

NCBI chr19:46,774,883...46,788,594
Ensembl chr19:46,774,883...46,788,594

G

solute carrier family 1 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A6 mRNA

NCBI chr19:14,950,033...15,010,643
Ensembl chr19:14,950,033...15,022,990

G

solute carrier family 1 member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A7 mRNA

NCBI chr 1:53,087,183...53,142,638
Ensembl chr 1:53,087,179...53,142,638

G

solute carrier family 22 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A1 mRNA

NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718

G

solute carrier family 22 member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A18 mRNA

NCBI chr11:2,899,691...2,925,246
Ensembl chr11:2,899,721...2,925,246

G

solute carrier family 22 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A3 mRNA

NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577

G

solute carrier family 22 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC22A4 mRNA

NCBI chr 5:132,294,394...132,344,190
Ensembl chr 5:132,294,394...132,344,190

G

solute carrier family 22 member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A5 mRNA

NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613

G

solute carrier family 22 member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A8 mRNA

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier family 25 member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC25A10 mRNA

NCBI chr17:81,712,284...81,721,012
Ensembl chr17:81,712,236...81,721,016

G

solute carrier family 25 member 28

increases expression

Dextran Sulfate results in increased expression of SLC25A28 mRNA

NCBI chr10:99,610,522...99,659,286
Ensembl chr10:99,610,519...99,622,793

G

solute carrier family 25 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC25A4 mRNA

NCBI chr 4:185,143,266...185,150,382
Ensembl chr 4:185,143,266...185,150,382

G

solute carrier family 26 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A1 mRNA

NCBI chr 4:978,991...993,404
Ensembl chr 4:979,073...993,440

G

solute carrier family 26 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A2 mRNA

NCBI chr 5:149,960,758...149,987,400
Ensembl chr 5:149,960,758...149,993,455

G

solute carrier family 26 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A3 mRNA

NCBI chr 7:107,765,469...107,803,223
Ensembl chr 7:107,765,467...107,803,225

G

solute carrier family 26 member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A7 mRNA

NCBI chr 8:91,209,496...91,398,155
Ensembl chr 8:91,209,494...91,398,155

G

solute carrier family 26 member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC26A9 mRNA

NCBI chr 1:205,913,052...205,943,456
Ensembl chr 1:205,913,048...205,943,460

G

solute carrier family 27 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A1 mRNA

NCBI chr19:17,468,767...17,506,168
Ensembl chr19:17,468,769...17,506,168

G

solute carrier family 27 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A4 mRNA

NCBI chr 9:128,340,527...128,361,470
Ensembl chr 9:128,340,527...128,361,470

G

solute carrier family 28 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC28A3 mRNA

NCBI chr 9:84,275,457...84,368,727
Ensembl chr 9:84,275,457...84,340,758

G

solute carrier family 29 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC29A2 mRNA

NCBI chr11:66,362,521...66,372,446
Ensembl chr11:66,362,521...66,372,214

G

solute carrier family 2 member 1

increases expression

Dextran Sulfate results in increased expression of SLC2A1 protein

NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893

G

solute carrier family 2 member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A12 mRNA

NCBI chr 6:133,987,581...134,052,624
Ensembl chr 6:133,987,581...134,052,624

G

solute carrier family 2 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A3 mRNA

NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007

G

solute carrier family 30 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC30A1 mRNA

NCBI chr 1:211,571,568...211,579,161
Ensembl chr 1:211,571,568...211,579,161

G

solute carrier family 30 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC30A2 mRNA

NCBI chr 1:26,037,252...26,046,118
Ensembl chr 1:26,037,252...26,046,118

G

solute carrier family 34 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC34A2 mRNA

NCBI chr 4:25,655,851...25,678,748
Ensembl chr 4:25,648,011...25,678,748

G

solute carrier family 35 member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A1 mRNA

NCBI chr 6:87,472,974...87,512,336
Ensembl chr 6:87,470,623...87,512,336

G

solute carrier family 35 member A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A3 mRNA

NCBI chr 1:99,969,996...100,035,634
Ensembl chr 1:99,969,351...100,035,634

G

solute carrier family 35 member D1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D1 mRNA

NCBI chr 1:66,972,976...67,054,148
Ensembl chr 1:66,999,350...67,054,148

G

solute carrier family 35 member D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D2 mRNA

NCBI chr 9:96,313,444...96,383,711
Ensembl chr 9:96,313,444...96,383,711

G

solute carrier family 36 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC36A1 mRNA

NCBI chr 5:151,344,596...151,556,085
Ensembl chr 5:151,437,046...151,492,379

G

solute carrier family 38 member 1

decreases expression

Dextran Sulfate results in decreased expression of SLC38A1 mRNA

NCBI chr12:46,183,063...46,269,043
Ensembl chr12:46,183,063...46,270,017

G

solute carrier family 38 member 2

increases expression

Dextran Sulfate results in increased expression of SLC38A2 mRNA

NCBI chr12:46,358,188...46,372,773
Ensembl chr12:46,358,188...46,372,773

G

solute carrier family 39 member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A10 mRNA

NCBI chr 2:195,613,029...195,737,700
Ensembl chr 2:195,575,977...195,737,702

G

solute carrier family 39 member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A14 mRNA

NCBI chr 8:22,367,278...22,434,129
Ensembl chr 8:22,367,278...22,434,129

G

solute carrier family 39 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A4 mRNA

NCBI chr 8:144,412,414...144,416,844
Ensembl chr 8:144,409,742...144,416,844

G

solute carrier family 39 member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A5 mRNA

NCBI chr12:56,230,051...56,237,846
Ensembl chr12:56,230,049...56,237,846

G

solute carrier family 39 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A6 mRNA

NCBI chr18:36,108,531...36,129,340
Ensembl chr18:36,108,531...36,129,385

G

solute carrier family 39 member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A8 mRNA

NCBI chr 4:102,251,041...102,345,482
Ensembl chr 4:102,251,080...102,431,258

G

solute carrier family 3 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC3A1 mRNA

NCBI chr 2:44,275,480...44,322,437
Ensembl chr 2:44,275,458...44,321,494

G

solute carrier family 40 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC40A1 mRNA

NCBI chr 2:189,560,590...189,580,786
Ensembl chr 2:189,560,590...189,583,758

G

solute carrier family 44 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A3 mRNA

NCBI chr 1:94,820,357...94,895,247
Ensembl chr 1:94,820,342...94,895,246

G

solute carrier family 44 member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A4 mRNA

NCBI chr 6:31,863,192...31,878,997
Ensembl chr 6:31,863,192...31,879,046

G

solute carrier family 46 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC46A1 mRNA

NCBI chr17:28,394,642...28,406,592
Ensembl chr17:28,394,642...28,407,197

G

solute carrier family 47 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A1 mRNA

NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034

G

solute carrier family 47 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A2 mRNA

NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979

G

solute carrier family 4 member 1 (Diego blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A1 mRNA

NCBI chr17:44,248,390...44,268,135
Ensembl chr17:44,248,390...44,268,141

G

solute carrier family 4 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A2 mRNA

NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526

G

solute carrier family 4 member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A7 mRNA

NCBI chr 3:27,372,723...27,484,384
Ensembl chr 3:27,372,723...27,484,420

G

solute carrier family 51 member A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51A mRNA

NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178

G

SLC51 subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51B mRNA

NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397

G

solute carrier family 52 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC52A2 mRNA

NCBI chr 8:144,358,552...144,361,272
Ensembl chr 8:144,333,957...144,361,286

G

solute carrier family 5 member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A1 mRNA

NCBI chr22:32,043,261...32,113,029
Ensembl chr22:32,043,261...32,113,029

G

solute carrier family 5 member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A11 mRNA

NCBI chr16:24,845,963...24,911,626
Ensembl chr16:24,845,841...24,911,628

G

solute carrier family 5 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC5A3 mRNA

NCBI chr21:34,073,578...34,106,260
Ensembl chr21:34,073,578...34,106,260

G

solute carrier family 5 member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A8 mRNA

NCBI chr12:101,155,493...101,210,238
Ensembl chr12:101,155,493...101,210,238

G

solute carrier family 5 member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A9 mRNA

NCBI chr 1:48,222,716...48,248,638
Ensembl chr 1:48,222,685...48,248,644

G

solute carrier family 6 member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A11 mRNA

NCBI chr 3:10,816,228...10,940,714
Ensembl chr 3:10,816,201...10,940,714

G

solute carrier family 6 member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A12 mRNA

NCBI chr12:183,848...214,157
Ensembl chr12:190,077...214,570

G

solute carrier family 6 member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A14 mRNA

NCBI chr X:116,436,606...116,461,458
Ensembl chr X:116,436,606...116,461,458

G

solute carrier family 6 member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A19 mRNA

NCBI chr 5:1,201,595...1,225,111
Ensembl chr 5:1,201,595...1,225,111

G

solute carrier family 6 member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A2 mRNA

NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645

G

solute carrier family 6 member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A3 mRNA

NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440

G

solute carrier family 6 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A6 mRNA

NCBI chr 3:14,402,576...14,489,349
Ensembl chr 3:14,402,576...14,489,349

G

solute carrier family 7 member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A5 mRNA

NCBI chr16:87,830,023...87,869,507
Ensembl chr16:87,830,016...87,869,507

G

solute carrier family 7 member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC7A6 mRNA

NCBI chr16:68,264,526...68,301,819
Ensembl chr16:68,264,516...68,301,823

G

solute carrier family 7 member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A9 mRNA

NCBI chr19:32,830,511...32,869,767
Ensembl chr19:32,830,509...32,869,767

G

solute carrier family 8 member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A1 mRNA

NCBI chr 2:40,097,270...40,512,435
Ensembl chr 2:40,097,270...40,611,053

G

solute carrier family 8 member A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A3 mRNA

NCBI chr14:70,044,215...70,189,405
Ensembl chr14:70,044,215...70,189,480

G

solute carrier family 9 member A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A2 mRNA

NCBI chr 2:102,619,553...102,711,355
Ensembl chr 2:102,619,553...102,711,355

G

solute carrier family 9 member A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A3 mRNA

NCBI chr 5:470,456...524,449
Ensembl chr 5:470,456...524,449

G

solute carrier family 9 member A7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC9A7 mRNA

NCBI chr X:46,599,251...46,759,118
Ensembl chr X:46,599,251...46,759,118

G

solute carrier organic anion transporter family member 2B1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO2B1 mRNA
Dextran Sulfate results in increased expression of SLCO2B1 mRNA; Dextran Sulfate results in increased expression of SLCO2B1 protein
Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]

PMID:29950665 PMID:38423481

NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549

G

solute carrier organic anion transporter family member 3A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLCO3A1 mRNA

NCBI chr15:91,853,708...92,172,435
Ensembl chr15:91,853,708...92,172,435

G

smoothened, frizzled class receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMO mRNA

NCBI chr 7:129,188,633...129,213,545
Ensembl chr 7:129,188,633...129,213,545

G

spermine oxidase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMOX mRNA

NCBI chr20:4,148,828...4,187,727
Ensembl chr20:4,120,980...4,187,747

G

sphingomyelin phosphodiesterase 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SMPD2 mRNA
Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD2 mRNA]

NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919

G

sphingomyelin phosphodiesterase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SMPD4 mRNA
Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD4 mRNA]

NCBI chr 2:130,151,392...130,181,757
Ensembl chr 2:130,151,392...130,182,750

G

snail family transcriptional repressor 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SNAI1 protein

NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886

G

small nucleolar RNA, C/D box 118

increases expression

Dextran Sulfate results in increased expression of SNORD118 mRNA

NCBI chr17:8,173,452...8,173,588
Ensembl chr17:8,173,454...8,173,587

G

sorting nexin 9

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SNX9 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SNX9 protein]

NCBI chr 6:157,823,246...157,945,077
Ensembl chr 6:157,700,387...157,945,077

G

SRY-box transcription factor 4

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of SOX4 mRNA

NCBI chr 6:21,593,751...21,598,619
Ensembl chr 6:21,593,751...21,598,619

G

SRY-box transcription factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SOX9 mRNA

NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416

G

secreted protein acidic and cysteine rich

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA

NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975

G

sphingosine kinase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPHK1 mRNA
Dextran Sulfate results in increased expression of SPHK1 protein
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SPHK1 protein]

PMID:29950665 PMID:30811821

NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860

G

sialophorin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPN mRNA

NCBI chr16:29,662,963...29,670,876
Ensembl chr16:29,662,979...29,670,876

G

secreted phosphoprotein 1

multiple interactions
decreases expression
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of SPP1 mRNA]
Dextran Sulfate results in decreased expression of SPP1 protein

PMID:32033881 PMID:35999755

NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532

G

small proline rich protein 1A

increases expression

Dextran Sulfate results in increased expression of SPRR1A mRNA

NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814

G

spectrin beta, non-erythrocytic 1

decreases expression

Dextran Sulfate results in decreased expression of SPTBN1 protein

NCBI chr 2:54,456,327...54,671,446
Ensembl chr 2:54,456,327...54,671,446

G

sequestosome 1

multiple interactions
increases expression
decreases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]

PMID:27611972 PMID:31676321 PMID:31926917 PMID:38648921

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

steroid 5 alpha-reductase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SRD5A2 mRNA

NCBI chr 2:31,522,480...31,663,009
Ensembl chr 2:31,522,480...31,580,938

G

SLIT-ROBO Rho GTPase activating protein 3

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SRGAP3 mRNA
Dextran Sulfate results in decreased expression of SRGAP3 mRNA

PMID:29950665 PMID:35093514

NCBI chr 3:8,980,591...9,363,027
Ensembl chr 3:8,980,591...9,363,053

G

signal recognition particle 9

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of SRP9 protein]

NCBI chr 1:225,777,826...225,790,464
Ensembl chr 1:225,777,813...225,790,468

G

serine and arginine rich splicing factor 4

increases expression

Dextran Sulfate results in increased expression of SRSF4 mRNA

NCBI chr 1:29,147,743...29,181,900
Ensembl chr 1:29,147,743...29,181,900

G

somatostatin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SSTR1 mRNA

NCBI chr14:38,207,904...38,213,067
Ensembl chr14:38,207,904...38,213,067

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ST3GAL3 mRNA

NCBI chr 1:43,707,536...43,931,159
Ensembl chr 1:43,705,824...43,931,165

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ST3GAL6 mRNA

NCBI chr 3:98,732,262...98,795,852
Ensembl chr 3:98,732,236...98,821,201

G

steroidogenic acute regulatory protein

decreases expression

Dextran Sulfate results in decreased expression of STAR mRNA

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

StAR related lipid transfer domain containing 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STARD5 mRNA

NCBI chr15:81,309,053...81,324,141
Ensembl chr15:81,309,053...81,324,183

G

signal transducer and activator of transcription 1

increases phosphorylation
multiple interactions

Dextran Sulfate results in increased phosphorylation of STAT1 protein
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT1 protein]

NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation
increases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein]
Dextran Sulfate results in increased phosphorylation of STAT3 protein
Dextran Sulfate results in increased expression of STAT3 protein
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of STAT3 protein; Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of STAT3 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]

PMID:19028472 PMID:20155626 PMID:22334590 PMID:25026504 PMID:26074695 More...

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

STEAP family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP1 mRNA

NCBI chr 7:90,154,469...90,164,827
Ensembl chr 7:90,154,456...90,164,829

G

STEAP2 metalloreductase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP2 mRNA

NCBI chr 7:90,211,740...90,243,408
Ensembl chr 7:90,167,590...90,238,137

G

stromal interaction molecule 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STIM1 mRNA

NCBI chr11:3,854,604...4,093,210
Ensembl chr11:3,854,527...4,093,210

G

stress induced phosphoprotein 1

decreases expression

Dextran Sulfate results in decreased expression of STIP1 protein

NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543

G

serine/threonine kinase 4

multiple interactions

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein

NCBI chr20:44,966,512...45,080,021
Ensembl chr20:44,966,494...45,084,214

G

stimulated by retinoic acid 8

increases expression

Dextran Sulfate results in increased expression of STRA8 mRNA

NCBI chr 7:135,231,915...135,258,663
Ensembl chr 7:135,231,979...135,258,663

G

syntaxin 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STX1A mRNA

NCBI chr 7:73,699,210...73,719,669
Ensembl chr 7:73,699,206...73,719,672

G

SUB1 regulator of transcription

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SUB1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUB1 protein]

NCBI chr 5:32,585,557...32,604,079
Ensembl chr 5:32,531,633...32,604,507

G

succinate-CoA ligase GDP-forming subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SUCLG2 mRNA

NCBI chr 3:67,360,460...67,654,612
Ensembl chr 3:67,360,460...67,654,612

G

sulfotransferase family 1A member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1A1 mRNA

NCBI chr16:28,591,943...28,597,050
Ensembl chr16:28,591,943...28,597,050

G

sulfotransferase family 1B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1B1 mRNA

NCBI chr 4:69,721,167...69,760,620
Ensembl chr 4:69,721,167...69,787,961

G

sulfotransferase family 1C member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1C2 mRNA

NCBI chr 2:108,288,895...108,309,915
Ensembl chr 2:108,288,639...108,309,915

G

sulfotransferase family 1E member 1

decreases expression

Dextran Sulfate results in decreased expression of SULT1E1 mRNA

NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145

G

sulfite oxidase

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUOX protein]

NCBI chr12:55,997,276...56,005,525
Ensembl chr12:55,997,180...56,006,641

G

SUV39H1 histone lysine methyltransferase

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]

NCBI chr X:48,695,554...48,709,016
Ensembl chr X:48,695,554...48,709,016

G

supervillin

decreases expression

Dextran Sulfate results in decreased expression of SVIL mRNA

NCBI chr10:29,457,338...29,736,936
Ensembl chr10:29,457,338...29,736,959

G

trace amine associated receptor 4, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAAR4 mRNA

NCBI chr 6:132,594,389...132,595,439
Ensembl chr 6:132,594,398...132,595,436

G

trace amine associated receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAAR5 mRNA

NCBI chr 6:132,588,592...132,616,747
Ensembl chr 6:132,588,592...132,589,741

G

tachykinin precursor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAC1 mRNA

NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472

G

tachykinin receptor 1

affects response to substance
multiple interactions

TACR1 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TACR1 mRNA

PMID:20889569 PMID:29950665

NCBI chr 2:75,046,463...75,199,520
Ensembl chr 2:75,046,463...75,199,520

G

tachykinin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TACR2 mRNA

NCBI chr10:69,403,903...69,416,918
Ensembl chr10:69,403,903...69,416,918

G

TATA-box binding protein associated factor 15

increases expression

Dextran Sulfate results in increased expression of TAF15 mRNA

NCBI chr17:35,809,484...35,847,242
Ensembl chr17:35,809,482...35,864,615

G

T cell activation RhoGTPase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAGAP mRNA

NCBI chr 6:159,034,481...159,044,991
Ensembl chr 6:159,034,468...159,095,823

G

transgelin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN protein

NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464

G

transgelin 2

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN2 protein
Dextran Sulfate results in decreased expression of TAGLN2 protein

NCBI chr 1:159,918,111...159,925,507
Ensembl chr 1:159,918,107...159,925,507

G

transporter 1, ATP binding cassette subfamily B member

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TAP1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAP1 mRNA

PMID:23894361 PMID:29950665

NCBI chr 6:32,845,209...32,853,704
Ensembl chr 6:32,845,209...32,853,816

G

taste 1 receptor member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TAS1R2 mRNA

NCBI chr 1:18,839,599...18,859,660
Ensembl chr 1:18,839,599...18,859,660

G

taste 1 receptor member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS1R3 mRNA

NCBI chr 1:1,331,280...1,335,314
Ensembl chr 1:1,331,280...1,335,314

G

taste 2 receptor member 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R118 mRNA

NCBI chr 7:122,994,704...122,995,700
Ensembl chr 7:122,994,704...122,995,700

G

taste 2 receptor member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R137 mRNA

NCBI chr 7:141,764,097...141,765,197
Ensembl chr 7:141,764,097...141,765,197

G

taste 2 receptor member 42

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS2R131 mRNA

NCBI chr12:11,185,993...11,186,937
Ensembl chr12:11,185,993...11,186,937

G

TBC1 domain family member 15

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of TBC1D15 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TBC1D15 protein]

NCBI chr12:71,839,759...71,924,313
Ensembl chr12:71,839,707...71,927,248

G

tubulin folding cofactor C

increases expression

Dextran Sulfate results in increased expression of TBCC mRNA

NCBI chr 6:42,744,498...42,746,103
Ensembl chr 6:42,744,498...42,746,103

G

T-box transcription factor 21

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TBX21 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TBX21 mRNA]

NCBI chr17:47,733,236...47,746,122
Ensembl chr17:47,733,236...47,746,122

G

thromboxane A synthase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TBXAS1 mRNA
Dextran Sulfate results in increased expression of TBXAS1 protein

PMID:29950665 PMID:30489199

NCBI chr 7:139,778,242...140,020,293
Ensembl chr 7:139,777,051...140,020,325

G

TRPM8 channel associated factor 1

decreases expression

Dextran Sulfate results in decreased expression of TCAF1 mRNA

NCBI chr 7:143,851,375...143,902,176
Ensembl chr 7:143,851,375...143,902,198

G

TRPM8 channel associated factor 2

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TCAF2 protein]

NCBI chr 7:143,620,974...143,730,410
Ensembl chr 7:143,620,952...143,730,410

G

titin-cap

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TCAP mRNA

NCBI chr17:39,665,349...39,666,554
Ensembl chr17:39,665,349...39,666,554

G

transcription factor 7

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA]

NCBI chr 5:134,108,218...134,148,210
Ensembl chr 5:134,114,681...134,151,865

G

trichoplein keratin filament binding

increases expression

Dextran Sulfate results in increased expression of TCHP mRNA

NCBI chr12:109,880,667...109,918,069
Ensembl chr12:109,900,264...109,983,841

G

transferrin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRF mRNA

NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641

G

trefoil factor 3

increases expression

Dextran Sulfate results in increased expression of TFF3 mRNA

NCBI chr21:42,311,667...42,315,409
Ensembl chr21:42,311,667...42,315,409

G

transferrin receptor

increases expression

Dextran Sulfate results in increased expression of TFRC protein

NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153

G

transforming growth factor beta 1

multiple interactions
decreases expression
increases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TGFB1 protein]
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of TGFB1 mRNA]

PMID:20881082 PMID:25026504 PMID:26074695 PMID:35439472

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transforming growth factor beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TGFB3 mRNA

NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011

G

thrombomodulin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBD mRNA
Dextran Sulfate results in decreased expression of THBD mRNA

PMID:29950665 PMID:35093514

NCBI chr20:23,045,633...23,049,672
Ensembl chr20:23,045,633...23,049,672

G

thrombospondin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS1 mRNA

NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466

G

thrombospondin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS4 mRNA

NCBI chr 5:79,991,332...80,083,287
Ensembl chr 5:79,991,311...80,083,287

G

Thy-1 cell surface antigen

increases expression
multiple interactions

Dextran Sulfate results in increased expression of THY1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of THY1 protein]

NCBI chr11:119,415,476...119,424,985
Ensembl chr11:119,415,476...119,424,985

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TIMP1 mRNA]

PMID:29950665 PMID:32033881

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

TIMP metallopeptidase inhibitor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP2 mRNA

NCBI chr17:78,852,977...78,925,387
Ensembl chr17:78,852,977...78,925,387

G

TIMP metallopeptidase inhibitor 3

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP3 mRNA; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]

PMID:24548422 PMID:29950665

NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041

G

tight junction protein 1

multiple interactions
decreases expression

[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 mRNA]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein]
Dextran Sulfate results in decreased expression of TJP1 mRNA; Dextran Sulfate results in decreased expression of TJP1 protein

PMID:27995407 PMID:35439472 PMID:35670535 PMID:36281492 PMID:37209277 More...

NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915

G

thymidine kinase 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA; alfacalcidol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA]

NCBI chr17:78,174,079...78,187,204
Ensembl chr17:78,174,091...78,187,233

G

transketolase

decreases expression

Dextran Sulfate results in decreased expression of TKT mRNA

NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052

G

tolloid like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLL1 mRNA

NCBI chr 4:165,873,237...166,104,457
Ensembl chr 4:165,873,237...166,104,457

G

talin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLN1 mRNA

NCBI chr 9:35,696,948...35,732,195
Ensembl chr 9:35,696,948...35,732,195

G

toll like receptor 2

multiple interactions

Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]; flavokawain B inhibits the reaction [Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]]

NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,050...153,706,260

G

toll like receptor 4

multiple interactions
affects response to substance
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR4 mRNA; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Lipopolysaccharides inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]
TLR4 protein affects the susceptibility to Dextran Sulfate

PMID:21359540 PMID:27995407 PMID:29950665 PMID:31442584 PMID:32272095 More...

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

toll like receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR7 mRNA

NCBI chr X:12,867,072...12,890,361
Ensembl chr X:12,867,072...12,890,361

G

transmembrane protein 109

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TMEM109 protein]

NCBI chr11:60,914,158...60,923,443
Ensembl chr11:60,913,907...60,923,443

G

transmembrane protein 164

decreases expression

Dextran Sulfate results in decreased expression of TMEM164 mRNA

NCBI chr X:110,002,369...110,184,251
Ensembl chr X:110,002,631...110,184,247

G

transmembrane protein 191C

increases expression

Dextran Sulfate results in increased expression of TMEM191C mRNA

NCBI chr22:21,467,387...21,469,935
Ensembl chr22:21,466,423...21,471,269

G

transmembrane protein 252

increases expression

Dextran Sulfate results in increased expression of TMEM252 mRNA

NCBI chr 9:68,536,580...68,540,883
Ensembl chr 9:68,536,580...68,540,883

G

thymosin beta 4 X-linked

decreases expression

Dextran Sulfate results in decreased expression of TMSB4X protein

NCBI chr X:12,975,110...12,977,223
Ensembl chr X:12,975,110...12,977,227

G

thiol methyltransferase 1B

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TMT1B protein]

NCBI chr12:55,681,736...55,684,611
Ensembl chr12:55,681,736...55,684,611

G

tumor necrosis factor

multiple interactions
increases expression
affects expression
increases secretion

(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of TNF protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; bisphenol A promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]]; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of TNF protein]; Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]; Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]; Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA]
Dextran Sulfate results in increased expression of TNF mRNA; Dextran Sulfate results in increased expression of TNF protein
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Dextran Sulfate co-treated with Rosiglitazone] results in increased expression of TNF protein; [2,2-bis(4-glycidyloxyphenyl)propane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]

PMID:12105854 PMID:16774945 PMID:17438113 PMID:19028472 PMID:19285099 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF receptor superfamily member 11a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFRSF11A mRNA

NCBI chr18:62,325,310...62,391,288
Ensembl chr18:62,325,287...62,391,288

G

TNF receptor superfamily member 12A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF12A mRNA

NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383

G

TNF receptor superfamily member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF18 mRNA

NCBI chr 1:1,203,508...1,206,592
Ensembl chr 1:1,203,508...1,206,592

G

TNF receptor superfamily member 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF1A mRNA

NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114

G

TNF receptor superfamily member 1B

increases expression

Dextran Sulfate results in increased expression of TNFRSF1B mRNA

NCBI chr 1:12,166,991...12,209,220
Ensembl chr 1:12,166,991...12,209,228

G

TNF receptor superfamily member 8

affects response to substance
multiple interactions

TNFRSF8 protein affects the susceptibility to Dextran Sulfate
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein

NCBI chr 1:12,063,303...12,144,207
Ensembl chr 1:12,063,303...12,144,207

G

TNF superfamily member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF12 mRNA

NCBI chr17:7,549,058...7,557,881
Ensembl chr17:7,548,508...7,557,890

G

TNF superfamily member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF14 mRNA

NCBI chr19:6,661,253...6,670,588
Ensembl chr19:6,658,085...6,670,588

G

TNF superfamily member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFSF15 mRNA

NCBI chr 9:114,784,635...114,806,039
Ensembl chr 9:114,784,652...114,806,039

G

TNF superfamily member 8

increases expression
affects response to substance
multiple interactions

Dextran Sulfate results in increased expression of TNFSF8 protein
TNFSF8 protein affects the susceptibility to Dextran Sulfate
[TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein

NCBI chr 9:114,893,343...114,930,595
Ensembl chr 9:114,893,343...114,930,595

G

TNF superfamily member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF9 mRNA

NCBI chr19:6,531,026...6,535,924
Ensembl chr19:6,531,026...6,535,924

G

troponin C1, slow skeletal and cardiac type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC1 mRNA

NCBI chr 3:52,451,100...52,454,041
Ensembl chr 3:52,451,100...52,454,041

G

troponin C2, fast skeletal type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC2 mRNA

NCBI chr20:45,823,214...45,833,306
Ensembl chr20:45,823,214...45,833,745

G

troponin I1, slow skeletal type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNNI1 mRNA

NCBI chr 1:201,403,784...201,421,730
Ensembl chr 1:201,403,784...201,429,866

G

troponin I2, fast skeletal type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNI2 mRNA

NCBI chr11:1,838,981...1,841,678
Ensembl chr11:1,838,981...1,841,680

G

troponin T3, fast skeletal type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNT3 mRNA

NCBI chr11:1,919,552...1,938,702
Ensembl chr11:1,919,703...1,938,706

G

toll interacting protein

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]

NCBI chr11:1,274,371...1,309,632
Ensembl chr11:1,274,371...1,309,654

G

translocase of outer mitochondrial membrane 7

increases expression

Dextran Sulfate results in increased expression of TOMM7 mRNA

NCBI chr 7:22,812,974...22,822,849
Ensembl chr 7:22,812,628...22,822,849

G

tumor protein p53

increases expression

Dextran Sulfate results in increased expression of TRP53 protein

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546

G

two pore segment channel 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPCN1 mRNA

NCBI chr12:113,221,464...113,298,585
Ensembl chr12:113,221,050...113,298,585

G

tryptophan hydroxylase 1

multiple interactions
increases expression

Granisetron inhibits the reaction [Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]

NCBI chr11:18,017,555...18,046,269
Ensembl chr11:18,017,555...18,046,269

G

triosephosphate isomerase 1

increases expression
decreases expression

Dextran Sulfate results in increased expression of TPI1 mRNA
Dextran Sulfate results in decreased expression of TPI1 protein

PMID:35093514 PMID:35999755

NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948

G

tropomyosin 2

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of TPM2 mRNA
Dextran Sulfate results in decreased expression of TPM2 protein

PMID:26271895 PMID:35999755

NCBI chr 9:35,681,993...35,690,056
Ensembl chr 9:35,681,992...35,690,056

G

tropomyosin 3

decreases expression

Dextran Sulfate results in decreased expression of TPM3 protein

NCBI chr 1:154,155,308...154,192,100
Ensembl chr 1:154,155,308...154,194,648

G

tropomyosin 4

decreases expression

Dextran Sulfate results in decreased expression of TPM4 protein

NCBI chr19:16,067,538...16,103,002
Ensembl chr19:16,067,021...16,103,005

G

thiopurine S-methyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPMT mRNA

NCBI chr 6:18,128,311...18,155,169
Ensembl chr 6:18,128,311...18,155,077

G

tryptase beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TPSB2 mRNA

NCBI chr16:1,228,336...1,230,184
Ensembl chr16:1,227,272...1,232,757

G

tumor protein, translationally-controlled 1

decreases expression

Dextran Sulfate results in decreased expression of TPT1 protein

NCBI chr13:45,333,471...45,341,183
Ensembl chr13:45,333,471...45,341,284

G

TRAF3 interacting protein 1

increases expression

Dextran Sulfate results in increased expression of TRAF3IP1 mRNA

NCBI chr 2:238,320,518...238,400,900
Ensembl chr 2:238,320,441...238,400,897

G

TNF receptor associated factor 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TRAF6 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]

NCBI chr11:36,483,769...36,510,272
Ensembl chr11:36,483,769...36,510,272

G

tetratricopeptide repeat and ankyrin repeat containing 1

decreases expression

Dextran Sulfate results in decreased expression of TRANK1 mRNA

NCBI chr 3:36,826,819...36,945,744
Ensembl chr 3:36,826,819...36,945,057

G

triggering receptor expressed on myeloid cells 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TREM2 protein
huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TREM2 protein]

NCBI chr 6:41,158,508...41,163,116
Ensembl chr 6:41,158,506...41,163,186

G

thyrotropin releasing hormone

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRH mRNA

NCBI chr 3:129,974,720...129,977,935
Ensembl chr 3:129,974,688...129,977,935

G

tribbles pseudokinase 2

decreases expression

Dextran Sulfate results in decreased expression of TRIB2 mRNA

NCBI chr 2:12,716,936...12,742,734
Ensembl chr 2:12,716,910...12,742,734

G

tripartite motif containing 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRIM25 mRNA

NCBI chr17:56,887,909...56,914,049
Ensembl chr17:56,836,387...56,914,080

G

tripartite motif containing 41

increases expression

Dextran Sulfate results in increased expression of TRIM41 mRNA

NCBI chr 5:181,223,281...181,235,808
Ensembl chr 5:181,222,499...181,235,808

G

telomerase RNA component interacting RNase

increases expression

Dextran Sulfate results in increased expression of TRIR mRNA

NCBI chr19:12,730,640...12,734,684
Ensembl chr19:12,730,640...12,734,684

G

transient receptor potential cation channel subfamily C member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC3 mRNA

NCBI chr 4:121,874,481...121,952,060
Ensembl chr 4:121,874,481...121,952,060

G

transient receptor potential cation channel subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC6 mRNA

NCBI chr11:101,451,564...101,584,007
Ensembl chr11:101,451,564...101,872,562

G

transient receptor potential cation channel subfamily C member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPC7 mRNA

NCBI chr 5:136,212,745...136,365,545
Ensembl chr 5:136,212,745...136,365,545

G

transient receptor potential cation channel subfamily M member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRPM1 mRNA

NCBI chr15:31,001,065...31,161,160
Ensembl chr15:31,001,065...31,161,160

G

transient receptor potential cation channel subfamily M member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM4 mRNA

NCBI chr19:49,157,792...49,211,836
Ensembl chr19:49,157,741...49,211,836

G

transient receptor potential cation channel subfamily M member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM6 mRNA

NCBI chr 9:74,722,495...74,887,921
Ensembl chr 9:74,722,495...74,888,094

G

transient receptor potential cation channel subfamily M member 8

increases expression

Dextran Sulfate results in increased expression of TRPM8 mRNA

NCBI chr 2:233,917,373...234,019,522
Ensembl chr 2:233,917,373...234,019,522

G

transient receptor potential cation channel subfamily V member 1

affects expression
multiple interactions

Dextran Sulfate affects the expression of TRPV1 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV1 mRNA

PMID:18687398 PMID:29950665

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

G

transient receptor potential cation channel subfamily V member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV2 mRNA

NCBI chr17:16,415,571...16,437,003
Ensembl chr17:16,415,571...16,437,003

G

transient receptor potential cation channel subfamily V member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV4 mRNA

NCBI chr12:109,783,087...109,833,398
Ensembl chr12:109,783,087...109,833,406

G

transient receptor potential cation channel subfamily V member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV6 mRNA

NCBI chr 7:142,871,208...142,885,745
Ensembl chr 7:142,871,208...142,885,745

G

TSC complex subunit 2

multiple interactions
decreases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]

NCBI chr16:2,047,985...2,089,491
Ensembl chr16:2,047,967...2,089,491

G

TSC22 domain family member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TSC22D3 mRNA

NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342

G

testis specific serine kinase substrate

increases expression

Dextran Sulfate results in increased expression of TSKS mRNA

NCBI chr19:49,739,760...49,763,306
Ensembl chr19:49,739,753...49,763,306

G

translin associated factor X

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TSNAX protein]

NCBI chr 1:231,528,669...231,566,524
Ensembl chr 1:231,528,541...231,566,524

G

thiosulfate sulfurtransferase

multiple interactions
decreases expression

Dextran Sulfate affects the activity of and results in decreased expression of TST protein
Dextran Sulfate results in decreased expression of TST mRNA

NCBI chr22:37,010,859...37,020,183
Ensembl chr22:37,010,859...37,020,183

G

titin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTN mRNA

NCBI chr 2:178,525,989...178,807,423
Ensembl chr 2:178,525,989...178,830,802

G

transthyretin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTR mRNA

NCBI chr18:31,591,877...31,598,821
Ensembl chr18:31,557,009...31,598,833

G

tubulin alpha 1a

decreases expression

Dextran Sulfate results in decreased expression of TUBA1A protein

NCBI chr12:49,184,795...49,189,080
Ensembl chr12:49,184,686...49,189,324

G

tubulin alpha 4a

decreases expression

Dextran Sulfate results in decreased expression of TUBA4A protein

NCBI chr 2:219,249,710...219,254,740
Ensembl chr 2:219,249,710...219,277,902

G

tubulin beta 1 class VI

decreases expression

Dextran Sulfate results in decreased expression of TUBB1 protein

NCBI chr20:59,016,438...59,026,654
Ensembl chr20:59,019,429...59,026,654

G

tubulin beta 6 class V

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TUBB6 protein]

NCBI chr18:12,307,669...12,329,826
Ensembl chr18:12,307,669...12,344,320

G

thymidylate synthetase

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA

NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578

G

transmembrane immune signaling adaptor TYROBP

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TYROBP mRNA; Dextran Sulfate results in increased expression of TYROBP protein
huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP mRNA]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP protein]

NCBI chr19:35,904,403...35,908,295
Ensembl chr19:35,904,401...35,908,295

G

UDP-N-acetylglucosamine pyrophosphorylase 1 like 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of UAP1L1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of UAP1L1 protein]

NCBI chr 9:137,077,517...137,084,538
Ensembl chr 9:137,077,517...137,084,539

G

ubiquitin like modifier activating enzyme 1

decreases expression

Dextran Sulfate results in decreased expression of UBA1 protein

NCBI chr X:47,190,847...47,215,128
Ensembl chr X:47,190,861...47,215,128

G

ubiquitin like modifier activating enzyme 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UBA7 mRNA

NCBI chr 3:49,805,209...49,813,953
Ensembl chr 3:49,805,209...49,813,953

G

ubiquilin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of UBQLN1 protein]

NCBI chr 9:83,659,968...83,707,958
Ensembl chr 9:83,659,968...83,707,958

G

uridine-cytidine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UCK2 mRNA

NCBI chr 1:165,827,614...165,911,618
Ensembl chr 1:165,827,614...165,911,618

G

UDP-glucose 6-dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGDH mRNA

NCBI chr 4:39,498,755...39,527,439
Ensembl chr 4:39,498,755...39,528,311

G

UDP glucuronosyltransferase family 1 member A10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A10 mRNA

NCBI chr 2:233,636,448...233,773,300
Ensembl chr 2:233,636,448...233,773,300

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A6B mRNA
Dextran Sulfate results in decreased expression of UGT1A6B mRNA

PMID:29950665 PMID:35093514

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

UDP glucuronosyltransferase family 2 member A1 complex locus

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2A1 mRNA

NCBI chr 4:69,588,417...69,653,247
Ensembl chr 4:69,588,417...69,653,249

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B34 mRNA

NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987

G

unc-51 like autophagy activating kinase 1

multiple interactions
decreases phosphorylation

biochanin A inhibits the reaction [Dextran Sulfate results in decreased phosphorylation of ULK1 protein]

NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150

G

unc-80 homolog, NALCN channel complex subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UNC80 mRNA

NCBI chr 2:209,771,832...209,999,296
Ensembl chr 2:209,771,569...209,999,300

G

beta-ureidopropionase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPB1 mRNA

NCBI chr22:24,495,332...24,528,390
Ensembl chr22:24,494,107...24,528,390

G

UPF3A regulator of nonsense mediated mRNA decay

increases expression

Dextran Sulfate results in increased expression of UPF3A mRNA

NCBI chr13:114,281,601...114,305,817
Ensembl chr13:114,281,601...114,305,817

G

uridine phosphorylase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPP2 mRNA

NCBI chr 2:157,995,179...158,136,154
Ensembl chr 2:157,876,679...158,136,154

G

ubiquinol-cytochrome c reductase complex III subunit VII

increases expression

Dextran Sulfate results in increased expression of UQCRQ mRNA

NCBI chr 5:132,866,642...132,868,847
Ensembl chr 5:132,866,630...132,868,847

G

vav guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV1 mRNA

NCBI chr19:6,772,708...6,857,361
Ensembl chr19:6,772,708...6,857,366

G

vav guanine nucleotide exchange factor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV3 mRNA

NCBI chr 1:107,571,161...107,965,180
Ensembl chr 1:107,571,161...107,965,180

G

vascular cell adhesion molecule 1

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]

PMID:21724996 PMID:25448682 PMID:38583725

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

versican

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA

NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303

G

vinculin

decreases expression

Dextran Sulfate results in decreased expression of VCL protein

NCBI chr10:73,998,116...74,121,363
Ensembl chr10:73,995,193...74,121,363

G

vitamin D receptor

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VDR mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of VDR protein]

PMID:29950665 PMID:38588969

NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048

G

vascular endothelial growth factor A

increases expression

Dextran Sulfate results in increased expression of VEGFA mRNA; Dextran Sulfate results in increased expression of VEGFA protein

PMID:20025956 PMID:35093514

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vascular endothelial growth factor C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFC mRNA

NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922

G

vascular endothelial growth factor D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFD mRNA

NCBI chr X:15,345,596...15,384,413
Ensembl chr X:15,345,596...15,384,413

G

vimentin

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of VIM protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIM protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VIM mRNA

PMID:29950665 PMID:34273909 PMID:36543318

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

vasoactive intestinal peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIPR1 mRNA

NCBI chr 3:42,489,299...42,537,568
Ensembl chr 3:42,489,299...42,537,573

G

WD repeat domain 1

decreases expression

Dextran Sulfate results in decreased expression of WDR1 protein

NCBI chr 4:10,074,339...10,116,799
Ensembl chr 4:10,068,089...10,116,972

G

WNT inhibitory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA]

PMID:26271895 PMID:31715269

NCBI chr12:65,050,626...65,121,305
Ensembl chr12:65,050,626...65,121,305

G

WNK lysine deficient protein kinase 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WNK1 mRNA

NCBI chr12:752,579...911,452
Ensembl chr12:752,579...911,452

G

WNK lysine deficient protein kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNK4 mRNA

NCBI chr17:42,780,610...42,797,066
Ensembl chr17:42,780,610...42,797,066

G

Wnt family member 10A

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA]

NCBI chr 2:218,874,116...218,893,928
Ensembl chr 2:218,880,852...218,899,581

G

Wnt family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of WNT2 mRNA

NCBI chr 7:117,275,451...117,323,058
Ensembl chr 7:117,275,451...117,323,152

G

Wnt family member 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNT2B mRNA

NCBI chr 1:112,466,541...112,530,165
Ensembl chr 1:112,466,541...112,530,165

G

Wnt family member 3

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA]

NCBI chr17:46,762,506...46,818,692
Ensembl chr17:46,762,506...46,833,154

G

Wnt family member 6

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA]

NCBI chr 2:218,859,805...218,874,233
Ensembl chr 2:218,859,805...218,874,233

G

Wnt family member 7B

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA]

NCBI chr22:45,920,366...45,977,162
Ensembl chr22:45,920,366...45,977,162

G

X-C motif chemokine ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCL1 mRNA

NCBI chr 1:168,576,605...168,582,069
Ensembl chr 1:168,576,605...168,582,069

G

X-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCR1 mRNA

NCBI chr 3:46,017,007...46,085,844
Ensembl chr 3:46,016,990...46,085,825

G

X-linked inhibitor of apoptosis

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]

NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972

G

X-prolyl aminopeptidase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XPNPEP2 mRNA

NCBI chr X:129,738,979...129,769,536
Ensembl chr X:129,738,949...129,769,536

G

Yes1 associated transcriptional regulator

multiple interactions

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein

NCBI chr11:102,110,447...102,233,424
Ensembl chr11:102,110,447...102,233,424

G

Y-box binding protein 2

increases expression

Dextran Sulfate results in increased expression of YBX2 mRNA

NCBI chr17:7,288,263...7,294,639
Ensembl chr17:7,288,263...7,294,639

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon

decreases expression

Dextran Sulfate results in decreased expression of YWHAE protein

NCBI chr17:1,344,275...1,400,222
Ensembl chr17:1,344,275...1,400,222

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta

decreases expression

Dextran Sulfate results in decreased expression of YWHAH protein

NCBI chr22:31,944,535...31,957,603
Ensembl chr22:31,944,522...31,957,603

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of YWHAQ protein

NCBI chr 2:9,583,967...9,630,997
Ensembl chr 2:9,583,967...9,630,997

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta

decreases expression

Dextran Sulfate results in decreased expression of YWHAZ protein

NCBI chr 8:100,916,523...100,953,382
Ensembl chr 8:100,916,523...100,953,388

G

Z-DNA binding protein 1

increases expression

Dextran Sulfate results in increased expression of ZBP1 mRNA

NCBI chr20:57,603,852...57,620,426
Ensembl chr20:57,603,846...57,620,576

G

zinc finger CCCH-type containing 18

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ZC3H18 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ZC3H18 protein]

NCBI chr16:88,570,403...88,631,964
Ensembl chr16:88,570,403...88,631,964

G

zinc finger FYVE-type containing 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ZFYVE9 mRNA

NCBI chr 1:52,142,089...52,346,634
Ensembl chr 1:52,142,089...52,348,671

G

zinc finger protein 821

increases expression

Dextran Sulfate results in increased expression of ZFP821 mRNA

NCBI chr16:71,859,680...71,895,256
Ensembl chr16:71,859,680...71,895,336

G

zinc and ring finger 4

increases expression

Dextran Sulfate results in increased expression of ZNRF4 mRNA

NCBI chr19:5,455,417...5,456,856
Ensembl chr19:5,455,417...5,456,856

diethyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

aldo-keto reductase family 1 member C2

increases expression

diethyl sulfate results in increased expression of AKR1C2 mRNA

NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031

G

BCL2 associated X, apoptosis regulator

increases expression

diethyl sulfate results in increased expression of BAX protein

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

decreases expression

diethyl sulfate results in decreased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

increases cleavage
increases expression

diethyl sulfate results in increased cleavage of CASP3 protein
diethyl sulfate results in increased expression of CASP3 protein modified form

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

cyclin A2

affects expression

diethyl sulfate affects the expression of CCNA2 protein

NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883

G

cyclin B1

affects expression

diethyl sulfate affects the expression of CCNB1 protein

NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245

G

cyclin dependent kinase 2

affects phosphorylation

diethyl sulfate affects the phosphorylation of CDK2 protein

NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789

G

cyclin dependent kinase 4

affects expression

diethyl sulfate affects the expression of CDK4 protein

NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013

G

checkpoint kinase 1

decreases expression
increases expression

diethyl sulfate results in decreased expression of CHEK1 protein modified form
diethyl sulfate results in increased expression of CHEK1 protein modified form

NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255

G

checkpoint kinase 2

decreases expression
increases expression

diethyl sulfate results in decreased expression of CHEK2 protein modified form
diethyl sulfate results in increased expression of CHEK2 protein modified form

NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422

G

cytochrome P450 family 1 subfamily A member 1

increases expression

diethyl sulfate results in increased expression of CYP1A1 mRNA

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

fatty acid binding protein 4

multiple interactions

diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

glutamate-cysteine ligase catalytic subunit

increases expression

diethyl sulfate results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

heme oxygenase 1

increases expression

diethyl sulfate results in increased expression of HMOX1 mRNA

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

insulin

multiple interactions

diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

MAF bZIP transcription factor F

increases expression

diethyl sulfate results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

tumor protein p53

decreases expression
increases expression

diethyl sulfate results in decreased expression of TP53 protein
diethyl sulfate results in increased expression of TP53 protein

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546

dimethyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

DNA methyltransferase 1

decreases expression

dimethyl sulfate results in decreased expression of DNMT1 protein

NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286

G

heme oxygenase 1

multiple interactions

dimethyl sulfate inhibits the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

O-6-methylguanine-DNA methyltransferase

increases alkylation

dimethyl sulfate results in increased alkylation of MGMT protein

NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983

G

N-methylpurine DNA glycosylase

increases response to substance

MPG protein results in increased susceptibility to dimethyl sulfate

NCBI chr16:77,007...85,846
Ensembl chr16:77,007...85,851

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

dimethyl sulfate results in increased expression of PMAIP1 mRNA

NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305

dodecyl hydrogen sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

transient receptor potential cation channel subfamily V member 1

multiple interactions
increases activity

capsazepine inhibits the reaction [dodecyl sulfate results in increased activity of TRPV1 protein]

NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411

estrone 3-sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 8

affects transport

ABCA8 protein affects the transport of estrone sulfate

NCBI chr17:68,867,289...68,955,392
Ensembl chr17:68,867,289...68,955,392

G

ATP binding cassette subfamily C member 2

affects export
increases activity

ABCC2 protein affects the export of estrone sulfate
estrone sulfate results in increased activity of ABCC2 protein; estrone sulfate results in increased activity of ABCC2 protein modified form

PMID:15652233 PMID:15904671 PMID:16046661

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily G member 2 (JR blood group)

affects export
increases export
increases uptake
multiple interactions
affects transport

ABCG2 protein affects the export of estrone sulfate
ABCG2 protein results in increased export of estrone sulfate
ABCG2 protein results in increased uptake of estrone sulfate
[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Androstenedione inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Estradiol inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; hippuric acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Indican inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Kynurenic Acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Progesterone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate]; Testosterone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]
ABCG2 protein affects the transport of estrone sulfate

PMID:15901800 PMID:18834354 PMID:19505989 PMID:21483698 PMID:22581381 More...

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

dehydrogenase/reductase 11

increases reduction

DHRS11 protein results in increased reduction of estrone sulfate

NCBI chr17:36,591,879...36,600,804
Ensembl chr17:36,591,879...36,600,804

G

estrogen receptor 2

affects binding

Estrone-3-sulfate binds to Esr2 protein

RGD

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

interleukin 1 alpha

decreases expression

estrone sulfate results in decreased expression of IL1A mRNA

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 6

decreases expression

estrone sulfate results in decreased expression of IL6 mRNA

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

platelet derived growth factor subunit A

decreases expression

estrone sulfate results in decreased expression of PDGFA mRNA

NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296

G

solute carrier family 10 member 1

multiple interactions

daidzein metabolite inhibits the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; daidzein metabolite promotes the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 10 member 6

increases transport
increases response to substance
increases uptake
multiple interactions

SLC10A6 protein results in increased transport of estrone sulfate
SLC10A6 protein results in increased susceptibility to estrone sulfate
SLC10A6 protein results in increased uptake of estrone sulfate
daidzein inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A6 protein results in increased transport of daidzein metabolite]; Sodium promotes the reaction [SLC10A6 protein results in increased uptake of estrone sulfate]

PMID:23562556 PMID:25319728 PMID:30186172

NCBI chr 4:86,823,468...86,849,384
Ensembl chr 4:86,823,468...86,849,384

G

solute carrier family 17 member 3

affects transport

SLC17A3 gene SNP affects the transport of estrone sulfate

NCBI chr 6:25,844,856...25,874,243
Ensembl chr 6:25,833,066...25,882,286

G

solute carrier family 22 member 11

multiple interactions
affects transport
increases uptake
increases import

4-methylumbelliferyl sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; 4-nitrophenyl sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; aristolochic acid I inhibits the reaction [SLC22A11 results in increased uptake of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; Corticosterone inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; daidzein inhibits the reaction [SLC22A11 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLC22A11 protein results in increased transport of estrone sulfate]; Diclofenac inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; estradiol sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC22A11 protein results in increased transport of daidzein metabolite]; estrone sulfate promotes the reaction [SLC22A11 results in increased export of p-Aminohippuric Acid]; Furosemide inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; glutaric acid promotes the reaction [SLC22A11 protein results in increased import of estrone sulfate]; Ibuprofen inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; Indomethacin inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; naphthyl sulfate inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; Oxypurinol inhibits the reaction [SLC22A11 protein results in increased uptake of estrone sulfate]; p-Aminohippuric Acid promotes the reaction [SLC22A11 protein results in increased import of estrone sulfate]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A11 protein results in increased import of estrone sulfate]; perfluoro-n-nonanoic acid inhibits the reaction [SLC22A11 protein results in increased import of estrone sulfate]; perfluorodecanoic acid inhibits the reaction [SLC22A11 protein results in increased import of estrone sulfate]; perfluorooctanoic acid inhibits the reaction [SLC22A11 protein results in increased import of estrone sulfate]; Probenecid inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A11 protein results in increased import of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLC22A11 protein affects the transport of estrone sulfate]; Uric Acid inhibits the reaction [SLC22A11 protein results in increased uptake of estrone sulfate]
SLC22A11 protein results in increased uptake of estrone sulfate; SLC22A11 results in increased uptake of estrone sulfate

PMID:10660625 PMID:16135657 PMID:19643159 PMID:20639259 PMID:25319728 More...

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

solute carrier family 22 member 12

increases uptake

SLC22A12 protein results in increased uptake of estrone sulfate

NCBI chr11:64,591,220...64,602,344
Ensembl chr11:64,590,641...64,602,353

G

solute carrier family 22 member 20, pseudogene

multiple interactions
increases uptake

2,4-Dichlorophenoxyacetic Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Glutarates promotes the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; ochratoxin A inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; p-Aminohippuric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Salicylates inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Uric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]

NCBI chr11:65,213,840...65,242,757
Ensembl chr11:65,213,873...65,242,086

G

solute carrier family 22 member 24

multiple interactions
affects transport

4-methylumbelliferyl sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Diclofenac inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; estradiol sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Furosemide inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Ibuprofen inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Succinic Acid affects the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]

NCBI chr11:63,079,940...63,144,221
Ensembl chr11:63,079,940...63,144,221

G

solute carrier family 22 member 6

increases uptake

SLC22A6 protein results in increased uptake of estrone sulfate

NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967

G

solute carrier family 22 member 7

multiple interactions
increases uptake

Fumarates promotes the reaction [SLC22A7 protein results in increased uptake of estrone sulfate]; Succinates promotes the reaction [SLC22A7 protein results in increased uptake of estrone sulfate]

NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538

G

solute carrier family 22 member 8

multiple interactions
increases import
affects transport
increases uptake

5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; aristolochic acid I inhibits the reaction [SLC22A8 results in increased uptake of estrone sulfate]; bisphenol A inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; bisphenol F inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; bisphenol S inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Cefaclor inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cefdinir inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cefotiam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Ceftibuten inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Ceftizoxime inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cephaloridine inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cholates inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Cimetidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; cyazofamid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Dehydroepiandrosterone inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Diclofenac inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Furosemide inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Ibuprofen inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Indomethacin inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Quercetin inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; rhein inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; rhein metabolite inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; tetrabromobisphenol A inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]
SLC22A8 protein results in increased uptake of estrone sulfate; SLC22A8 results in increased uptake of estrone sulfate
3,4-dihydroxymandelic acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; 3,4-Dihydroxyphenylacetic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; 5-methoxyindoleacetic acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Furosemide inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; hexadecafluoro-nonanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Homovanillic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Indocyanine Green inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; methoxytryptophol inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; perfluorodecanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; perfluorooctanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Piroxicam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Vanilmandelic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:15496291 More...

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier family 22 member 9

multiple interactions
increases import
affects transport
increases uptake

candesartan cilexetil inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; candesartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; losartan carboxylic acid inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Losartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; pranlukast inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A9 protein results in increased import of estrone sulfate]; Probenecid inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLC22A9 protein results in increased import of estrone sulfate]; Valsartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]
SLC22A9 protein affects the transport of estrone sulfate
4-methylumbelliferyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Glutarates affects the reaction [SLC22A9 protein affects the transport of estrone sulfate]; naphthyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Succinic Acid inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]
estrone sulfate inhibits the reaction [SLC22A19 protein results in increased uptake of ochratoxin A]

PMID:15068970 PMID:16079298 PMID:17132213 PMID:18441515 PMID:28629854

NCBI chr11:63,369,785...63,410,294
Ensembl chr11:63,369,785...63,410,294

G

solute carrier organic anion transporter family member 1A2

multiple interactions
increases transport
increases uptake
increases import

7-hydroxymethotrexate inhibits the reaction [SLCO1A2 mRNA results in increased import of estrone sulfate]; artemisinin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Chloroquine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Mefloquine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Methotrexate inhibits the reaction [SLCO1A2 mRNA results in increased import of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein alternative form results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased transport of estrone sulfate]; perfluorodecanoic acid inhibits the reaction [SLCO1A2 protein results in increased import of estrone sulfate]; Pyrimethamine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Quinine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]
SLCO1A2 protein alternative form results in increased uptake of estrone sulfate; SLCO1A2 protein results in increased uptake of estrone sulfate
SLCO1A2 mRNA results in increased import of estrone sulfate; SLCO1A2 protein results in increased import of estrone sulfate

PMID:16702441 PMID:20639259 PMID:25466967 PMID:27504015

NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594

G

solute carrier organic anion transporter family member 1B1

affects uptake
increases import
multiple interactions
increases uptake
increases transport
decreases transport

SLCO1B1 protein affects the uptake of estrone sulfate
SLCO1B1 protein results in increased import of estrone sulfate
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone promotes the reaction [SLCO1B1 protein results in increased import of estrone sulfate]; 4-biphenylamine inhibits the reaction [SLCO1B1 protein results in increased import of estrone sulfate]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SLCO1B1 protein mutant form] which binds to and results in increased uptake of estrone sulfate; bisphenol A inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; bisphenol F inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; cyazofamid inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; estrone sulfate affects the reaction [SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; SLCO1B1 protein binds to and results in increased uptake of estrone sulfate; Sulfobromophthalein inhibits the reaction [SLCO1B1 protein results in increased import of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; tetrabromobisphenol A inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLCO1B1 protein results in increased import of estrone sulfate]
SLCO1B1 protein results in increased transport of estrone sulfate
SLCO1B1 protein mutant form results in decreased transport of estrone sulfate

PMID:15652233 PMID:19238167 PMID:21457551 PMID:25106415 PMID:27450509 More...

NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796

G

solute carrier organic anion transporter family member 1B3

multiple interactions
increases uptake

cyazofamid inhibits the reaction [SLCO1B3 protein results in increased uptake of estrone sulfate]

PMID:32003934 PMID:34619012

NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911

G

solute carrier organic anion transporter family member 2B1

increases import
increases uptake
multiple interactions

SLCO2B1 protein results in increased import of estrone sulfate; SLCO2B1 results in increased import of estrone sulfate
SLCO2B1 protein results in increased uptake of estrone sulfate
2,2',4,4',5,6'-hexabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; [icariin results in decreased activity of SLCO2B1 protein] which results in decreased uptake of estrone sulfate; daidzein inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLCO2B1 protein results in increased transport of daidzein metabolite]; estrone sulfate inhibits the reaction [SLCO2B1 protein results in increased uptake of Quercetin]; Mefloquine affects the reaction [SLCO2B1 protein results in increased uptake of estrone sulfate]; pentabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLCO2B1 protein results in increased import of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLCO2B1 protein results in increased import of estrone sulfate]

PMID:16714376 PMID:20176623 PMID:24265111 PMID:24285294 PMID:24947867 More...

NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549

G

solute carrier organic anion transporter family member 3A1

multiple interactions

estrone sulfate promotes the reaction [SLCO3A1 protein results in increased uptake of simvastatin acid]

NCBI chr15:91,853,708...92,172,435
Ensembl chr15:91,853,708...92,172,435

G

steroid sulfatase

affects metabolic processing
decreases sulfation

STS protein affects the metabolism of estrone sulfate
STS protein results in decreased sulfation of estrone sulfate

PMID:15597397 PMID:16054388

NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358

G

sulfotransferase family 1E member 1

multiple interactions

[[Oxygen deficiency co-treated with Oxygen] results in increased expression of SULT1E1 protein] which results in increased abundance of estrone sulfate

NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145

estropipate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions

estropipate promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins]

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

fondaparinux

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

coagulation factor X

decreases activity

fondaparinux results in decreased activity of F10 protein

NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529

fucoidan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat containing 2

decreases expression

fucoidan results in decreased expression of BIRC2 protein

NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670

G

baculoviral IAP repeat containing 5

decreases expression

fucoidan results in decreased expression of BIRC5 protein

NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636

G

C-C motif chemokine ligand 5

decreases expression

fucoidan results in decreased expression of CCL5 protein

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

cyclin D2

decreases expression

fucoidan results in decreased expression of CCND2 protein

NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353

G

cyclin dependent kinase inhibitor 1A

increases expression

fucoidan results in increased expression of CDKN1A

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397

G

gastrin

multiple interactions

fucoidan analog inhibits the reaction [Cisplatin results in decreased expression of GAST protein]

NCBI chr17:41,712,331...41,715,969
Ensembl chr17:41,712,331...41,715,969

G

glutamic--pyruvic transaminase

multiple interactions

fucoidan inhibits the reaction [Aspirin results in increased expression of GPT protein]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

interferon gamma

multiple interactions

fucoidan promotes the reaction [Aspirin results in increased expression of IFNG protein]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interleukin 10

multiple interactions

fucoidan promotes the reaction [Aspirin results in increased expression of IL10 protein]

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

multiple interactions

fucoidan inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions

fucoidan inhibits the reaction [Aspirin results in increased expression of IL6 protein]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

JunD proto-oncogene, AP-1 transcription factor subunit

decreases activity

fucoidan results in decreased activity of JUND protein

NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622

G

matrix metallopeptidase 2

decreases secretion

fucoidan results in decreased secretion of MMP2 protein

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 3

multiple interactions

fucoidan inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]

NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609

G

matrix metallopeptidase 9

decreases expression
multiple interactions

fucoidan results in decreased expression of MMP9
wortmannin inhibits the reaction [fucoidan results in decreased expression of MMP9]

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

myeloperoxidase

multiple interactions

fucoidan inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:15138204 PMID:18209962

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

fucoidan results in decreased expression of MYC protein

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

nuclear factor kappa B subunit 1

decreases activity

fucoidan results in decreased activity of NFKB1 protein

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

prostaglandin-endoperoxide synthase 2

multiple interactions

fucoidan inhibits the reaction [Nanotubes, Carbon inhibits the reaction [endotoxin, Escherichia coli results in increased expression of PTGS2 protein]]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RB transcriptional corepressor 1

decreases expression

fucoidan results in decreased expression of RB1 protein

NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436

G

REL proto-oncogene, NF-kB subunit

decreases activity

fucoidan results in decreased activity of REL protein

NCBI chr 2:60,881,574...60,931,612
Ensembl chr 2:60,881,491...60,931,612

G

RELA proto-oncogene, NF-kB subunit

decreases activity

fucoidan results in decreased activity of RELA protein

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

TIMP metallopeptidase inhibitor 1

decreases secretion

fucoidan results in decreased secretion of TIMP1 protein

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

heparan sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 5

multiple interactions

Heparitin Sulfate inhibits the reaction [Hydrogen Peroxide results in increased degradation of [CCL5 protein binds to CCL5 protein]]; Heparitin Sulfate inhibits the reaction [Hydrogen Peroxide results in increased degradation of CCL5 protein]

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

C-X-C motif chemokine ligand 1

multiple interactions

CXCL10 protein inhibits the reaction [CXCL1 protein binds to Heparitin Sulfate]

NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308

G

C-X-C motif chemokine ligand 10

multiple interactions

CXCL10 protein inhibits the reaction [CXCL1 protein binds to Heparitin Sulfate]

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

fibroblast growth factor 1

affects binding

FGF1 protein binds to Heparitin Sulfate binds to FGFR1 protein

NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070

G

fibroblast growth factor 10

affects activity

Heparitin Sulfate affects the activity of FGF10 protein

PMID:12781692 PMID:12818887

NCBI chr 5:44,300,247...44,389,420
Ensembl chr 5:44,300,247...44,389,706

G

fibroblast growth factor 2

multiple interactions
affects binding
increases activity

Heparitin Sulfate binds to and affects the activity of FGF2 protein
Heparitin Sulfate binds to FGF2 protein
Heparitin Sulfate analog results in increased activity of FGF2 protein

PMID:12460940 PMID:15464572 PMID:15958608

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 4

affects binding

Heparitin Sulfate binds to FGF4 protein

NCBI chr11:69,771,022...69,775,341
Ensembl chr11:69,771,022...69,775,341

G

fibroblast growth factor 7

affects binding

Heparitin Sulfate binds to FGF7 protein

NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775

G

fibroblast growth factor 8

affects binding
increases activity

Heparitin Sulfate binds to FGF8 protein alternative form
Heparitin Sulfate analog results in increased activity of FGF8 protein

PMID:12460940 PMID:15769253

NCBI chr10:101,770,109...101,780,369
Ensembl chr10:101,770,109...101,780,371

G

fibroblast growth factor receptor 1

affects binding
increases activity

FGF1 protein binds to Heparitin Sulfate binds to FGFR1 protein
Heparitin Sulfate analog results in increased activity of FGFR1 protein alternative form

PMID:12460940 PMID:12604602

NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834

G

fibroblast growth factor receptor 2

decreases activity

Heparitin Sulfate analog results in decreased activity of FGFR2 protein mutant form

NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458

G

fibroblast growth factor receptor 3

increases activity

Heparitin Sulfate analog results in increased activity of FGFR3 protein alternative form

NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872

G

fibroblast growth factor receptor 4

affects binding

Heparitin Sulfate analog binds to FGFR4 protein

NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144

G

glucosamine (N-acetyl)-6-sulfatase

affects degradation

GNS affects the degradation of Heparitin Sulfate

NCBI chr12:64,713,449...64,759,406
Ensembl chr12:64,713,445...64,759,431

G

glypican 1

affects binding
multiple interactions

GPC1 protein binds to Heparitin Sulfate
GPC1 protein modified form results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]; nitroxyl affects the reaction [GPC1 protein results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]]; Zinc affects the reaction [GPC1 protein results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]]

NCBI chr 2:240,435,663...240,468,076
Ensembl chr 2:240,435,663...240,468,076

G

heparanase

multiple interactions
decreases abundance
affects abundance

[Heparin results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate; [phosphomannopentaose sulfate results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate
HPSE protein results in decreased abundance of Heparitin Sulfate
HPSE protein affects the abundance of Heparitin Sulfate

PMID:16899518 PMID:17121850

NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153

G

mitogen-activated protein kinase 1

multiple interactions

Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

N-deacetylase and N-sulfotransferase 1

multiple interactions

Heparitin Sulfate affects the susceptibility to [NDST1 protein co-treated with NDST2 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein]

NCBI chr 5:150,497,779...150,558,211
Ensembl chr 5:150,485,818...150,558,211

G

N-deacetylase and N-sulfotransferase 2

multiple interactions

Heparitin Sulfate affects the susceptibility to [NDST1 protein co-treated with NDST2 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein]

NCBI chr10:73,801,916...73,811,820
Ensembl chr10:73,801,911...73,811,798

G

prion protein (Kanno blood group)

affects binding

PRNP protein modified form binds to Heparitin Sulfate metabolite

NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590

G

TIMP metallopeptidase inhibitor 3

multiple interactions

[N6L peptide binds to Heparitin Sulfate] which results in increased secretion of TIMP3 protein

NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041

G

vascular endothelial growth factor A

multiple interactions

Heparitin Sulfate promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

heparin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

affects activity
multiple interactions

Heparin affects the activity of ABCC1 protein
Heparin affects the reaction [ABCC1 protein affects the transport of Doxorubicin]

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

atypical chemokine receptor 3

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA]

NCBI chr 2:236,537,122...236,582,354
Ensembl chr 2:236,567,787...236,582,354

G

actin alpha 2, smooth muscle

multiple interactions

Heparin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339

G

actin related protein 3

increases expression

Heparin results in increased expression of ACTR3 protein

NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA]

NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409

G

angiotensinogen

multiple interactions

Heparin inhibits the reaction [AGT protein affects the localization of Calcium]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

AKT serine/threonine kinase 1

multiple interactions

Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

annexin A6

increases expression

Heparin results in increased expression of ANXA6 protein

NCBI chr 5:151,100,706...151,157,779
Ensembl chr 5:151,100,706...151,157,815

G

amyloid P component, serum

increases expression

Heparin results in increased expression of APCS protein

NCBI chr 1:159,587,826...159,588,865
Ensembl chr 1:159,587,826...159,588,865

G

amyloid beta precursor protein

multiple interactions

Copper promotes the reaction [Heparin binds to APP protein]; Zinc promotes the reaction [Heparin binds to APP protein]

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

Rho GDP dissociation inhibitor alpha

increases expression

Heparin results in increased expression of ARHGDIA protein

NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,719...81,871,378

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA]

NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Heparin results in increased expression of BAX protein
Heparin inhibits the reaction [arsenite results in increased expression of BAX protein]

PMID:11787776 PMID:26677073

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

increases expression
multiple interactions

Heparin results in increased expression of BCL2 protein
Heparin inhibits the reaction [arsenite results in decreased expression of BCL2 protein]

PMID:11787776 PMID:15205081 PMID:15671997 PMID:26677073

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

bone morphogenetic protein 6

multiple interactions
decreases expression

Heparin inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Heparin inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]
Heparin results in decreased expression of BMP6 mRNA

NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728

G

bone morphogenetic protein receptor type 1A

decreases expression

Heparin results in decreased expression of BMPR1A mRNA

NCBI chr10:86,755,763...86,932,844
Ensembl chr10:86,755,786...86,932,825

G

complement C3

decreases expression

Heparin results in decreased expression of C3 protein

PMID:7948777 PMID:10568115

NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562

G

complement C5

decreases expression

Heparin results in decreased expression of C5 protein

NCBI chr 9:120,952,335...121,074,865
Ensembl chr 9:120,932,987...121,075,195

G

calcium voltage-gated channel subunit alpha1 E

multiple interactions

Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]

NCBI chr 1:181,317,699...181,808,084
Ensembl chr 1:181,317,690...181,813,262

G

capping actin protein, gelsolin like

increases expression

Heparin results in increased expression of CAPG protein

NCBI chr 2:85,391,602...85,419,540
Ensembl chr 2:85,394,753...85,418,432

G

calpain 1

multiple interactions

Heparin inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein]

NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006

G

calpain 2

multiple interactions

Heparin inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein]

NCBI chr 1:223,701,597...223,776,018
Ensembl chr 1:223,701,593...223,776,018

G

caspase 12 (gene/pseudogene)

multiple interactions

Heparin inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]

PMID:20079824 PMID:26998625

NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670

G

caspase 3

decreases activity
multiple interactions

Heparin results in decreased activity of CASP3 protein
Heparin inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein]
Heparin promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Lithium Chloride inhibits the reaction [Heparin promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]

PMID:16556679 PMID:26998625 PMID:30377735

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

catalase

increases activity

Heparin results in increased activity of CAT protein

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 11

affects binding
multiple interactions

Heparin binds to CCL11 protein
Heparin inhibits the reaction [PLG protein affects the degradation of CCL11 protein]

NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334

G

C-C motif chemokine ligand 2

decreases expression

Heparin results in decreased expression of CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

CD40 ligand

decreases expression

Heparin results in decreased expression of CD40LG protein

NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390

G

cyclin dependent kinase inhibitor 1A

increases expression

Heparin results in increased expression of CDKN1A protein

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397

G

cyclin dependent kinase inhibitor 1B

decreases expression
increases expression

Heparin analog results in decreased expression of CDKN1B protein
Heparin analog results in increased expression of CDKN1B protein

PMID:18057711 PMID:20201787

NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369

G

collagen type XVIII alpha 1 chain

affects binding

Heparin binds to COL18A1 protein alternative form

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

complement C3b/C4b receptor 1 (Knops blood group)

decreases expression

Heparin results in decreased expression of CR1 protein

NCBI chr 1:207,496,157...207,641,765
Ensembl chr 1:207,496,147...207,641,765

G

C-reactive protein

increases expression

Heparin results in increased expression of CRP protein

NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589

G

colony stimulating factor 3

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA]

NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813

G

catenin beta 1

multiple interactions

Heparin promotes the reaction [Doxorubicin results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [Heparin promotes the reaction [Doxorubicin results in decreased expression of CTNNB1 protein]]

NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096

G

C-X-C motif chemokine ligand 10

multiple interactions

Heparin inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL10 mRNA]

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 12

decreases expression

Heparin analog results in decreased expression of CXCL12 mRNA; Heparin analog results in decreased expression of CXCL12 protein

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 2

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]]

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 8

increases secretion

Heparin analog results in increased secretion of CXCL8 protein; Heparin results in increased secretion of CXCL8 protein

PMID:8595612 PMID:26476401

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

C-X-C motif chemokine receptor 4

decreases expression

Heparin analog results in decreased expression of CXCR4 mRNA; Heparin analog results in decreased expression of CXCR4 protein

NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177

G

DDAH family member 2, ADMA-independent

decreases expression

Heparin results in decreased expression of DDAH2 protein

NCBI chr 6:31,727,040...31,730,263
Ensembl chr 6:31,727,038...31,730,617

G

desmin

decreases expression

Heparin results in decreased expression of DES protein

NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735

G

E2F transcription factor 1

decreases expression

Heparin analog results in decreased expression of E2F1 protein

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

endothelin 1

multiple interactions
decreases expression
decreases secretion

Heparin inhibits the reaction [F2 protein results in increased expression of EDN1 mRNA]; Heparin inhibits the reaction [F2 protein results in increased secretion of EDN1 protein]
Heparin results in decreased expression of EDN1 mRNA
Heparin inhibits the reaction [EDN1 protein results in increased abundance of Calcium]; Heparin inhibits the reaction [EDN1 protein results in increased abundance of Inositol 1,4,5-Trisphosphate]
Heparin results in decreased secretion of EDN1 protein

PMID:1443220 PMID:7509996 PMID:8408661

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

epidermal growth factor

decreases activity

Heparin results in decreased activity of EGF protein

NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766

G

epidermal growth factor receptor

decreases expression
increases phosphorylation

Heparin results in decreased expression of EGFR mRNA; Heparin results in decreased expression of EGFR protein
Heparin results in increased phosphorylation of EGFR protein

PMID:16475731 PMID:16556679

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

egl-9 family hypoxia inducible factor 3

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA]

NCBI chr14:33,924,227...33,951,074
Ensembl chr14:33,924,227...34,462,774

G

coagulation factor X

decreases activity

Heparin results in decreased activity of F10 protein

NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529

G

coagulation factor II, thrombin

multiple interactions
decreases expression
increases expression

F2 protein promotes the reaction [Heparin results in increased abundance of Nitric Oxide]; Heparin deficiency results in increased cleavage of and results in increased activity of F2 protein; Heparin deficiency results in increased expression of [SERPINC1 protein binds to F2 protein]; Heparin inhibits the reaction [F2 protein affects the localization of SELP protein]; Heparin inhibits the reaction [F2 protein results in increased cleavage of F2R protein]; Heparin inhibits the reaction [F2 protein results in increased expression of EDN1 mRNA]; Heparin inhibits the reaction [F2 protein results in increased secretion of EDN1 protein]
Heparin results in increased expression of [F2 protein binds to SERPINC1 protein]
Heparin results in decreased expression of F2 protein
Heparin deficiency results in increased expression of F2 protein; Heparin results in increased expression of F2 protein

PMID:7509996 PMID:7895349 PMID:8408661 PMID:9740346 PMID:11869846 More...

NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506

G

coagulation factor II thrombin receptor

multiple interactions

Heparin inhibits the reaction [F2 protein results in increased cleavage of F2R protein]

NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770

G

Fas cell surface death receptor

increases expression

Heparin results in increased expression of FAS protein

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

Fc gamma receptor IIa

affects binding

[Heparin binds to PF4 protein] which binds to FCGR2A protein

NCBI chr 1:161,505,457...161,524,048
Ensembl chr 1:161,505,430...161,524,013

G

fibrinogen alpha chain

increases cleavage

Heparin deficiency results in increased cleavage of FGA protein

NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742

G

fibroblast growth factor 1

multiple interactions
affects binding

[Heparin analog binds to FGFR2 protein alternative form] which binds to and results in increased activity of FGF1 protein; Heparin analog promotes the reaction [FGF1 protein binds to FGF1 protein]
[Heparin binds to FGFR2 protein alternative form] which binds to FGF1 protein
Heparin affects the reaction [FGF1 protein binds to FGFR4 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK3 protein]; Heparin promotes the reaction [FGF1 protein results in increased expression of FGF1 protein]
Heparin promotes the reaction [FGFR1 protein binds to FGF1 protein]; Heparin promotes the reaction [FGFR3 protein binds to FGF1 protein]

PMID:1379594 PMID:8576258 PMID:10336501 PMID:10860838 PMID:14966081 More...

NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070

G

fibroblast growth factor 10

multiple interactions

Heparin promotes the reaction [FGF10 protein binds to FGFR2 protein]

NCBI chr 5:44,300,247...44,389,420
Ensembl chr 5:44,300,247...44,389,706

G

fibroblast growth factor 19

affects binding
multiple interactions

Heparin binds to FGF19 protein
Heparin promotes the reaction [FGF19 protein binds to FGFR4 protein]

PMID:10525310 PMID:14730967

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

fibroblast growth factor 2

affects binding
decreases expression
multiple interactions
affects activity

Heparin binds to FGF2 protein; Heparin binds to FGFR1 protein binds to FGF2 protein
Heparin results in decreased expression of FGF2 protein
[Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein
Heparin affects the reaction [FGF2 protein binds to FGFR4 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]
Heparin affects the activity of FGF2 protein
Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein]; Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein]

PMID:1373495 PMID:1379594 PMID:8441232 PMID:10336501 PMID:10860838 More...

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 23

increases activity

Heparin analog results in increased activity of FGF23 protein

NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712

G

fibroblast growth factor 3

affects activity

Heparin affects the activity of FGF3 protein

NCBI chr11:69,809,968...69,819,416
Ensembl chr11:69,809,968...69,819,416

G

fibroblast growth factor 4

multiple interactions

Heparin binds to and results in increased activity of FGF4 protein

NCBI chr11:69,771,022...69,775,341
Ensembl chr11:69,771,022...69,775,341

G

fibroblast growth factor 5

affects activity

Heparin affects the activity of FGF5 protein

NCBI chr 4:80,266,588...80,291,017
Ensembl chr 4:80,266,639...80,336,680

G

fibroblast growth factor 7

affects binding

[Heparin binds to FGFR2 protein alternative form] which binds to FGF7 protein

NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775

G

fibroblast growth factor receptor 1

affects binding
multiple interactions

Heparin binds to FGFR1 protein binds to FGF2 protein
Heparin promotes the reaction [FGFR1 protein binds to FGF1 protein]; Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein]

PMID:1379594 PMID:15096041

NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834

G

fibroblast growth factor receptor 2

multiple interactions
affects binding
affects activity

[Heparin analog binds to FGFR2 protein alternative form] which binds to and results in increased activity of FGF1 protein; Heparin promotes the reaction [FGF10 protein binds to FGFR2 protein]
[Heparin binds to FGFR2 protein alternative form] which binds to FGF1 protein; [Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein; [Heparin binds to FGFR2 protein alternative form] which binds to FGF7 protein
Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein]
Heparin affects the activity of FGFR2 protein

PMID:1373495 PMID:10860838 PMID:15632068 PMID:16219767

NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458

G

fibroblast growth factor receptor 3

affects activity
multiple interactions

Heparin affects the activity of FGFR3 protein
Heparin promotes the reaction [FGFR3 protein binds to FGF1 protein]

NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872

G

fibroblast growth factor receptor 4

affects binding
multiple interactions

Heparin analog binds to FGFR4 protein
Heparin affects the reaction [FGF1 protein binds to FGFR4 protein]; Heparin affects the reaction [FGF2 protein binds to FGFR4 protein]
Heparin promotes the reaction [FGF19 protein binds to FGFR4 protein]; Heparin promotes the reaction [FGFR4 protein binds to FGFR4 protein]

PMID:10336501 PMID:10525310 PMID:10736564 PMID:11278860

NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
decreases expression
multiple interactions

Heparin results in increased expression of FOS protein
Heparin results in decreased expression of FOS mRNA
Heparin inhibits the reaction [4-O-methyl-12-O-tetradecanoylphorbol 13-acetate results in increased expression of FOS mRNA]

PMID:2099192 PMID:9083085

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190

G

GATA binding protein 4

multiple interactions

Heparin inhibits the reaction [Inositol 1,4,5-Trisphosphate results in increased expression of GATA4 protein]

NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002

G

glucosamine (N-acetyl)-6-sulfatase

affects degradation

GNS affects the degradation of Heparin

NCBI chr12:64,713,449...64,759,406
Ensembl chr12:64,713,445...64,759,431

G

glutamic--pyruvic transaminase

multiple interactions

Heparin inhibits the reaction [Diclofenac promotes the reaction [endotoxin, Escherichia coli results in increased activity of GPT protein]]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

granzyme B

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA]

NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267

G

hepcidin antimicrobial peptide

decreases expression
decreases secretion
multiple interactions

Heparin results in decreased expression of HAMP mRNA
Heparin results in decreased secretion of HAMP protein modified form
Heparin inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Heparin inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Heparin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]

PMID:25633564 PMID:25686467

NCBI chr19:35,282,528...35,285,143
Ensembl chr19:35,280,716...35,285,143

G

hepatocyte growth factor

multiple interactions
affects binding
increases expression

Heparin promotes the reaction [HGF protein binds to and results in increased activity of MET protein]
HGF protein binds to Heparin
Heparin results in increased expression of HGF protein

PMID:9083085 PMID:18243369

NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438

G

heme oxygenase 1

multiple interactions

Heparin inhibits the reaction [endotoxin, Escherichia coli results in increased expression of HMOX1 mRNA]

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heparanase

multiple interactions

[Heparin results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate

NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153

G

histidine rich glycoprotein

multiple interactions

Heparin inhibits the reaction [Zinc results in increased activity of HRG protein]

NCBI chr 3:186,666,014...186,678,234
Ensembl chr 3:186,660,216...186,678,234

G

immunoglobulin superfamily member 10

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA]

NCBI chr 3:151,432,432...151,619,925
Ensembl chr 3:151,425,384...151,461,061

G

interleukin 6

increases expression
increases secretion
multiple interactions

Heparin results in increased expression of IL6 protein
Heparin analog results in increased secretion of IL6 protein
Heparin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA]

PMID:16391376 PMID:16401727 PMID:25633564 PMID:26476401

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

integrin subunit alpha M

decreases expression
increases expression

Heparin results in decreased expression of ITGAM protein
Heparin results in increased expression of ITGAM protein

PMID:8595612 PMID:8993250

NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892

G

integrin subunit alpha X

decreases expression

Heparin results in decreased expression of ITGAX protein

NCBI chr16:31,355,176...31,382,999
Ensembl chr16:31,355,134...31,382,999

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Heparin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of JUN protein]

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

KLF transcription factor 4

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA]

NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482

G

keratin 18

increases expression

Heparin results in increased expression of KRT18 protein

NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906

G

lactate dehydrogenase B

decreases expression

Heparin results in decreased expression of LDHB protein

NCBI chr12:21,635,342...21,657,842
Ensembl chr12:21,635,342...21,757,857

G

lipoprotein lipase

multiple interactions

[etofibrate co-treated with Heparin] results in increased secretion of LPL protein
Heparin results in increased expression of and results in increased activity of LPL protein

PMID:2313202 PMID:3179329

NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259

G

mitogen-activated protein kinase kinase 1

multiple interactions

Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase kinase 2

multiple interactions

Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein]

NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122

G

mitogen-activated protein kinase 1

multiple interactions
increases activity

Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]
Heparin inhibits the reaction [sodium chlorate results in decreased phosphorylation of MAPK1 protein]
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]
Heparin results in increased activity of MAPK1 protein

PMID:14966081 PMID:16556679 PMID:18057711 PMID:19937756

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases activity

Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]
Heparin inhibits the reaction [sodium chlorate results in decreased phosphorylation of MAPK3 protein]
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK3 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]
Heparin results in increased activity of MAPK3 protein

PMID:14966081 PMID:16556679 PMID:18057711 PMID:19937756

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

microtubule associated protein tau

multiple interactions

Heparin promotes the reaction [MAPT protein binds to MAPT protein]; Mercuric Chloride promotes the reaction [Heparin promotes the reaction [MAPT protein binds to MAPT protein]]

PMID:20665688 PMID:31678113

NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

Heparin promotes the reaction [HGF protein binds to and results in increased activity of MET protein]

NCBI chr 7:116,672,196...116,798,377
Ensembl chr 7:116,672,196...116,798,377

G

macrophage migration inhibitory factor

affects binding

MIF protein binds to Heparin

NCBI chr22:23,894,383...23,895,223
Ensembl chr22:23,894,383...23,895,227

G

matrix metallopeptidase 1

decreases activity

Heparin results in decreased activity of MMP1 protein

NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160

G

matrix metallopeptidase 14

decreases expression

Heparin analog results in decreased expression of MMP14 mRNA

NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041

G

matrix metallopeptidase 2

decreases activity

Heparin results in decreased activity of MMP2 protein

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 9

decreases activity
increases expression
multiple interactions

Heparin results in decreased activity of MMP9 protein
Heparin results in increased expression of MMP9 mRNA; Heparin results in increased expression of MMP9 protein
Heparin results in increased metabolism of and results in increased activity of MMP9 protein

PMID:10958381 PMID:14630814 PMID:16190367

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

myeloperoxidase

multiple interactions

Heparin inhibits the reaction [4-amino-TEMPO inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]; Heparin inhibits the reaction [[1,6-diaminohexane binds to TEMPO] inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]; Heparin inhibits the reaction [[Cadaverine binds to TEMPO] inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]; Heparin inhibits the reaction [[Putrescine binds to TEMPO] inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]; Heparin inhibits the reaction [[Spermine binds to TEMPO] inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]; Heparin inhibits the reaction [[trimethylenediamine binds to TEMPO] inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

moesin

increases expression

Heparin results in increased expression of MSN protein

NCBI chr X:65,588,377...65,741,931
Ensembl chr X:65,588,377...65,741,931

G

MYC proto-oncogene, bHLH transcription factor

increases expression
decreases expression

Heparin results in increased expression of MYC protein
Heparin results in decreased expression of MYC mRNA

PMID:2099192 PMID:11787776 PMID:16475731

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

nuclear factor of activated T cells 3

multiple interactions

Heparin inhibits the reaction [Inositol 1,4,5-Trisphosphate results in increased expression of NFATC3 protein]

NCBI chr16:68,085,370...68,229,259
Ensembl chr16:68,084,751...68,229,259

G

NFE2 like bZIP transcription factor 2

increases expression

Heparin analog results in increased expression of NFE2L2 mRNA

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

Parkinsonism associated deglycase

increases expression

Heparin results in increased expression of PARK7 protein

NCBI chr 1:7,961,711...7,985,505
Ensembl chr 1:7,954,291...7,985,505

G

poly(ADP-ribose) polymerase 1

multiple interactions

Heparin promotes the reaction [Doxorubicin results in increased cleavage of PARP1 protein]

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

platelet derived growth factor subunit B

affects expression

Heparin affects the expression of PDGFB protein

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

platelet derived growth factor receptor alpha

decreases expression

Heparin results in decreased expression of PDGFRA mRNA

NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245

G

pyruvate dehydrogenase E1 subunit beta

decreases expression

Heparin results in decreased expression of PDHB protein

NCBI chr 3:58,427,630...58,433,832
Ensembl chr 3:58,427,630...58,433,857

G

platelet factor 4

affects binding
increases secretion

[Heparin binds to PF4 protein] which binds to FCGR2A protein; Heparin binds to PF4 protein
Heparin results in increased secretion of PF4 protein

PMID:2437338 PMID:2709525 PMID:8282825 PMID:20162249

NCBI chr 4:73,980,811...73,982,124
Ensembl chr 4:73,980,811...73,982,027

G

phosphatidylinositol transfer protein alpha

increases expression

Heparin results in increased expression of PITPNA protein

NCBI chr17:1,517,718...1,562,792
Ensembl chr17:1,517,718...1,562,792

G

plasminogen activator, tissue type

increases expression

Heparin results in increased expression of PLAT mRNA; Heparin results in increased expression of PLAT protein

PMID:14630814 PMID:16190367

NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709

G

plasminogen activator, urokinase

decreases expression

Heparin analog results in decreased expression of PLAU mRNA

NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496

G

plasminogen

multiple interactions

Heparin inhibits the reaction [PLG protein affects the degradation of CCL11 protein]

NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097

G

pro-platelet basic protein

increases secretion

Heparin results in increased secretion of PPBP protein

NCBI chr 4:73,986,439...73,988,190
Ensembl chr 4:73,985,966...73,988,276

G

protein C, inactivator of coagulation factors Va and VIIIa

increases activity

Heparin deficiency results in increased activity of PROC protein

NCBI chr 2:127,418,427...127,429,242
Ensembl chr 2:127,418,427...127,429,242

G

proteasome 20S subunit beta 5

decreases activity
decreases expression

Heparin analog results in decreased activity of PSMB5 protein
Heparin analog results in decreased expression of PSMB5 mRNA

NCBI chr14:23,025,851...23,035,220
Ensembl chr14:23,016,543...23,035,230

G

proteasome 20S subunit beta 6

decreases expression

Heparin analog results in decreased expression of PSMB6 mRNA

NCBI chr17:4,796,164...4,798,495
Ensembl chr17:4,796,144...4,798,502

G

proteasome 20S subunit beta 7

decreases expression

Heparin analog results in decreased expression of PSMB7 mRNA

NCBI chr 9:124,353,465...124,415,442
Ensembl chr 9:124,353,465...124,415,444

G

proteasome activator subunit 1

increases expression

Heparin results in increased expression of PSME1 protein

NCBI chr14:24,136,194...24,138,962
Ensembl chr14:24,136,163...24,138,967

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

protein tyrosine kinase 2

decreases phosphorylation

Heparin results in decreased phosphorylation of PTK2 protein

NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216

G

paxillin

decreases phosphorylation

Heparin results in decreased phosphorylation of PXN protein

NCBI chr12:120,210,447...120,265,730
Ensembl chr12:120,210,439...120,265,771

G

Rac family small GTPase 1

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA]

NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967

G

RB transcriptional corepressor 1

multiple interactions

Heparin analog results in decreased expression of and results in decreased phosphorylation of RB1 protein

NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Heparin inhibits the reaction [arsenite affects the localization of RELA protein]; Heparin inhibits the reaction [TNF protein affects the localization of RELA protein]

PMID:10843908 PMID:26677073

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

S100 calcium binding protein A1

affects expression

Heparin affects the expression of S100A1 protein

NCBI chr 1:153,628,434...153,632,039
Ensembl chr 1:153,627,926...153,632,039

G

S100 calcium binding protein A6

affects expression
increases expression

Heparin affects the expression of S100A6 protein
Heparin results in increased expression of S100A6 protein

PMID:12186470 PMID:17488504

NCBI chr 1:153,534,599...153,535,991
Ensembl chr 1:153,534,599...153,536,244

G

S100 calcium binding protein B

affects expression

Heparin affects the expression of S100B protein

NCBI chr21:46,598,604...46,605,082
Ensembl chr21:46,598,604...46,605,208

G

syndecan 1

decreases expression

Heparin analog results in decreased expression of SDC1 mRNA

NCBI chr 2:20,200,797...20,225,475
Ensembl chr 2:20,200,797...20,225,433

G

syndecan 2

decreases expression

Heparin analog results in decreased expression of SDC2 mRNA

NCBI chr 8:96,493,813...96,611,790
Ensembl chr 8:96,493,813...96,611,790

G

syndecan 4

increases expression

Heparin analog results in increased expression of SDC4 mRNA

NCBI chr20:45,325,288...45,348,424
Ensembl chr20:45,325,288...45,348,424

G

selectin L

decreases expression
increases expression

Heparin results in decreased expression of SELL protein
Heparin results in increased expression of SELL protein

PMID:8595612 PMID:8993250

NCBI chr 1:169,690,667...169,711,620
Ensembl chr 1:169,690,665...169,711,702

G

selectin P

multiple interactions
increases expression

Heparin inhibits the reaction [F2 protein affects the localization of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]
Heparin results in increased expression of SELP protein

PMID:9740346 PMID:10544909

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

septin 2

increases expression

Heparin results in increased expression of SEPTIN2 protein

NCBI chr 2:241,315,355...241,354,027
Ensembl chr 2:241,315,100...241,354,027

G

serpin family C member 1

decreases expression
multiple interactions

Heparin deficiency results in decreased expression of SERPINC1 protein; Heparin results in decreased expression of SERPINC1 protein
Heparin results in increased expression of [F2 protein binds to SERPINC1 protein]
Heparin deficiency results in increased expression of [SERPINC1 protein binds to F2 protein]

PMID:73932 PMID:7895349 PMID:8122184 PMID:11869846 PMID:16961586

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

G

serpin family E member 1

multiple interactions

Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Heparin promotes the reaction [[Famotidine co-treated with Lipopolysaccharides] results in increased expression of SERPINE1 protein]

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

secreted frizzled related protein 1

multiple interactions

Heparin promotes the reaction [Doxorubicin results in increased secretion of SFRP1 protein]

NCBI chr 8:41,261,962...41,309,473
Ensembl chr 8:41,261,962...41,309,473

G

solute carrier family 5 member 3

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA]

NCBI chr21:34,073,578...34,106,260
Ensembl chr21:34,073,578...34,106,260

G

STE20 like kinase

multiple interactions

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA]

NCBI chr10:103,967,140...104,029,233
Ensembl chr10:103,967,140...104,029,233

G

stress induced phosphoprotein 1

increases expression

Heparin results in increased expression of STIP1 protein

NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543

G

transgelin 2

decreases expression

Heparin results in decreased expression of TAGLN2 protein

NCBI chr 1:159,918,111...159,925,507
Ensembl chr 1:159,918,107...159,925,507

G

transferrin receptor

multiple interactions
decreases expression

Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA]
Heparin results in decreased expression of TFRC protein

PMID:16401727 PMID:25633564

NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153

G

transforming growth factor beta 1

decreases expression

Heparin results in decreased expression of TGFB1 mRNA

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tumor necrosis factor

multiple interactions
increases expression

Heparin inhibits the reaction [TNF protein affects the localization of RELA protein]
Heparin results in increased expression of TNF protein

PMID:10843908 PMID:17162433

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

decreases expression

Heparin analog results in decreased expression of TP53 protein

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546

G

vascular endothelial growth factor A

affects binding

Heparin binds to VEGFA protein alternative form

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

indoxyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4 (PEL blood group)

multiple interactions

Indican inhibits the reaction [ABCC4 protein results in increased export of Methotrexate]

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

ATP binding cassette subfamily G member 2 (JR blood group)

multiple interactions

Indican inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

angiotensin I converting enzyme

increases expression

Indican results in increased expression of ACE mRNA

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

aryl hydrocarbon receptor

multiple interactions
increases localization
increases expression
affects localization
increases binding
increases activity

AHR protein promotes the reaction [Indican results in increased expression of NPPA mRNA]; AHR protein promotes the reaction [Indican results in increased expression of NPPB mRNA]; Flavones inhibits the reaction [Indican results in increased activity of AHR protein]; Indican binds to and results in increased activity of AHR protein; N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine inhibits the reaction [Indican results in increased expression of AHR mRNA]
Indican results in increased localization of AHR protein
indoxyl sulfate increases expression of mRNA, protein in HK-2 human kidney proximal tubule cell line
indoxyl sulfate increases expression of protein in rat kidney
indoxyl sulfate affects localization in rat cultured cardiomyocyte cells
indoxyl sulfate increases DNA promoter binding in rat cultured cardiomyocyte cells
indoxyl sulfate increases expression of mRNA, protein in rat cultured cardiomyocyte cells and mouse heart
Indican promotes the reaction [[AHR protein binds to ARNT protein] which binds to CCL20 promoter]

CTD
RGD

PMID:20000589 PMID:21493753 PMID:23639249 PMID:26259605 PMID:38670245 More...

RGD:401793752, RGD:401793752, RGD:401793746, RGD:401793746, RGD:401793746

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

aryl hydrocarbon receptor repressor

increases expression

Indican results in increased expression of AHRR protein

NCBI chr 5:321,714...438,285
Ensembl chr 5:321,714...438,291

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

Indican promotes the reaction [[AHR protein binds to ARNT protein] which binds to CCL20 promoter]

NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708

G

caspase 3

increases cleavage

Indican results in increased cleavage of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

C-C motif chemokine ligand 2

increases expression
increases expression

Indican results in increased expression of CCL2 mRNA; Indican results in increased expression of CCL2 protein
indoxyl sulfate increases expression of mRNA, protein in HK-2 human kidney proximal tubule cell line
indoxyl sulfate increases expression of protein in rat kidney

CTD
RGD

PMID:22056374 PMID:29238104 PMID:29238104

RGD:401793752, RGD:401793752

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 20

multiple interactions

Indican promotes the reaction [[AHR protein binds to ARNT protein] which binds to CCL20 promoter]

NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564

G

cyclin dependent kinase inhibitor 1A

increases expression
multiple interactions

Indican results in increased expression of CDKN1A protein
Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]; Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397

G

cytochrome P450 family 1 subfamily A member 1

increases expression
multiple interactions
increases expression

Indican results in increased expression of CYP1A1 mRNA
Indican results in increased expression of and results in increased activity of CYP1A1 protein
indoxyl sulfate increases expression of mRNA, protein in HK-2 human kidney proximal tubule cell line
indoxyl sulfate increases expression of protein in rat kidney

CTD
RGD

PMID:20000589 PMID:23639249 PMID:38670245 PMID:29238104 PMID:29238104

RGD:401793752, RGD:401793752

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

increases expression
multiple interactions

Indican results in increased expression of CYP1A2 mRNA
Indican results in increased expression of and results in increased activity of CYP1A2 protein

PMID:20000589 PMID:38670245

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 1 subfamily B member 1

increases expression
increases expression

Indican results in increased expression of CYP1B1 mRNA
indoxyl sulfate increases expression of mRNA, protein in rat cultured cardiomyocyte cells and mouse heart

CTD
RGD

PMID:20000589 PMID:31746392

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Indican results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Indican results in increased phosphorylation of EIF2S1 protein]

NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516

G

endothelial PAS domain protein 1

multiple interactions

Indican inhibits the reaction [cobaltous chloride affects the localization of EPAS1 protein]

NCBI chr 2:46,297,407...46,386,697
Ensembl chr 2:46,293,667...46,386,697

G

erythropoietin

multiple interactions

Indican inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA]; Indican inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]

NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700

G

F2R like trypsin receptor 1

increases expression
multiple interactions

Indican results in increased expression of F2RL1 mRNA; Indican results in increased expression of F2RL1 protein
Trypsin Inhibitors inhibits the reaction [Indican results in increased expression of F2RL1 mRNA]; Trypsin Inhibitors inhibits the reaction [Indican results in increased expression of F2RL1 protein]

NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315

G

F-box protein 32

increases expression
multiple interactions

Indican results in increased expression of FBXO32 mRNA; Indican results in increased expression of FBXO32 protein
Acetylcysteine inhibits the reaction [Indican results in increased expression of FBXO32 protein]; pyrazolanthrone inhibits the reaction [Indican results in increased expression of FBXO32 protein]

PMID:29380555 PMID:30849338

NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206

G

gap junction protein alpha 1

multiple interactions
decreases expression

Indican results in decreased expression of and affects the localization of GJA1 protein; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of and affects the localization of GJA1 protein]; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of GJA1 mRNA]
Indican results in decreased expression of GJA1 mRNA; Indican results in decreased expression of GJA1 protein modified form

NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Indican inhibits the reaction [cobaltous chloride affects the localization of HIF1A protein]

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

heat shock protein family A (Hsp70) member 5

increases expression

Indican results in increased expression of HSPA5 mRNA

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

intercellular adhesion molecule 1

increases expression
multiple interactions

Indican results in increased expression of ICAM1 mRNA; Indican results in increased expression of ICAM1 protein
KL protein inhibits the reaction [Indican results in increased expression of ICAM1 protein]

PMID:22056374 PMID:33458837

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

klotho

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [Indican results in decreased expression of KL mRNA]; Acetylcysteine inhibits the reaction [Indican results in decreased expression of KL protein]; isohelenin inhibits the reaction [Indican results in decreased expression of KL mRNA]; isohelenin inhibits the reaction [Indican results in decreased expression of KL protein]; KL protein inhibits the reaction [Indican results in increased expression of ICAM1 protein]; KL protein inhibits the reaction [Indican results in increased expression of VCAM1 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Indican results in decreased expression of KL mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Indican results in decreased expression of KL protein]
Indican results in decreased expression of KL mRNA; Indican results in decreased expression of KL protein

PMID:21389697 PMID:33458837

NCBI chr13:33,016,243...33,066,143
Ensembl chr13:33,016,423...33,066,143

G

leptin receptor

affects abundance

LEPR affects the abundance of Indican

NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559

G

microtubule associated protein 1 light chain 3 beta

increases expression
multiple interactions

Indican results in increased expression of MAP1LC3B protein
Acetylcysteine inhibits the reaction [Indican results in increased expression of MAP1LC3B protein]

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Indican results in increased phosphorylation of MAPK1 protein]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Indican results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Indican results in increased phosphorylation of MAPK1 protein]; alizarin inhibits the reaction [Indican results in increased phosphorylation of MAPK1 protein]

PMID:30849338 PMID:38670245

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Indican results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

Indican results in increased expression of and results in increased phosphorylation of MAPK8 protein
Indican results in increased phosphorylation of MAPK8 protein

PMID:30849338 PMID:32045570

NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360

G

mitogen-activated protein kinase 9

increases phosphorylation

Indican results in increased phosphorylation of MAPK9 protein

NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099

G

MAS1 proto-oncogene, G protein-coupled receptor

decreases expression

indoxyl sulfate decreases expression of Mas1 protein in rat kidney

RGD

NCBI chr 6:159,888,787...159,917,447
Ensembl chr 6:159,890,988...159,917,447

G

myosin heavy chain 2

decreases expression

Indican results in decreased expression of MYH2 mRNA

NCBI chr17:10,521,148...10,549,658
Ensembl chr17:10,521,148...10,549,700

G

myosin heavy chain 3

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [Indican results in decreased expression of MYH3 protein]

NCBI chr17:10,628,532...10,678,417
Ensembl chr17:10,628,526...10,657,309

G

myosin heavy chain 7

increases expression

Indican results in increased expression of MYH7 mRNA

NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660

G

myosin light chain 9

multiple interactions

Indican results in decreased expression of and results in increased phosphorylation of MYL9 protein

NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447

G

myogenic differentiation 1

decreases expression

Indican results in decreased expression of MYOD1 protein

NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136

G

myogenin

decreases expression
multiple interactions

Indican results in decreased expression of MYOG mRNA; Indican results in decreased expression of MYOG protein
Acetylcysteine inhibits the reaction [Indican results in decreased expression of MYOG protein]

NCBI chr 1:203,083,129...203,086,012
Ensembl chr 1:203,083,129...203,086,012

G

NADPH oxidase 4

increases expression

Indican results in increased expression of NOX4 mRNA

NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187

G

natriuretic peptide A

increases expression
multiple interactions
increases expression

Indican results in increased expression of NPPA mRNA
AHR protein promotes the reaction [Indican results in increased expression of NPPA mRNA]
indoxyl sulfate increases expression of mRNA in mouse heart

CTD
RGD

PMID:25703824 PMID:38670245 PMID:31746392

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

natriuretic peptide B

increases expression
multiple interactions
increases expression

Indican results in increased expression of NPPB mRNA
AHR protein promotes the reaction [Indican results in increased expression of NPPB mRNA]
indoxyl sulfate increases expression of mRNA in mouse heart

CTD
RGD

PMID:25703824 PMID:38670245 PMID:31746392

NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945

G

prion protein (Kanno blood group)

multiple interactions

PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]

NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590

G

prostaglandin-endoperoxide synthase 2

increases expression

Indican results in increased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

renin

increases expression

Indican results in increased expression of REN mRNA

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

regucalcin

multiple interactions
decreases expression

Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]; Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]; Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]]

NCBI chr X:47,078,443...47,093,313
Ensembl chr X:47,078,355...47,093,314

G

RAR related orphan receptor C

increases expression

Indican results in increased expression of RORC mRNA

NCBI chr 1:151,806,071...151,831,802
Ensembl chr 1:151,806,071...151,831,845

G

solute carrier family 10 member 1

decreases expression

Indican results in decreased expression of SLC10A1 mRNA

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 22 member 8

multiple interactions

[Lansoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican; [Omeprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican; [Pantoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier organic anion transporter family member 1B3

decreases expression

Indican results in decreased expression of SLCO1B3 mRNA

NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911

G

solute carrier organic anion transporter family member 3A1

multiple interactions

Indican promotes the reaction [SLCO3A1 protein results in increased uptake of simvastatin acid]

NCBI chr15:91,853,708...92,172,435
Ensembl chr15:91,853,708...92,172,435

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation

[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Indican results in increased phosphorylation of SRC protein]; [AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Indican results in increased phosphorylation of STAT3 protein]

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

signal transducer and activator of transcription 3

multiple interactions

[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Indican results in increased phosphorylation of STAT3 protein]; Indican results in increased phosphorylation of and results in increased activity of STAT3 protein
indoxyl sulfate increases expression and increases phosphorylation of Stat3 in HK-2 human kidney proximal tubule cell line

CTD
RGD

PMID:23639249 PMID:29238104

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transforming growth factor beta 1

increases expression

indoxyl sulfate increases expression of protein in rat kidney
indoxyl sulfate increases expression of mRNA, protein in HK-2 human kidney proximal tubule cell line

RGD

PMID:29238104 PMID:29238104

RGD:401793752, RGD:401793752

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

uncoupling protein 2

multiple interactions
decreases response to substance
decreases expression

AICA ribonucleotide inhibits the reaction [Indican results in decreased expression of UCP2 mRNA]
UCP2 protein results in decreased susceptibility to Indican

NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,061...73,982,843

G

UDP glucuronosyltransferase family 1 member A1

increases expression

Indican results in increased expression of UGT1A1 mRNA

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

UDP glucuronosyltransferase family 1 member A6

increases expression

Indican results in increased expression of UGT1A6 mRNA

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

Indican results in increased expression of VCAM1 mRNA; Indican results in increased expression of VCAM1 protein
KL protein inhibits the reaction [Indican results in increased expression of VCAM1 protein]

PMID:22056374 PMID:33458837

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

X-box binding protein 1

increases splicing

Indican results in increased splicing of XBP1 mRNA

NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597

keratan sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2

increases chemical synthesis

B3GNT2 protein results in increased chemical synthesis of Keratan Sulfate

NCBI chr 2:62,196,115...62,224,731
Ensembl chr 2:62,196,115...62,224,731

G

beta-1,4-galactosyltransferase 1

increases chemical synthesis

B4GALT1 protein results in increased chemical synthesis of Keratan Sulfate

NCBI chr 9:33,104,077...33,185,089
Ensembl chr 9:33,100,493...33,167,336

G

carbohydrate sulfotransferase 6

multiple interactions

CHST6 protein results in increased sulfation of and results in increased chemical synthesis of Keratan Sulfate
CHST5 protein results in increased sulfation of and results in increased chemical synthesis of Keratan Sulfate

NCBI chr16:75,472,042...75,495,441
Ensembl chr16:75,472,052...75,495,445

G

glucosamine (N-acetyl)-6-sulfatase

affects degradation

GNS affects the degradation of Keratan Sulfate

NCBI chr12:64,713,449...64,759,406
Ensembl chr12:64,713,445...64,759,431

Laurolactam

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

laurolactam binds to and results in decreased activity of AR protein

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

estrogen receptor 1

multiple interactions

laurolactam binds to and results in decreased activity of ESR1 protein

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

nuclear receptor subfamily 3 group C member 1

multiple interactions

laurolactam binds to and results in decreased activity of NR3C1 protein

NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512

G

progesterone receptor

multiple interactions

laurolactam binds to and results in decreased activity of PGR protein

NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813

lithocholic acid sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

multiple interactions

sulfolithocholic acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

glutathione S-transferase alpha 4

multiple interactions

sulfolithocholic acid binds to and results in decreased activity of GSTA4 protein

NCBI chr 6:52,977,953...52,995,284
Ensembl chr 6:52,977,948...52,995,304

G

glutathione S-transferase mu 1

multiple interactions

sulfolithocholic acid binds to and results in decreased activity of GSTM1 protein

NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039

G

glutathione S-transferase mu 2

multiple interactions

sulfolithocholic acid binds to and results in decreased activity of GSTM2 protein

NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551

Mycotrienin I

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

intercellular adhesion molecule 1

multiple interactions

mycotrienin I inhibits the reaction [TNF protein results in increased expression of and affects the localization of ICAM1 protein]

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

tumor necrosis factor

multiple interactions

mycotrienin I inhibits the reaction [TNF protein results in increased expression of and affects the localization of ICAM1 protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

paracetamol sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

O-linked N-acetylglucosamine (GlcNAc) transferase

multiple interactions

OGT gene mutant form inhibits the reaction [Acetaminophen results in increased abundance of acetaminophen sulfate ester]

NCBI chr X:71,533,104...71,575,892
Ensembl chr X:71,533,087...71,575,892

pregnenolone sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-aminobutyric acid type A receptor subunit alpha1

multiple interactions

pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr 5:161,847,191...161,899,971
Ensembl chr 5:161,847,063...161,899,981

G

gamma-aminobutyric acid type A receptor subunit beta2

multiple interactions

pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr 5:161,288,436...161,548,404
Ensembl chr 5:161,288,429...161,549,044

G

gamma-aminobutyric acid type A receptor subunit gamma2

multiple interactions

pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]

NCBI chr 5:162,067,465...162,155,539
Ensembl chr 5:162,000,057...162,162,977

G

glycine receptor alpha 1

decreases activity

pregnenolone sulfate results in decreased activity of GLRA1 protein

NCBI chr 5:151,822,513...151,924,851
Ensembl chr 5:151,822,513...151,924,851

G

solute carrier family 10 member 6

increases transport

SLC10A6 protein results in increased transport of pregnenolone sulfate

NCBI chr 4:86,823,468...86,849,384
Ensembl chr 4:86,823,468...86,849,384

G

transient receptor potential cation channel subfamily M member 3

multiple interactions

pregnenolone sulfate binds to and results in increased activity of TRPM3 protein

NCBI chr 9:70,529,060...71,446,971
Ensembl chr 9:70,529,060...71,446,977

quercetin 3-sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase

multiple interactions

quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

prostaglandin-endoperoxide synthase 2

decreases expression

quercetin 3'-sulfate results in decreased expression of PTGS2 mRNA

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

solute carrier family 22 member 6

multiple interactions
increases uptake

quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein affects the susceptibility to adefovir]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein results in increased uptake of quercetin 3'-sulfate

NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967

G

solute carrier family 22 member 8

multiple interactions

quercetin 3'-sulfate inhibits the reaction [SLC22A8 protein results in increased transport of 4-carboxyfluorescein]

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

tumor necrosis factor

multiple interactions

quercetin 3'-sulfate inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with TNF protein] results in increased expression of VCAM1 protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular cell adhesion molecule 1

multiple interactions

quercetin 3'-sulfate inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with TNF protein] results in increased expression of VCAM1 protein]

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

sodium myristyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

multiple interactions

Sodium Tetradecyl Sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969

sucrose octasulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

fibroblast growth factor receptor 2

affects binding

sucrose octasulfate binds to FGFR2 protein

NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458

sulfoglycolithocholic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 10 member 1

increases uptake

SLC10A1 protein results in increased uptake of sulfolithocholylglycine

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

sulfolipid I

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nucleotide binding oligomerization domain containing 2

multiple interactions
affects binding

sulfolipid I inhibits the reaction [NOD2 protein binds to Sulfoglycosphingolipids]
NOD2 protein binds to sulfolipid I

NCBI chr16:50,693,606...50,733,075
Ensembl chr16:50,693,588...50,733,077

taurolithocholic acid sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions
decreases response to substance

AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]
AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

caspase 3

multiple interactions
increases activity

AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

CF transmembrane conductance regulator

decreases activity

taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein

NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971

G

cholinergic receptor muscarinic 1

affects binding

taurolithocholic acid 3-sulfate binds to CHRM1 protein

NCBI chr11:62,908,679...62,921,878
Ensembl chr11:62,908,679...62,921,807

G

interferon gamma

multiple interactions
increases expression

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interleukin 6

multiple interactions
increases expression

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26504
role	26326
chemical role	24361
catalyst	8772
sulfuric acid	8724
sulfuric acid derivative	8724
sulfuric ester	1861
(3-aminopropoxy)sulfonic acid	0
(3E)-dec-3-en-1-yl hydrogen sulfate	0
(3S,4E)-3-methyldec-4-en-1-yl hydrogen sulfate	0
(3Z)-9-methyldec-3-en-1-yl hydrogen sulfate	0
(3Z)-dec-3-en-1-yl hydrogen sulfate	0
(3Z)-dodec-3-en-1-yl hydrogen sulfate	0
(3Z,6Z)-dodeca-3,6-dien-1-yl hydrogen sulfate	0
(3Z,6Z,9Z)-dodeca-3,6,9-trien-1-yl hydrogen sulfate	0
(4Z,7Z)-deca-4,7-dien-1-yl hydrogen sulfate	0
(6S)-6-methyloctyl sulfate	0
(E)-2-Propenyl [3-(2-propenylthio)-2-propenyl] sulfate	0
2-(sulfooxy)acetate	0
2-(sulfooxy)acetic acid	0
3,4-dihydroxy-5-(sulfooxy)cyclohex-1-ene-1-carboxylic acid	0
3,5-dihydroxy-4-(sulfooxy)cyclohex-1-ene-1-carboxylic acid	0
5-(Hydroxyphenyl)-gamma-valerolactone-O-sulphate	0
Benzeneacetamide-4-O-sulphate	0
Butyl hydrogen sulfate	0
Diisopropyl sulfate	0
Docosanediol-1,14-disulfate	0
Ethyl hydrogen sulfate	0
Hymatoxin A	0
O-sulfoamino acid +	0
Sulfuric acid, monooctadecyl ester	0
[(3-methylbut-2-en-1-yl)oxy]sulfonic acid	0
[(oxolan-2-yl)methoxy]sulfonic acid	0
[2-(dimethylamino)ethoxy]sulfonic acid	0
\{[5-(hydroxymethyl)furan-2-yl]methoxy\}sulfonic acid	0
alkyl sulfate +	23
aryl sulfate +	62
carbohydrate sulfate +	1783
choline sulfates +	0
fatsicarpain B	0
heterocyclyl sulfate +	6
propyl hydrogen sulfate	0
sodium myristyl sulfate	1
steroid sulfate +	68
torvanol A hydrogen sulfate	0
vanillyl alcohol monosulfate	0
Path 2
Term	Annotations
CHEBI ontology	26504
subatomic particle	26480
composite particle	26480
hadron	26480
baryon	26480
nucleon	26480
atomic nucleus	26480
atom	26480
main group element atom	26217
p-block element atom	26217
chalcogen	25126
oxygen atom	24933
oxygen molecular entity	24933
hydroxides	24116
oxoacid	23051
chalcogen oxoacid	14561
sulfur oxoacid	14311
sulfuric acid	8724
sulfuric acid derivative	8724
sulfuric ester	1861
(3-aminopropoxy)sulfonic acid	0
(3E)-dec-3-en-1-yl hydrogen sulfate	0
(3S,4E)-3-methyldec-4-en-1-yl hydrogen sulfate	0
(3Z)-9-methyldec-3-en-1-yl hydrogen sulfate	0
(3Z)-dec-3-en-1-yl hydrogen sulfate	0
(3Z)-dodec-3-en-1-yl hydrogen sulfate	0
(3Z,6Z)-dodeca-3,6-dien-1-yl hydrogen sulfate	0
(3Z,6Z,9Z)-dodeca-3,6,9-trien-1-yl hydrogen sulfate	0
(4Z,7Z)-deca-4,7-dien-1-yl hydrogen sulfate	0
(6S)-6-methyloctyl sulfate	0
(E)-2-Propenyl [3-(2-propenylthio)-2-propenyl] sulfate	0
2-(sulfooxy)acetate	0
2-(sulfooxy)acetic acid	0
3,4-dihydroxy-5-(sulfooxy)cyclohex-1-ene-1-carboxylic acid	0
3,5-dihydroxy-4-(sulfooxy)cyclohex-1-ene-1-carboxylic acid	0
5-(Hydroxyphenyl)-gamma-valerolactone-O-sulphate	0
Benzeneacetamide-4-O-sulphate	0
Butyl hydrogen sulfate	0
Diisopropyl sulfate	0
Docosanediol-1,14-disulfate	0
Ethyl hydrogen sulfate	0
Hymatoxin A	0
O-sulfoamino acid +	0
Sulfuric acid, monooctadecyl ester	0
[(3-methylbut-2-en-1-yl)oxy]sulfonic acid	0
[(oxolan-2-yl)methoxy]sulfonic acid	0
[2-(dimethylamino)ethoxy]sulfonic acid	0
\{[5-(hydroxymethyl)furan-2-yl]methoxy\}sulfonic acid	0
alkyl sulfate +	23
aryl sulfate +	62
carbohydrate sulfate +	1783
choline sulfates +	0
fatsicarpain B	0
heterocyclyl sulfate +	6
propyl hydrogen sulfate	0
sodium myristyl sulfate	1
steroid sulfate +	68
torvanol A hydrogen sulfate	0
vanillyl alcohol monosulfate	0

paths to the root